WO2010046291A2 - Use of hydroxycinnamic acids and derivatives thereof and/or of plant extracts for treating body odor - Google Patents

Use of hydroxycinnamic acids and derivatives thereof and/or of plant extracts for treating body odor Download PDF

Info

Publication number
WO2010046291A2
WO2010046291A2 PCT/EP2009/063412 EP2009063412W WO2010046291A2 WO 2010046291 A2 WO2010046291 A2 WO 2010046291A2 EP 2009063412 W EP2009063412 W EP 2009063412W WO 2010046291 A2 WO2010046291 A2 WO 2010046291A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
extract
derivatives
acids
hydroxycinnamic
Prior art date
Application number
PCT/EP2009/063412
Other languages
German (de)
French (fr)
Other versions
WO2010046291A3 (en
Inventor
Markus Egert
Heide-Marie Höhne
Rainer Simmering
Bernhard Banowski
Roland Breves
Thomas Weber
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2010046291A2 publication Critical patent/WO2010046291A2/en
Publication of WO2010046291A3 publication Critical patent/WO2010046291A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755—Gymnosperms [Coniferophyta]
    • A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Definitions

  • the present invention relates to the use of hydroxycinnamic acids and / or their derivatives and of plant extracts selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof for inhibiting enzymes, in particular cystathionine-beta-lyase. and / or for the prevention or treatment of body odor, in particular in the axillary area, as well as cosmetic and pharmaceutical preparations, in particular deodorants and antiperspirants, which contain these active substances.
  • body odor primarily results from the breakdown of sweat constituents by bacteria of the skin flora, especially in the axillary area.
  • a similar problem as for body odor is also for bad breath. Again, the starting substances are bacterially converted into malodorous degradation products.
  • agents for controlling body odor in particular for the axillary and oral area, in particular those which are more effective against body odor and / or bad breath than the previously known agents, preferably without an unselective antibacterial Effect at the site of application.
  • highly malodorous components of human body odor and halitosis are volatile sulfur compounds released by enzymatic reaction (“VSC”) Sulfur-containing compounds, as water-soluble amino acid conjugates, sweat onto human skin they are released from skin bacteria (especially staphylococci and corynebacteria) by enzymatic reaction.
  • cystathionine beta-lyase One enzyme that plays a key role in the release of VSCs is cystathionine beta-lyase. This enzyme cleaves VSCs from the amino acids and is thus an important cause of body odor formation (see, for example, Natsch et al., (2004) Chemistry and Biodiversity 1, 1058-1072, Troccaz et al., (2004) Chemistry and Biodiversity 1, 1022-1035; Starkenmann et al. (2005) Chemistry and Biodiversity 2, 705-716).
  • An advantage of the use of substances that specifically inhibit the enzyme activity of cystathionine beta-lyase is that a more targeted control of the cause of the odor can occur and preferably continue to be largely dispensed with the use of antibacterial active substances, or at least limited their use can.
  • cysta- thionine beta-lyase from Staphylococcus is.
  • benzyl cysteine can be used as a substrate for cystathionine beta-lyase.
  • the enzymatic conversion of the benzylic cysteine liberates cysteine, which can subsequently be detected with the aid of detection reagents.
  • monobromobimane forms a fluorescent complex with cysteine, which can be detected spectrometrically.
  • Inhibitors reduce the activity of cystathionine beta-lyase and thereby also the amount of detectable released cysteine.
  • hydroxycinnamic acids, derivatives of hydroxycinnamic acids and also plant extracts, in particular meadowsweet extract and St. John's Wort extract, and also extracts which contain hydroxycinnamic acids and / or their derivatives, very effectively inhibit cystathionine-beta-lyase can be achieved.
  • a first subject of the present invention is therefore the use of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof for inhibition an enzyme, wherein the enzyme is preferably a cystathionine beta-lyase, and preferably used in a cosmetic agent.
  • the present invention therefore furthermore relates to the use of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof for the purpose of prevention or treatment body odor, especially in the axillary or oral area, the use preferably being in a cosmetic agent.
  • the present invention furthermore relates to cosmetic or pharmaceutical compositions for the treatment or prevention of body odor or halitosis containing at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts, the hydroxycinnamic acids and / or their derivatives.
  • the present invention therefore further provides for the use of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or their derivatives for the production of a cosmetic or pharmaceutical composition for the treatment or prevention of body odor, in particular in the axillary or oral area.
  • Hydroxy cinnamic acids are according to the invention compounds of the general formula (I)
  • R1 and R2 are independently selected from hydrogen, C-
  • the derivative of hydroxycinnamic acid is an ester of hydroxycinnamic acid with an alcohol, wherein in a preferred embodiment the alcohol is a polyhydroxy compound.
  • the polyhydroxy compound is the quinic acid.
  • the ester of hydroxycinnamic acid is selected from chlorogenic acid (5-0-caffeoylquinic acid, (1S) -3 ⁇ - (3,4-dihydroxycinnamoyloxy) -1a, 4a, 5a-trihydroxycyclohexanecarboxylic acid) and a di-caffeoylquinic acid, especially from 3,5 di-O-caffeoylquinic.
  • chlorogenic acid 5-0-caffeoylquinic acid, (1S) -3 ⁇ - (3,4-dihydroxycinnamoyloxy) -1a, 4a, 5a-trihydroxycyclohexanecarboxylic acid
  • di-caffeoylquinic acid especially from 3,5 di-O-caffeoylquinic.
  • the derivative of hydroxycinnamic acid may furthermore be a hydroxycinnamic acid or an ester of hydroxycinnamic acid with an alcohol, characterized in that the compound is monosubstituted or polysubstituted, preferably monosubstituted, disubstituted or trisubstituted, preferably by substituents selected from the group consisting of C 1. 6 alkyl, hydroxy, C ⁇ 6 - alkoxy, carboxy and halogen, especially fluorine, chlorine or bromine.
  • the extract containing caffeic acid may in particular be an extract of Ipomoea purga, in particular of the tubers of Ipomoea purga, Pyrus communis (pear), in particular of the fruits of Pyrus communis, Pyrus malus (apple), in particular of the fruits of Pyrus malus, Ocimum basilicum (basil), in particular from the leaves of Ocimum basilicum, Thymus vulgaris (thyme), in particular from the leaves of Thymus vulgaris, Teucrium scorodonia, in particular from the leaves of Teucrium scorodonia, Verbena officinalis, in particular from the leaves of Verbena officinalis, Artemisia dracunculus, in particular from the sprouts of Artemisia dracunculus, Thymus serpyll
  • the plant extract to be used according to the invention which contains a hydroxycinnamic acid or a derivative thereof, is a plant extract which contains chlorogenic acid.
  • the extract containing chlorogenic acid may in particular be an extract from coffee (Coffea arabica), in particular from the seed of Coffea arabica, from sunflower (Helianthus annuus), in particular from the seed of Helianthus annuus, from Damascus rose (Rosa damascena ), in particular from the pollen and spores of Rosa damascena, from blueberry (Vaccinium corymbosum), in particular from the fruits of Vaccinium corymbosum, from Pyrus malus (apple), in particular from the fruits of Pyrus malus, from Melissa officinalis, in particular from the herb from Melissa officinalis, from Camellia sinensis, in particular from the leaves of Camellia sinensis, from Japanese honeysuckle (Lonicera japonica), in particular from the
  • the plant extract to be used according to the invention is selected from extracts of Lonicera japonica flowers, Arnica montana flowers and Eucommia ulmoides leaves, and mixtures thereof. Because these extracts showed despite a relatively low content of hydroxycinnamic acids or their derivatives nevertheless an extremely strong inhibitory effect on the cystathionine beta-lyase, so that it can be assumed that the components contained in these extracts in combination with the cinnamic acids a synergistic Effect effect.
  • the plant extract to be used according to the invention is selected from extracts of meadowsweet (Filipendula ulmaria, Spiraea ulmaria, also known by the names “meadow queen” or “Waldbart”) and St. John's wort (Hypericum perforatum).
  • a meadowsweet extract preferably used according to the invention is obtained by extraction of the flowers and / or the leaves with a water / ethanol mixture, a water / C 2 -C 6 -polyol mixture or at least one C 2 -C 6 -polyIl.
  • Preferred C 2 -C 6 polyols for extraction are selected from ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, dipropylene glycol and glycerol.
  • Meadowsweet extracts based on water / 1, 2-propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable according to the invention.
  • John's Wort extract preferably used according to the invention is obtained by extraction of the flowers and the leaves with a water / ethanol mixture, a water / C 2 -C 6 -polyol mixture or at least one C 2 -C 6 -polyIl.
  • Preferred C 2 -C 6 polyols for extraction are selected from ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, dipropylene glycol and glycerol.
  • St. John's wort extracts based on water / 1,2-propylene glycol in a ratio of 1: 5 to 5: 1 have proven to be particularly suitable according to the invention.
  • oils and other suitable solvents can be used.
  • suitable alcohols include, for example, lower alcohols such as ethanol and isopropanol, but especially also polyhydric alcohols such as ethylene glycol, 1,2-propylene glycol, butylene glycol, dipropylene glycol and glycerol, both as the sole extractant and in admixture with water.
  • plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven particularly suitable.
  • the extraction can be carried out, for example, in the form of steam distillation.
  • a carbon dioxide extraction can take place.
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% dry matter and as a solvent used in their extraction agent or extractant mixture. Depending on the choice of extractants, it may be preferable to stabilize the plant extract by adding a solubilizer. Suitable solubilizers are, for. B. Ethoxylation products of optionally hydrogenated vegetable and animal oils. Preferred solubilizing agents are ethoxylated mono-, di- and triglycerides of C 8 - 22 - fatty acids having from 4 to 50 ethylene oxide units, for example.
  • the plant extracts can, in a preferred embodiment according to the invention, also be applied to carriers, in particular in order to be better able to be incorporated into products.
  • Suitable carriers according to the invention are, for example, maltodextrin, talc and silica.
  • the plant extracts are commercially available, for example, from Cosmetochem (Germany), Cognis (Germany), Symrise (Germany) or Rahn (Germany).
  • Hydroxy cinnamic acids and / or their derivatives and plant extracts selected from meadowsweet extract, St. John's wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof are preferably present in agents according to the invention in a total amount of up to 20% by weight, more preferably in one Total amount of 0.001 to 10 wt .-%, in particular from 0.01 to 5 wt .-%, especially from 0.1 to 2 wt .-%, contain.
  • the cosmetic or pharmaceutical composition according to the invention may be any dosage form, for example a solid or liquid soap, a lotion, a spray, a cream, a gel, an emulsion, a cleaning liquid or cleansing milk, a stick, a deodorant, an antiperspirant or an ointment, and it may also be included in any of the described or other dosage forms, for example, in a patch, especially in a gel reservoir or matrix patch.
  • the cosmetic or pharmaceutical composition is a deodorant and / or antiperspirant.
  • the deodorant and / or antiperspirant is preferably present as a powder, in stick form, as a syndet, washing lotion, aerosol spray, pump spray, liquid or gel roll-on application, cream, foam, liquid or solid soap, gel or impregnated as a flexible substrate.
  • applicators for example, depending on the application form, for example, pen barrel, roll-on, pump, tube, crucible, dispenser, cloth, aerosol can or bottle can be used.
  • the site of application is the skin of each area of the body, in particular the facial skin, the scalp, the skin on the feet and hands. In a particularly preferred embodiment, the site of application is the skin in the axillary area. In a further particularly preferred embodiment, the site of application is the oral area.
  • the cosmetic or pharmaceutical composition according to the invention may also contain further constituents than those mentioned above. In a preferred embodiment, it contains at least one of the substances enumerated below. It may also contain any combination of the ingredients listed below.
  • Cosmetic or pharmaceutical compositions which have shown mixtures of hydroxycinnamic acids and / or their derivatives and / or of plant extracts selected from meadowsweet extract, St. John's wort extract and extracts which contain hydroxycinnamic acids and / or their derivatives, and in particular have turned out to be particularly advantageous a substance prebiotically active in the axillary area (as disclosed in WO2005 / 011716 or WO2005 / 092279), in particular selected from plant extracts from Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp., Ribes sp., Hibiscus Spec, Malva spec, Vitis spec, Daucus spec, Commiphora spec, Simmondsia spec or Calendula spec, glycerol monoalkyl, especially ⁇ -monoalkyl glycerol ether with a branched or linear saturated or
  • cosmetic or pharmaceutical compositions which have been found to comprise mixtures of hydroxycinnamic acids and / or their derivatives and / or of plant extracts selected from meadowsweet extract, St. John's wort extract and extracts which contain hydroxycinnamic acids and / or derivatives thereof, and at least a further deodorant active ingredient, in particular an antimicrobially active substance, preferably an aromatic alcohol, and in a preferred embodiment, additionally at least one of the aforementioned substances which are prebiotically active in the axillary area.
  • an antimicrobially active substance preferably an aromatic alcohol
  • inhibitors of cystathionine beta-lyase and antimicrobial deodorant agents both reduce the number of odor-causing bacteria and reduce their odor-causing capacity. Due to the additional presence of a prebiotically active substance, the ratio between odor-causing bacteria and odor-neutral bacteria is further shifted in favor of the odor-neutral bacteria, so that an even more effective body odor control is possible as a result. Due to the combined effect of antimicrobial substances on the one hand and prebiotically active substances on the other hand, the desired bacteria are then more able to spread on the skin than would be the case in the presence of a purely prebiotic effect.
  • Fragrances, odor absorbers, deodorizing ion exchangers, antimicrobial or germ-inhibiting substances, further enzyme-inhibiting substances, antioxidants and odor adsorbents are particularly suitable according to the invention as further deodorant active substances.
  • Particularly suitable as odor absorbers are silicates. These also simultaneously support the rheological properties of the composition according to the invention in an advantageous manner.
  • the silicates used particularly preferably according to the invention as odor absorbers include, in particular, layered silicates and, among these, in particular montmorillonite, kaolinite, illite, beidellite, nontronite, saponite, hectorite, bentonite, smectite and talcum.
  • Other preferred odor absorbers are, for example, zeolites, Zinkricinoleat, cyclodextrins, certain metal oxides, such as. As alumina, and chlorophyll.
  • Preferred antimicrobial or antimicrobial agents according to the invention are in particular organohalogen compounds and halides, quaternary ammonium compounds, a number of plant extracts and zinc compounds.
  • Triclosan Irgasan® DP 300
  • triethyl citrate chlorhexidine, chlorhexidine gluconate, 3,4,4'-trichlorocarbanilide, bromochlorophene, dichlorophen, chlorothymol, chloroxylenol, hexachlorophene, dichloro-m-xylenol, dequalinium chloride, domiphenbromide, ammonium phenolsulfonate, benzalkonium halides, benzalkonium cetyl phosphate, benzalkonium saccharinates, Benzethonium chloride, cetylpyridinium chloride, laurylpyridinium chloride, laurylisoquinolinium bromide and methylbenzethonium chloride.
  • phenol disodium dihydroxyethylsulfosuccinyl undecylenate, sodium bicarbonate, zinc lactate, sodium phenol sulfonate, zinc phenolsulfonate, ketoglutaric acid, bisabolol, terpene alcohols such.
  • chlorophyllin copper complexes carboxylic acid esters of mono-, di- and triglycerol (eg., Glycerin monolaurate, diglycerol monocaprinate), lantibiotics and certain plant extracts (eg., Green tea and the components of lime blossom oil and chamomile oil ) can be used.
  • Preferred further enzyme-inhibiting substances are inhibitors for further enzymes of the axillary germ flora, which are involved in the development of body odor. These are preferably inhibitors of lipases, arylsulfatases (see WO 01/99376), ⁇ -glucuronidases (see WO 03/039505), 5- ⁇ -reductases and aminoacylases.
  • glycoglycerolipids sphingolipids (ceramides), sterols and other agents that inhibit bacterial adhesion to the skin, e.g. As glycosidases, lipases, proteases, carbohydrates, di- and Oligosaccharidfettklar and alkylated mono- and oligosaccharides.
  • water-soluble polyols selected from water-soluble diols, triols and higher-grade alcohols and also polyethylene glycols.
  • diols are C 2 -Ci 2 -DbIe, in particular 1, 2-propylene glycol, butylene glycols such.
  • B. 1, 2-butylene glycol, 1, 3-butylene glycol and 1, 4-butylene glycol, pentanediols, z.
  • glycerol and technical Oligoglyce- ringemische with an intrinsic degree of condensation of 1, 5 to 10 such as technical Diglycerin mixtures having a Diglycerine content of 40 to 50 wt .-% or triglycerol, further 1, 2,6-hexanetriol and polyethylene glycols ( PEG) having an average molecular weight of 100 to 1000 daltons, for example PEG-400, PEG-600 or PEG-1000.
  • PEG polyethylene glycols
  • suitable higher-value alcohols are the C 4 , C 5 and C 6 monosaccharides and the corresponding sugar alcohols, eg. Mannitol or sorbitol.
  • an aromatic alcohol is used as further deodorant active ingredient.
  • the aromatic alcohol according to the invention is preferably a compound of the general formula
  • R 1 - R 6 independently of one another represent a hydrogen atom, a linear or branched and optionally substituted C 1-. 10 alkyl group or a linear or branched and optionally substituted C 2 -i 0 alkenyl group, wherein the substituents are each preferably selected from hydroxy and CI_ 6 alkoxy,
  • Aromatic alcohols of the aforementioned structure which are preferred according to the invention are selected from phenoxyethanol, phenoxyisopropanol (3-phenoxy-propan-2-ol), anisalcohol, 2-methyl-5-phenyl-pentan-1-ol, 1,1-dimethyl-3 phenyl-propan-1-ol, benzyl alcohol, 2-phenylethan-1-ol, 3-phenylpropan-1-ol, 4-phenylbutan-1-ol, 5-phenylpentan-1-ol, 2-benzylheptan-1-ol, 2,2-Dimethyl-3-phenylpropan-1-ol, 2,2-dimethyl-3- (3'-methylphenyl) -propan-1-ol, 2-ethyl-3-phenylpropan-1-ol, 2-ethyl -3- (3'-methylphenyl) -propan-1-ol, 3- (3'-chlorophenyl) -2-ethyl-propan-1
  • Antioxidant substances can counteract the oxidative decomposition of the welding components and in this way inhibit odor development.
  • Preferred antioxidants are imidazole and imidazole derivatives (eg urocaninic acid), peptides, such as e.g. B.
  • D, L-carnosine, D-carnosine, L-carnosine and their derivatives eg, anserine
  • carotenoids eg, carotenes (eg, ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives
  • Lipoic acid and its derivatives eg dihydrolipoic acid
  • aurothioglucose propylthiouracil and other thio compounds
  • Ethyl, propyl, amyl, butyl, lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters and their salts, dilauryl thiodipropionat
  • B ⁇ -linolenic acid, linoleic acid, arachidonic acid, oleic acid), folic acid and their derivatives, hydroquinone and its derivatives (eg arbutin), ubiquinone and ubiquinol and their derivatives, vitamin C and its derivatives (eg ascorbyl palmitate, stearate, dipalmitate, acetate, Mg ascorbyl phosphates, sodium and magnesium ascorbate , Disodium ascorbyl phosphate and sulfate, potassium ascorbyl tocopheryl phosphate, chitosan ascorbate), isoascorbic acid and its derivatives, tocopherols and their derivatives (for example tocopheryl acetate, linoleate, oleate and succinate, tocopheryl-5, tocophereth-10, tocophereth-12, Tocophereth-18, tocophereth-50, tocopherol), vitamin A and derivatives (e.
  • Stilbene oxide trans-stilbene oxide
  • Suitable derivatives salts, esters, sugars, nucleotides, nucleosides, peptides and lipids
  • mixtures of these active substances or anhydrous plant extracts containing these antioxidants can be used according to the invention.
  • Preferred lipophilic, oil-soluble antioxidants from this group are tocopherol and its derivatives, in particular tocopheryl acetate, and carotenoids, as well as butylhydroxytoluene and butylhydroxyanisole.
  • a composition which is preferred according to the invention contains at least one of the abovementioned additional deodorant active ingredients, the total amount of additional deodorant active substances preferably being 0.1-10% by weight, preferably 0.2-7% by weight, particularly preferably 0.3 - 5 wt .-% and in particular 0.4 - 1, 0 wt .-% is.
  • cosmetic or pharmaceutical compositions which have been found to comprise mixtures of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one extra-selected plant selected from meadowsweet extract, St. John's wort extract and extracts, the hydroxycinnamic acids and or contain derivatives thereof, and at least one antiperspirant active ingredient (antiperspirant active ingredient), preferably further in combination with at least one prebiotically active substance and / or another deodorant active ingredient.
  • antiperspirant active ingredient antiperspirant active ingredient
  • Suitable antiperspirant active substances according to the invention are, in particular, water-soluble astringent or protein coagulating metallic salts, in particular inorganic and organic salts of aluminum, zirconium, zinc and titanium, and any desired mixtures of these salts.
  • preferred antiperspirant active substances are selected from aluminum chlorohydrates, especially aluminum chlorohydrates having the general formula [Al 2 (OH) 5 CI 2-3 ⁇ H 2 O] n, which may be present in non-activated or activated in (depolymerized) Form , furthermore aluminum sesquichlorohydrate, aluminum chlorohydrex-propylene glycol (PG) or polyethylene glycol (PEG), aluminum sesquichlorohydrex PG or PEG, aluminum PG-dichlorohydrex or aluminum PEG-dichlorhydrex, aluminum hydroxide, furthermore selected from the aluminum zirconium chlorohydrates, such as aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, alumina niumzirconiumpentachlorhydrat, Aluminiumzirconiumoctachlorhydrat, the aluminum-zirconium chlorohydrate glycine complexes, such as Aluminiumzirconiumtrichlorhydrexglycin, Aluminiumzir
  • a solubility of at least 5 wt .-% at 20 0 C is understood according to the invention, solubility in water, that is, amounts of at least 5 g of the antiperspirant active ingredient in 95 g of water are soluble at 20 0 C.
  • the antiperspirant active ingredients can be used as aqueous solutions.
  • the inventive composition as antiperspirant comprises an astringent aluminum salt, especially aluminum chlorohydrate, for example, in powder form as Micro Dry ® Ultrafine or Micro Dry ® SUF from Reheis, in the form of an aqueous solution as Locron ® L from Clariant, as Chlorhydrol ® and in activated form as Reach® 103 or Reach® 501 from Reheis. Under the name Reach® 301 an aluminum sesquichlorohydrate from Reheis is offered, which is likewise particularly preferred.
  • the use of aluminum zirconium tetrachlorohydrex glycine complexes which are, for example, by Reheis under the name Rezal ® 36G or Reach ® 908 commercially, may be particularly preferred according to the invention.
  • the antiperspirant active is contained in the compositions according to the invention in an amount of 0.01-40% by weight, preferably 2-30% by weight and more preferably 5-25% by weight.
  • a composition according to the invention may also contain other and / or other plant extracts in addition to the abovementioned plant extracts which can be used according to the invention. These further and / or other plant extracts can be prepared for example by extraction of the entire plant, but also exclusively by extraction from flowers and / or leaves and / or seeds and / or other parts of plants.
  • the extracts from the meristem so the divisible educated tissue of the plants, and the extracts of special plants such as green tea, witch hazel, chamomile, pansy, Paeonie, aloe vera, horse chestnut, sage, willow bark, cinnamon tree (cinnamon tree), Chrysanthemums, Oak bark, Stinging nettle, Hops, Burdock root, Horsetail, Hawthorn, Lime blossom, Almonds, Spruce needles, Sandalwood, Juniper, Coconut, Kiwi, Guava, Lime, Mango, Apricot, Wheat, Melon, Orange, Grapefruit, avocado, Rosemary, Birch, Beech shoots, meadowfoam, yarrow, quenelle, thyme, lemon balm, toadstool, marshmallow (Althaea), violets, blackcurrant leaves, coltsfoot, Popefingerkraut, ginseng, ginger root and sweet potato are preferred as another plant extract.
  • special plants such as green
  • Algae extracts can also be used to advantage.
  • the Algae extracts used according to the invention are derived from green algae, brown algae, red algae or blue-green algae (cyanobacteria).
  • the algae used for extraction can be obtained both from natural sources as well as by biotechnological processes and, if desired, be modified from the natural form.
  • the alteration of the organisms may be by genetic engineering, by breeding or by cultivation in media enriched with selected nutrients.
  • Preferred algae extracts are from seaweed, blue-green algae, from the green alga Codium tomentosum and from the brown algae Fucus vesiculosus.
  • a particularly preferred algae extract is derived from blue-green algae of the species Spirulina, which were cultured in a magnesium-enriched medium.
  • compositions according to the invention may also contain mixtures of several, in particular two, different plant extracts as additional plant extract.
  • the cosmetic or pharmaceutical compositions may further contain fatty substances.
  • Fatty substances are to be understood as meaning fatty acids, fatty alcohols, natural and synthetic cosmetic oil components as well as natural and synthetic waxes, which can be in solid or liquid form in aqueous or oily dispersion.
  • fatty acids can be used linear and / or branched, saturated and / or unsaturated C 8 - 3 o fatty acids.
  • Ciol- 22- fatty acids are preferred.
  • Examples are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidonic acid, gadoleic acid, behenic acid and erucic acid, and their technical mixtures. Particularly preferred is the use of stearic acid.
  • the fatty acids used can carry one or more hydroxyl groups.
  • Preferred examples of these are the ⁇ -hydroxy-C 8 -C 8 -carboxylic acids and 12-hydroxystearic acid.
  • the amount used is 0.1 to 15 wt .-%, preferably 0.5 to 10 wt .-%, particularly preferably 1 to 5 wt .-%, each based on the total composition.
  • fatty alcohols it is possible to use saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 6 to 30, preferably 10 to 22 and very particularly preferably 12 to 22 carbon atoms.
  • Applicable according to the invention are e.g. Decanol, octanol, dodecadienol, decadienol, oleyl alcohol, eruca alcohol, ricinoleic alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol, and the like Guerbet.
  • waxes are often used.
  • solid paraffins or isoparaffins plant waxes such as candelilla wax, carnauba wax, esparto grass wax, Japan wax, cork wax, Sugarcane wax, ouricury wax, Kester wax, montan wax, sunflower wax, fruit waxes and animal waxes, such as.
  • paraffin waxes As petrolatum, paraffin waxes, Microwachse of polyethylene or polypropylene and polyethylene glycol waxes. It may be advantageous to use hydrogenated or hardened waxes. Furthermore, chemically modified waxes, especially the hard waxes, z. As montan ester waxes, Sasol waxes and hydrogenated jojoba waxes, can be used.
  • Syncrowachs ® or polyols having 2 - 6 carbon atoms, fatty acid monoalkanolamides with a C 12 _ 22 - acyl group and a C 2 ⁇ alkanol, esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 1 to 80 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 1 to 80 carbon atoms, including z.
  • Example synthetic fatty acid fatty alcohol esters such as stearyl stearate or cetyl palmitate, esters of aromatic carboxylic acids, dicarboxylic acids or hydroxycarboxylic acids (eg., 12-hydroxystearic acid) and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 1 to 80 C-atoms, lactides of long-chain hydroxycarboxylic acids and full esters of fatty alcohols and di- and tricarboxylic acids, eg.
  • dicetyl succinate or dicetyl / stearyl adipate, and mixtures of these substances provided that the individual wax components or their mixture are solid at room temperature.
  • wax components from the group of esters of saturated, unbranched alkanecarboxylic acids having a chain length of 14 to 44 carbon atoms and saturated, unbranched alcohols of a chain length of 14 to 44 carbon atoms, provided the wax component or the entirety of the wax components are solid at room temperature.
  • the wax components from the group of Ci 6 can - 36 alkyl stearates, C-40 ⁇ o- alkyl stearates, C 2-4 o-Alkylisostearate, the C 20 - 40 dialkyl esters of dimer acids, of the C 8-38 - Alkylhydroxystearoylstearates, the C 20 - 40 -Alkylerucate be selected, also C 30 - 50 -alkyl beeswax and Cetearylbehenat be used. Silicone waxes, for example stearyltrimethylsilane / stearyl alcohol, may also be advantageous.
  • Particularly preferred wax components are the esters of saturated, monohydric C 20 -C 60 alcohols, and saturated C 8 -C 30 mono-carboxylic acids, in particular a C 20 -C 40 alkyl preferred, under the name ® Kesterwachs K82H by the company Koster Keunen Inc. is available.
  • the wax or the wax components should be solid at 25 ° C, but in the range of 35 - 95 ° C to melt, with a range from 45 to 85 0 C is preferred.
  • Natural, chemically modified and synthetic waxes may be used alone or in combination.
  • the wax components are present in an amount of from 0.1 to 40% by weight, based on the total composition, preferably from 1 to 30% by weight and in particular from 5 to 25% by weight.
  • the compositions of the invention may further contain at least one nonpolar or polar liquid oil, which may be natural or synthetic.
  • the polar oil component may be selected from vegetable oils, e.g. B.
  • ester oils that is the esters of C 6 - 3 o-fatty acids with C 2 - 3 o-fatty alcohols, from dicarboxylic acid esters such as di-n-butyl adipate, di (2-ethylhexyl) adipate and di (2-ethylhexyl) succinate and diol esters such as ethylene glycol dioleate and propylene glycol di (2-ethylhexanoate), from symmetrical, unsymmetrical or cyclic esters of carbonic acid with fatty alcohols , for example described in DE-OS 197 56 454, glycerol carbonate or dicaprylyl carbonate (Cetiol ® CC), from mono, - di- and trifatty acid esters of saturated and / or unsaturated linear and / or
  • alkyl methyl ethers or di-n-alkyl ethers each having a total of 12 to 24 carbon atoms, in particular di-n-octyl ether (Cetiol ® OE ex Cognis), as well as adducts of ethylene oxide and / or propylene oxide to mono- or polyvalent C 3 . 2 o-alkanols such as butanol and glycerol, z.
  • the non-polar oil component may be selected from liquid paraffin oils, isoparaffin oils, e.g. Isohexadecane and isoeicosane, from hydrogenated polyalkenes, especially poly-1-decenes (commercially available as Nexbase 2004, 2006 or 2008 FG (Fortum, Belgium)), from synthetic hydrocarbons, e.g. B.
  • cyclic such as. B. decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane, or may be linear, for.
  • linear dimethyl polysiloxane commercially available for. Example under the name Dow Corning ® 190, 200, 244, 245, 344 or 345 and Baysilon ® 350 M.
  • compositions of the invention may further contain at least one water-soluble alcohol.
  • Water solubility is understood according to the invention that at least 5 wt .-% of the alcohol at 20 0 C clear dissolve or - in the case of long-chain or polymeric alcohols - by heating the solution to 50 0 C to 60 0 C can be brought into solution.
  • monohydric alcohols such as ethanol, propanol or isopropanol.
  • water-soluble polyols include water-soluble diols, triols and higher alcohols and polyethylene glycols.
  • the diols are C 2 -Ci 2 -DbIe, in particular 1, 2-propylene glycol, butylene glycols such.
  • the amount of the alcohol or the alcohol mixture in the compositions according to the invention is 1-98 or 1-70% by weight and preferably 5-40 or 5-55% by weight, based on the total composition. According to the invention, both an alcohol and a mixture of several alcohols can be used.
  • compositions of the invention may be substantially anhydrous, that is containing a maximum of 5 wt .-%, preferably at most 1 wt .-% water.
  • the water content is 5 to 98% by weight, preferably 10 to 90 and particularly preferably 15 to 85% by weight, based on the total composition.
  • compositions of the invention may further comprise at least one hydrophilic modified silicone. They allow the formulation of highly transparent compositions, reduce the stickiness and leave a fresh feeling on the skin.
  • Hydrophilically modified silicones are understood according to the invention to mean polyorganosiloxanes having hydrophilic substituents which cause the water solubility of the silicones. According to the invention is understood to mean water-solubility that solve at least 2 wt .-% of the modified silicone with hydrophilic groups in water at 20 0 C.
  • Corresponding hydrophilic substituents are, for example, hydroxy, polyethylene glycol or polyethylene glycol / polypropylene glycol side chains and ethoxylated ester side chains.
  • suitable hydrophilic modified silicone copolyols in particular dimethicone copolyols, for example, by Wacker-Chemie under the name Belsil ® DMC 6031, Belsil ® DMC 6032, Belsil ® DMC 6038 or Belsil ® DMC 3071 VP or Dow Corning under the name DC 2501 are commercially available.
  • Particularly preferably suitable is the use of Belsil® ® DMC 6038, as it allows the formulation of highly transparent compositions that achieve higher consumer acceptance.
  • ABIL EM97 from Degussa / Goldschmidt can also be used as the hydrophilic silicone derivative. According to the invention, it is also possible to use any desired mixture of the silicones mentioned.
  • the amount of the hydrophilic modified silicone or the alcohol mixture in the compositions according to the invention is 0.5-10% by weight, preferably 1-8% by weight and more preferably 2-6% by weight, based on the total weight of the Composition.
  • the compositions of the invention may further contain emulsifiers and / or surfactants.
  • any other emulsifiers and / or surfactants can be used.
  • Emulsifiers which can be used according to the invention in this sense are, for example, addition products of from 4 to 30 mol of ethylene oxide and / or from 0 to 5 mol of propylene oxide to linear or branched C 8 -C 22 fatty alcohols, C 12 -C 22 fatty acids and C 8 -C 15 alkylphenols, C 12 -C 22 fatty acid mono- and diesters of addition products of from 1 to 30 moles of ethylene oxide onto C 3 -C 6 -polyols, in particular of glycerol, ethylene oxide and polyglycerol addition products of methyl glucoside fatty acid esters, fatty acid alkanolamides and fatty acid glucamides, C 8 -C 22 alkyl mono- and oligoglycosides and their ethoxylated analogs, wherein degrees of oligomerization of 1, 1 to 5, in particular 1, 2 to 2.0, and glucose are preferred as the sugar component, mixtures of alkyl (oligo
  • Sterols are understood to mean a group of steroids which have a hydroxyl group at C atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are beta-sitosterol, stigmasterol, campesterol and ergosterol.
  • egg yolk or plant seeds eg., Soybean
  • fatty acid ester of sugars and sugar alcohols such as sorbitol, polyglycerols and polyglycerol, preferably Polyglyceryl-2-dipolyhydro- xystearat (commercial product Dehymuls ® PGPH) and polyglyceryl-3-diisostearate (commercial product Lameform ® TGI), linear and branched C 8 -C 30 fatty acids and their Na, K, ammonium, Ca, Mg and Zn salts.
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1 to 25% by weight, in particular 0.5 to 15% by weight, based on the total agent.
  • at least one ionic emulsifier selected from anionic, zwitterionic, ampholytic and cationic emulsifiers is contained.
  • Preferred anionic emulsifiers are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups, monoglyceride sulfates, alkyl and Alkenyletherphosphate and protein fatty acid condensates.
  • Zwitterionic emulsifiers carry in the molecule at least one quaternary ammonium group and at least one -COO " - or -SO 3 " group.
  • Particularly suitable zwitterionic emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, N-acylaminopropyl-N, N-dimethylammonium glycinates and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines in each case 8 to 18 C atoms in the alkyl or acyl group and the Kokosacylaminoethylhydroxyethylcarboxymethylglycinat.
  • Ampholytic emulsifiers contain, in addition to a C 8 -C 24 -alkyl or -acyl group, at least one free amino group and at least one -COOH or -SO 3 H group in the molecule and can form internal salts.
  • ampholytic emulsifiers are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxy- ethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group.
  • the ionic emulsifiers are contained in an amount of 0.01 to 5 wt .-%, preferably from 0.05 to 3 wt .-% and particularly preferably from 0.1 to 1 wt .-%, based on the total agent ,
  • compositions according to the invention may contain at least one protein hydrolyzate or its derivative.
  • Both vegetable and animal protein hydrolysates can be used according to the invention.
  • Animal protein hydrolysates are z.
  • Vegetable protein hydrolysates eg. Soy, wheat, almonds, peas, potato and rice protein hydrolysates.
  • amino acid mixtures obtained on the one hand and, on the other hand, individual amino acids and their physiologically tolerated salts can also be used.
  • inventively preferred amino acids include glycine, serine, threonine, cysteine, asparagine, glutamine, pyroglutamic acid, alanine, VaNn, leucine, isoleucine, proline, tryptophan, phenylalanine, methionine, aspartic acid, glutamic acid, lysine, arginine and histidine, and the zinc salts and Acid addition salts of said amino acids.
  • derivatives of protein hydrolysates, z In the form of their fatty acid condensation products. Cationized protein hydrolysates can also be used according to the invention, it being possible for the underlying protein hydrolyzate to originate from the animal, from the plant, from marine life forms or from biotechnologically obtained protein hydrolysates.
  • compositions according to the invention are the protein hydrolysates and their derivatives or the amino acids and their derivatives in amounts of up to 10 wt .-%, based on the total agent included. Amounts of 0.1 to 5 wt .-%, in particular 0.1 to 3 wt .-%, are particularly preferred.
  • compositions according to the invention may contain at least one mono-, oligo- or polysaccharide or derivatives thereof.
  • suitable monosaccharides are z.
  • glucose fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, man- nose, gulose, idose and talose, the deoxy sugars fucose and rhamnose and amino sugars such.
  • glucosamine or galactosamine Preferred are glucose, fructose, galactose, arabinose and fucose; Glucose is particularly preferred.
  • suitable oligosaccharides are composed of two to ten monosaccharide units, for.
  • sucrose, lactose or trehalose A particularly preferred oligosaccharide is sucrose.
  • honey which contains predominantly glucose and sucrose.
  • Polysaccharides which are suitable according to the invention are composed of more than ten monosaccharide units.
  • Preferred polysaccharides are the starches made from ⁇ -D-glucose units and starch degradation products such as amylose, amylopectin and dextrins. Particularly advantageous according to the invention are chemically and / or thermally modified starches, for.
  • Dextrans and their derivatives eg. B. dextran sulfate.
  • nonionic cellulose derivatives such as methylcellulose, hydroxypropylcellulose or hydroxyethylcellulose, as well as cationic cellulose derivatives, e.g. , The commercial products Celquat ® and Polymer JR ®, and preferably CEI quat ® H 100, Celquat L 200 and Polymer JR ® ® 400 (Polyquaternium-10) as well as Polyquaternium-24th
  • polysaccharides from fucose units e.g. B.
  • the commercial product Fucogel ® Particularly preferred are the polysaccharides composed of amino sugar units, in particular chitins and their deacetylated derivatives, the chitosans, and mucopolysaccharides.
  • the inventively preferred mucopolysaccharides include hyaluronic acid and its derivatives, e.g. As sodium hyaluronate or Dimethylsilanolhyaluronat, and chondroitin and its derivatives, for. B. chondroitin sulfate.
  • compositions according to the invention comprise at least one film-forming, emulsion-stabilizing, thickening or adhesive polymer selected from natural and synthetic polymers which may be cationic, anionic, amphoteric or nonionic. Cationic, anionic and nonionic polymers are preferred according to the invention.
  • Preferred anionic polymers which can support the action of the active ingredient used according to the invention comprise carboxylate and / or sulfonate groups and as monomers, for example, acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • anionic polymers contain, as the sole monomer or comonomer, 2-acrylamido-2-methylpropanesulfonic acid, it being possible for the sulfonic acid group to be wholly or partly in salt form.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with monomers containing sulfonic acid groups.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid groups are wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt present.
  • This copolymer can also be present in crosslinked form, with crosslinking agents preferably used being poly-olefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide.
  • crosslinking agents preferably used being poly-olefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide.
  • crosslinking agents preferably used being poly-olefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • the use of this compound has proven to be particularly advantageous in the context of the teaching of the invention.
  • anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example the commercial products Carbopol ®.
  • a particularly preferred anionic copolymer contains as monomer 80-98% of an unsaturated, optionally substituted C 3 . 6- carboxylic acid or its anhydride and to 2 - 20%, if desired, substituted acrylic acid esters of saturated Cio 30 carboxylic acids, wherein the copolymer can be crosslinked with the aforementioned crosslinking agents.
  • Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for.
  • Mowiol ® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidone z. B. under the trademark Luviskol ® (BASF) are sold.
  • the compositions of the invention may further contain at least one ⁇ -hydroxycarboxylic acid or ⁇ -ketocarboxylic acid or their ester, lactone or salt form.
  • Suitable ⁇ -hydroxycarboxylic acids or ⁇ -ketocarboxylic acids are selected from lactic acid, tartaric acid, citric acid, 2-hydroxybutanoic acid, 2,3-dihydroxypropanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxydecanoic acid, 2 Hydroxydodecanoic acid, 2-hydroxytetradecanoic acid, 2-hydroxyhexadecanoic acid, 2-hydroxyoctadecanoic acid, mandelic acid, 4-hydroxymandelic acid, malic acid, erythraric acid, threaric acid, glucaric acid, galactaric acid, mannaric acid, gularic acid, 2-hydroxy-2-methylsuccinic acid, gluconic acid, pyruvic acid , Glucuronic acid and galacturonic acid.
  • esters of said acids are selected from the methyl, ethyl, propyl, isopropyl, butyl, amyl, pentyl, hexyl, 2-ethylhexyl, octyl, decyl, dodecyl and hexadecyl esters.
  • the ⁇ -hydroxycarboxylic acids or ⁇ -ketocarboxylic acids or their derivatives are present in amounts of from 0.1 to 10% by weight, preferably 0.5 to 5% by weight, in each case based on the total composition.
  • compositions of the invention may contain other active ingredients, auxiliaries and additives, for.
  • vitamins, provitamins and vitamin precursors from groups A, C, E and F in particular 3,4-dide hydroretinol (vitamin A 2 ), ß-carotene (provitamin of vitamin A 1 ), ascorbic acid (vitamin C), and the palmitic acid esters, glucosides or phosphates of ascorbic acid, tocopherols, in particular ⁇ -tocopherol and its esters, for.
  • the acetate, the nicotinate, the phosphate and the succinate also vitamin F, which is understood as meaning essential fatty acids, especially linoleic acid, linolenic acid and arachidonic acid; an ester of retinol (vitamin A 1 ) with a C 2 - 8 carboxylic acid, especially retinyl acetate or retinyl palmitate; Vitamins, provitamins or vitamin precursors of the vitamin B group or derivatives thereof and derivatives of 2-furanone, in particular vitamin B 1 (thiamine), vitamin B 2 (riboflavin), vitamin B 3 (nicotinic acid and / or nicotinic acid amide), vitamin B 5 ( Pantothenic acid and / or panthenol), vitamin B 6 (pyridoxine, pyridoxamine and / or pyridoxal) and / or vitamin B 7 (biotin), allantoin, ceramides and pseudoceramides, triterpenes, in particular Tri
  • plant matter such as agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum or locust bean gum, natural and synthetic clays and phyllosilicates, z.
  • bentonite, hectorite, montmorillonite or Laponite ® fully synthetic hydrocolloids such.
  • polyvinyl alcohol and also Ca, Mg or Zn soaps of fatty acids, vegetable glycosides, structurants such as maleic acid and lactic acid, dimethyl isosorbide, alpha, beta and gamma cyclodextrins, especially for the stabilization of retinol, solvents, swelling and penetrating agents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerol and diethylene glycol, carbonates, bicarbonates, guanidines, ureas and primary, secondary and tertiary phosphates, perfume oils, pigments and dyes for dyeing the agent, substances for adjusting the pH, z.
  • structurants such as maleic acid and lactic acid, dimethyl isosorbide, alpha, beta and gamma cyclodextrins
  • solvents swelling and penetrating agents
  • swelling and penetrating agents such as ethanol
  • ⁇ - and ß-hydroxycarboxylic acids complexing agents such as EDTA, NTA, ß-Alanindiessigklad and phosphonic acids, opacifiers such as latex, styrene / PVP and styrene / acrylic amide copolymers, propellants such as propane-butane mixtures, N 2 O, Dimethyl ether, CO 2 and air, MMP-1-inhibiting substances, in particular selected from photolyase and / or T4 endonuclease V, propyl gallate, precocenes, 6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) - benzopyran and 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) -benzopyran, organic, mineral and / or modified mineral sunscreen filters, in particular UVA filters and / or UVB filters.
  • complexing agents such as EDTA, NTA, ß-Alanindiessigklad
  • Deodorant or antiperspirant sticks according to the invention may be in gelled form, on anhydrous wax base and based on W / O emulsions and O / W emulsions.
  • Gel sticks can be prepared on the basis of fatty acid soaps, dibenzylidene sorbitol, N-acyl amino acid amides, 12-hydroxystearic acid and other gelling agents.
  • Aerosol sprays, pump sprays, roll on applications and creams can be used as water in oil emulsion, oil in water emulsion, silicone oil in water emulsion, water in oil microemulsion, oil in water.
  • Microemulsion, silicone oil-in-water microemulsion, anhydrous suspension, alcoholic and hydroalcoholic solution, aqueous gel and as an oil All of the above compositions may be thickened, e.g. B. on the basis of fatty acid soaps, Dibenzylidensorbitol, N-Acylaminoklareamiden, 12-hydroxy stearic acid, carbomeric and carbopol type polyacrylates, polyacrylamides and polysaccharides, which may be chemically and / or physically modified, and based on fatty alcohols in combination with hardened triglycerides, especially in combination with hydrogenated castor oil (Cutina® HR).
  • the emulsions and microemulsions may be transparent, translucent or opaque.
  • Liquid and gelatin dosage forms of the compositions of the invention may contain thickening agents, e.g. As cellulose ethers such as hydroxypropyl cellulose, hydroxy ethyl cellulose and methyl hydroxypropyl cellulose, thickening polymers based on polyacrylates, which may be crosslinked, if desired, for.
  • thickening agents e.g. As cellulose ethers such as hydroxypropyl cellulose, hydroxy ethyl cellulose and methyl hydroxypropyl cellulose, thickening polymers based on polyacrylates, which may be crosslinked, if desired, for.
  • compositions of the invention may contain other cosmetically and dermatologically active substances, such as anti-inflammatory substances, solids selected from silicic acids, eg. As Aerosil ® types, silica gels, silica, clays, z. B. bentonite or kaolin, magnesium aluminum silicates, z. Talc, boron nitride, titanium dioxide, which may if desired be coated, optionally modified starches and starch derivatives, cellulose powders and polymer powders, furthermore plant extracts, protein hydrolysates, vitamins, perfume oils, sebostatics, anti-acne agents and keratolytics.
  • solids selected from silicic acids, eg. As Aerosil ® types, silica gels, silica, clays, z. B. bentonite or kaolin, magnesium aluminum silicates, z. Talc, boron nitride, titanium dioxide, which may if desired be coated, optionally modified starches and starch derivatives
  • compositions according to the invention can, insofar as they are in liquid form, be applied to flexible and absorbent carriers and be offered as deodorant or antiperspirant wipes or sponges.
  • a flexible and absorbent carrier in the context of the invention z.
  • Textile fibers may be both natural fibers such as cellulose (cotton, linen), silk, wool, regenerated cellulose (viscose, rayon), cellulose derivatives and synthetic fibers such as e.g. Polyester, polyacrylonitrile, polyamide or polyolefin fibers or mixtures of such fibers woven or unwoven be used. These fibers may be made into absorbent cotton pads, nonwovens or woven or knitted fabrics.
  • the substrate may have one, two, three and more than three layers, wherein the individual layers may consist of the same or different materials.
  • Each substrate layer may have a homogeneous or an inhomogeneous structure with, for example, different zones of different densities.
  • Absorbent for the purposes of the invention are those support substrates which, at 20 ° C., can bind at least 10% by weight, based on the dry weight, of water adsorptively or capillary.
  • Preferably, however, are those carriers which can bind at least 100 wt .-% water adsorptive and capillary.
  • the equipment of the carrier substrates is carried out in such a way that the absorbent, flexible carrier substrates, preferably from textile fibers, collagen or polymeric foams treated with the compositions according to the invention and optionally dried.
  • the treatment (equipment) of the carrier substrates by any method, for. B. by spraying, dipping and squeezing, soaking or simply by injecting the composition of the invention into the carrier substrates.
  • the dosage form as an aerosol
  • the cosmetic composition containing a propellant, preferably selected from propane, butane, isobutane, pentane, isopentane, dimethyl ether, fluorohydrocarbons and chlorofluorocarbons.
  • a compressed propellant such as air, nitrogen or carbon dioxide can be used.
  • mixtures of the stated blowing agents can be used.
  • the compositions according to the invention are in the form of a liquid or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsifier.
  • sion emulsion, microemulsion, PIT emulsion or Pickering emulsion, a hydrogel, a lipogel, a mono- or multiphase solution, a foam, a powder or a mixture with at least one polymer suitable as a medical adhesive.
  • the agents may also be presented in anhydrous form, such as an oil or a balm.
  • the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • the agents are present as microemulsions.
  • microemulsions are understood as meaning, in addition to the thermodynamically stable microemulsions, also the so-called "PIT" emulsions
  • PIT phase inversion temperature
  • these emulsions are systems containing the three components water, oil and emulsifier, which are oil-in at room temperature When these systems are heated, microemulsions are formed in a certain temperature range (referred to as phase inversion temperature or "PIT"), which on further heating convert to water-in-oil (W / O) emulsions O / W emulsions are again formed, but are also present at room temperature as microemulsions or as very finely divided emulsions having an average particle diameter of less than 400 nm and in particular of approximately 100 to 300 nm. Emulsions having an average particle diameter of about 200 nm may be preferred.
  • compositions for oral care which are to be understood as oral, dental and / or dental prosthesis care compositions containing at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's wort Extract and extracts containing Hydroxyzimt yarnren and / or their derivatives contain.
  • the oral, dental and / or dental prosthesis care agents according to the invention can be present, for example, as a mouthwash, gel, liquid toothbrush lotion, stiff toothpaste, chewing gum, denture cleaner or denture adhesive cream.
  • a suitable carrier for example, a suitable carrier.
  • pulverulent preparations or aqueous-alcoholic solutions serve as mouthwash 0 to 15 wt .-% ethanol, 1 to 1, 5 wt .-% flavor oils and 0.01 to 0.5 wt .-% sweeteners or as mouthwash concentrates From 15 to 60% by weight of ethanol, from 0.05 to 5% by weight of flavoring oils, from 0.1 to 3% by weight of sweeteners and, if appropriate, further auxiliaries may be included and diluted with water before use.
  • the concentration of the components must be so high that, after dilution, the specified lower concentration limits are not undershot during use.
  • gels and more or less flowable pastes which are expressed from flexible plastic containers or tubes and applied to the teeth with the aid of a toothbrush, can also serve as the carrier.
  • Such products contain higher levels of humectants and binders or consistency regulators and polishing components.
  • aromatic oils, sweeteners and water are also contained in these preparations.
  • glycerol, sorbitol, xylitol, propylene glycols, polyethylene glycols or mixtures of these polyols, in particular those polyethyleneglycols having molecular weights of from 200 to 800 (from 400 to 2000), may be present as humectants.
  • sorbitol is contained as humectant in an amount of 25-40 wt .-%.
  • condensed phosphates may be present in the form of their alkali metal salts, preferably in the form of their sodium or potassium salts.
  • the aqueous solutions of these phosphates react alkaline due to hydrolytic effects.
  • the pH of the oral, dental and / or dental care of the present invention centering care I to the preferred values of 7.5 to 9 set.
  • the condensed phosphate is a sodium or potassium tripolyphosphate in an amount of 5-10% by weight of the composition.
  • a preferred active ingredient is a caries-inhibiting fluorine compound, preferably from the group of fluorides or monofluorophosphates in an amount of 0.1 to 0.5 wt .-% fluorine.
  • Suitable fluorine compounds are, for example, sodium monofluorophosphate (Na 2 PO 3 F), potassium monofluorophosphate, sodium or potassium fluoride, tin fluoride or the fluoride of an organic amino compound.
  • binders and consistency regulators are natural and synthetic water-soluble polymers such as carrageenan, tragacanth, guar, starch and their nonionic derivatives such as, for example, hydroxypropylguar, hydroxyethyl starch, cellulose ethers such as hydroxyethylcellulose or methylhydroxypropylcellulose.
  • agar-agar, xanthan gum, pectins water-soluble carboxyvinyl polymers (for example Carbopol ® types), polyvinyl alcohol, polyvinyl pyrrolidone, high molecular weight polyethylene glycols (molecular weight 10 3 to 10 6 D).
  • Further substances which are suitable for viscosity control are phyllosilicates, such as, for example, montmorillonite clays, colloidal thickening silicas, for example airgel silicic acid or pyrogenic silicic acids.
  • polishing components may all heretofore known polishing agent, but preferably precipitated and gel silicas, aluminum hydroxide, aluminum silicate, alumina, alumina trihydrate, insoluble sodium metaphosphate, calcium pyrophosphate, calcium hydrogen phosphate, dicalcium phosphate, chalk, hydroxyapatite, hydrotalcites, talc, magnesium aluminum silicate (Veegum ®), calcium sulfate, Magnesium carbonate, magnesium oxide, sodium aluminum silicates, such as zeolite A or organic polymers, such as polymethacrylate, are used.
  • the polishing agents are preferably used in smaller amounts of eg 1-10% by weight.
  • Aromatic oils are all natural and synthetic flavors which are customary for oral, dental and / or dental care products. Natural flavors can be used both in the form of the essential oils isolated from the drugs and those isolated from individual components become.
  • at least one aromatic oil from the group of peppermint oil, spearmint oil, aniseed oil, caraway oil, eucalyptus oil, fennel oil, cinnamon oil, geranium oil, sage oil, thyme oil, marjoram oil, basil oil, citrus oil, Gaultheria oil or one or more synthetic components of these oils isolated therefrom should be included.
  • oils mentioned are, for example, menthol, carvone, anethole, cineole, eugenol, cinnamaldehyde, geraniol, citronellol, linalool, salvos, thymol, terpinene, terpinol, methylchavicol and methyl salicylate.
  • suitable flavors are, for example, menthyl acetate, vanillin, ionone, linalyl acetate, rhodinol and piperitone.
  • Suitable sweeteners are either natural sugars such as sucrose, maltose, lactose and fructose or synthetic sweeteners such as saccharin sodium salt, sodium cyclamate or aspartame.
  • alkyl and / or alkenyl (oligo) glycosides can be used as surfactants. Their preparation and use as surfactants are described, for example, in US-A-3,839,318, US-A-3,707,535, US-A-3,547,828, DE-A-19 43 689, DE-A-20 36 472 and US Pat DE-A-30 01 064 and EP-A-77 167 known.
  • the degree of oligomerization is a statistical mean, which is based on a homolog distribution typical for such technical products.
  • alkyl and / or alkenyl (oligo) glycoside As alkyl and / or alkenyl (oligo) glycoside, an alkyl and / or alkenyl (oligo) glucoside of the formula RO (C 6 H 10 O) x -H in which R is an alkyl radical and is preferably suitable / or alkenyl group having 8 to 14 carbon atoms and x has an average of 1 to 4. Particular preference is given to alkyl oligoglucosides based on hydrogenated C 12/14 coconut alcohol having a DP of from 1 to 3.
  • the alkyl and / or alkenyl glycoside surfactant can be used very sparingly, amounts of from 0.005 to 1% by weight already being used. % are sufficient.
  • nonionic, ampholytic and cationic surfactants may also be present, for example: fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, monoglyceride ether sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides, fatty acid glutamates, ether carboxylic acids, Fatty acid glucamides, alkylamido-betaines and / or protein fatty acid condensates, the latter preferably based on wheat proteins.
  • a non-ionic solubilizer from the group of surface-active compounds may be required.
  • Particularly suitable for this purpose are, for example, ethoxylated fatty acid glycerides, ethoxylated fatty acid sorbitan partial esters or fatty acid partial esters of glycerol or sorbitan ethoxylates.
  • Solubilizers from the group of ethoxylated Fettklareglyceride include especially addition products of 20 to 60 moles of ethylene oxide with mono- and diglycerides of linear fatty acids having 12 to 18 carbon atoms or triglycerides of hydroxy fatty acids such as oxystearic acid or ricinoleic acid.
  • solubilizers are ethoxylated fatty acid sorbitan partial esters; these are preferably addition products of 20 to 60 moles of ethylene oxide with sorbitan monoesters and sorbitan diesters of fatty acids with 12 to 18 carbon atoms.
  • fatty acid partial esters of glycerol or sorbitan ethoxylates are preferably mono- and diesters of C 2 -C 18 -fatty acids and adducts of 20 to 60 moles of ethylene oxide with 1 mole of glycerol or with 1 mole of sorbitol.
  • the oral, dental and / or dental prosthesis care agents according to the invention preferably contain as solubilizer for optionally contained aroma oils addition products of 20 to 60 moles of ethylene oxide to hardened or unhardened castor oil (ie to Oxystearinklare- or ricinoleic acid triglyceride), glycerol mono- and / or distearate or sorbitan mono- and / or distearate.
  • aroma oils addition products of 20 to 60 moles of ethylene oxide to hardened or unhardened castor oil (ie to Oxystearinklare- or ricinoleic acid triglyceride), glycerol mono- and / or distearate or sorbitan mono- and / or distearate.
  • pigments for example titanium dioxide, and / or dyes
  • pH regulators and buffer substances such as sodium bicarbonate, sodium citrate, sodium benzoate, citric acid, phosphoric acid or acidic salts, eg NaH 2 PO 4
  • wound healing and anti-inflammatory substances such as allantoin, urea, panthenol, azulene or camomile extract, other active against tartar substances such as organophosphonates, eg Hydroxyethandiphosphonate or Azacycloheptandiphosphonat, preservatives such as sorbic acid salts, p-hydroxybenzoic acid esters , Plaque inhibitors such as hexachlorophene, chlorhexidine, hexetidine, triclosan, bromochlorophene, phenylsalicylic acid esters.
  • the composition is a mouthwash, a mouthwash, a denture cleanser or a denture adhesive.
  • per-compounds such as, for example, peroxoborate, peroxomonosulfate or percarbonate are additionally suitable for prosthesis cleaners according to the invention, in particular prosthesis cleansing tablets and powders. They have the advantage that, in addition to the bleaching effect, they also have a deodorizing and / or disinfecting effect.
  • the use of such per-compounds in prosthesis cleaners is between 0.01 and 10 wt .-%, in particular between 0.5 and 5 wt .-%.
  • ingredients are also enzymes, e.g. Proteases and carbohydrase, suitable for the breakdown of proteins and carbohydrates.
  • the pH can be between pH 4 and pH 12, in particular between pH 5 and pH 1 1.
  • auxiliaries are necessary in addition, such.
  • agents which cause a bubbling effect such as CO 2 releasing substances such as sodium bicarbonate, fillers, eg sodium sulfate or dextrose, lubricants, for example magnesium stearate, flow control agents such as colloidal silica and granulating agents, such as the already mentioned high molecular weight polyethylene glycols or polyvinylpyrrolidone ,
  • Denture adhesives can be offered as powders, creams, foils or liquids and support the adhesion of the prostheses.
  • natural and synthetic swelling substances are suitable.
  • natural swelling agents besides alginates, plant gums, such as e.g. Gum arabic, tragacanth and karaya gum as well as natural rubber.
  • alginates and synthetic bulking agents e.g. Sodium carboxymethyl cellulose, high molecular weight ethylene oxide copolymers, salts of poly (vinyl ether-co-maleic acid) and polyacrylamides.
  • hydrophobic bases in particular hydrocarbons, such as white Vaseline (DAB) or paraffin oil.
  • Camellia sinensis extract (1%) 2 ⁇ 0 Cosmetochem, CH-Steinhausen
  • Antiperspirant sticks according to the invention based on an oil-in-water emulsion (amounts in% by weight)
  • the emulsion according to Formulation Example 8 had the first day after the preparation has a viscosity of 2200 mPas, measured with a Brookfield viscometer, spindle RV 4, 20 s "1 without Helipath, at 20 0 C ambient temperature and 20 0 C sample temperature; it was filled into a roll-on applicator.
  • the emulsion according to Formulation Example 9 had the first day after the preparation has a viscosity of 1700 mPas, measured with a Brookfield viscometer, spindle RV 4, 20 s "1 without Helipath, at 20 0 C ambient temperature and 20 0 C sample temperature; it was filled into a roll-on applicator.
  • Sprayable, translucent antiperspirant microemulsions (in% by weight)
  • Soap-containing pens (in% by weight)
  • Anhydrous deodorant spray (in% by weight)
  • Antiperspirant wipes (Formulation Examples No. 17.1 - 17.4)
  • a single-layer substrate of 100% viscose with a weight per unit area of 50 g / m 2 was used , each with 75 g of the example emulsions
  • Example Composition 19.1 contains an antiperspirant emulsion according to the invention with 9.9% by weight aluminum chlorohydrate, based on the weight of the propellant-free emulsion. With a spray rate of 0.35 g / s, 0.035 g of the antiperspirant active ingredient aluminum chlorohydrate are sprayed onto the skin surface every second.
  • Example Composition 19.2 contains an antiperspirant emulsion according to the invention with 17.49% by weight aluminum chlorohydrate, based on the weight of the propellant-free emulsion. At a spray rate of 0.2 g / s, 0.035 g of the antiperspirant active ingredient aluminum chlorohydrate is sprayed onto the skin surface every second.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to the use of hydroxycinnamic acids and/or derivatives thereof and of plant extracts selected from meadowsweet extract, St. John's wort extract, and extracts that contain hydroxycinnamic acids and/or derivatives thereof, for inhibiting enzymes, particularly the cystathionine-beta-lyases, and/or for preventing or treating body odor, particularly in the axillary area, and to cosmetic and pharmaceutical preparations, particularly deodorants and antiperspirants, that contain said active ingredients.

Description

Verwendung von Hydroxyzimtsäuren und ihren Derivaten und/oder von Pflanzenextrakten zur Use of hydroxycinnamic acids and their derivatives and / or plant extracts
Behandlung von KörpergeruchTreatment of body odor
Die vorliegende Erfindung betrifft die Verwendung von Hydroxyzimtsäuren und/oder ihren Derivaten sowie von Pflanzenextrakten ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, zur Inhibierung von Enzymen, insbesondere der Cystathionin-Beta-Lyase, und/oder zur Verhinderung oder Behandlung von Körpergeruch, insbesondere im axillaren Bereich, sowie kosmetische und pharmazeutische Zubereitungen, insbesondere Deodorantien und Antitranspirantien, die diese Wirkstoffe enthalten. Es gilt mittlerweile als erwiesen, dass Körpergeruch in erster Linie durch den Abbau von Schweißbestandteilen durch Bakterien der Hautflora, insbesondere im axillaren Bereich, entsteht. Neben Parfüms zur Überdeckung von Körpergeruch werden daher in Deodorantien zur Vermeidung von Körpergeruch bislang schwerpunktmäßig unselektiv wirksame Biozide zur Abtötung der Bakterien im axillaren Bereich eingesetzt. Die Verwendung von unselektiv antibakteriell wirksamen Substanzen hat allerdings den Nachteil, dass auch Bakterien, die keinen Geruch verursachen, gehemmt oder abgetötet werden. Die Schutzfunktion für die Haut, die von diesen Bakterien ausgeht, wird durch die Anwendung unselektiv antibakterieller Wirkstoffe somit zerstört. Zusätzlich ist bekannt, dass viele antibakterielle Wirkstoffe schlecht gegen Körpergeruch wirken. Daraus lässt sich schließen, dass durch die eingesetzten antibakteriellen Wirkstoffe die geruchsbildenden Bakterien nicht oder nur ungenügend gehemmt werden bzw. dass möglicherweise Zusammenhänge in der bakteriellen Lebensgemeinschaft existieren (z.B. bislang unbekannte geruchsproduzierende Arten), deren Auswirkungen auf die Bildung von Körpergeruch von den eingesetzten Substanzen nicht erfasst werden.The present invention relates to the use of hydroxycinnamic acids and / or their derivatives and of plant extracts selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof for inhibiting enzymes, in particular cystathionine-beta-lyase. and / or for the prevention or treatment of body odor, in particular in the axillary area, as well as cosmetic and pharmaceutical preparations, in particular deodorants and antiperspirants, which contain these active substances. In the meantime, it has been proven that body odor primarily results from the breakdown of sweat constituents by bacteria of the skin flora, especially in the axillary area. In addition to perfumes to cover body odor so far mainly in deodorants to prevent body odor unselective effective biocides used to kill the bacteria in the axillary area. However, the use of unselective antibacterial substances has the disadvantage that even bacteria that cause no odor, are inhibited or killed. The protective function of the skin emanating from these bacteria is thus destroyed by the use of unselective antibacterial agents. In addition, it is known that many antibacterial agents have a bad effect against body odor. From this it can be concluded that the odor-producing bacteria are not or only insufficiently inhibited by the antibacterial agents used or that there may be connections in the bacterial community (eg hitherto unknown odor-producing species), their effects on the formation of body odor from the substances used be recorded.
Ein ähnliches Problem wie für Körpergeruch besteht auch für Mundgeruch. Auch hier werden die Ausgangssubstanzen bakteriell in übelriechende Abbauprodukte umgewandelt. Es besteht daher weiterhin Bedarf, Mittel zur Bekämpfung von Körpergeruch, insbesondere für den axillaren und oralen Bereich, zur Verfügung zu haben, insbesondere solche, die besser gegenüber Körpergeruch und/oder Mundgeruch wirksam sind, als die bislang bekannten Mittel, vorzugsweise ohne einen unselektiv antibakteriellen Effekt am Applikationsort zu bewirken. In diesem Zusammenhang ist bekannt, dass stark übelriechende Komponenten des menschlichen Körpergeruchs und Mundgeruchs insbesondere durch enzymatische Reaktion freigesetzte flüchtige Schwefelverbindungen, sogenannte „volatile sulfur Compounds" (VSC) darstellen. Schwefelhaltige Verbindungen kommen als wasserlösliche Aminosäurekonjugate mit dem Schweiß auf die menschliche Haut. Dort werden sie von Hautbakterien (v.a. von Staphylokokken und Corynebakte- rien) durch enzymatische Reaktion freigesetzt. Ein Enzym, das bei der Freisetzung von VSCs eine besondere Rolle spielt, ist die Cystathionin- Beta-Lyase. Dieses Enzym spaltet VSCs von den Aminosäuren ab und ist somit eine wichtige Ursache bei der Entstehung von Körpergeruch (siehe etwa Natsch et al. (2004) Chemistry and Biodiversity 1 , 1058-1072; Troccaz et al. (2004) Chemistry and Biodiversity 1 , 1022-1035; Starkenmann et al. (2005) Chemistry and Biodiversity 2, 705-716).A similar problem as for body odor is also for bad breath. Again, the starting substances are bacterially converted into malodorous degradation products. There is therefore still a need to have available agents for controlling body odor, in particular for the axillary and oral area, in particular those which are more effective against body odor and / or bad breath than the previously known agents, preferably without an unselective antibacterial Effect at the site of application. In this context, it is known that highly malodorous components of human body odor and halitosis are volatile sulfur compounds released by enzymatic reaction ("VSC") Sulfur-containing compounds, as water-soluble amino acid conjugates, sweat onto human skin they are released from skin bacteria (especially staphylococci and corynebacteria) by enzymatic reaction. One enzyme that plays a key role in the release of VSCs is cystathionine beta-lyase. This enzyme cleaves VSCs from the amino acids and is thus an important cause of body odor formation (see, for example, Natsch et al., (2004) Chemistry and Biodiversity 1, 1058-1072, Troccaz et al., (2004) Chemistry and Biodiversity 1, 1022-1035; Starkenmann et al. (2005) Chemistry and Biodiversity 2, 705-716).
Zum Auffinden von Wirkstoffen zur Verhinderung von Körpergeruch wurde in WO 2006/079934 vorgeschlagen, nach Substanzen zu suchen, die die Bildung von VSC ausgehend von deren Vorläufern in Anwesenheit der Cystathionin-Beta-Lyase inhibieren. Als solche Substanzen werden in diesem Dokument insbesondere Moleküle genannt, die den Vorläufern der VSC strukturell ähneln, so dass der Wirkmechanismus dieser Substanzen vermutlich in einer kompetitiven Blockierung des aktiven Zentrums der Cystathionin-Beta-Lyase liegt.In order to find active ingredients for the prevention of body odor, it was proposed in WO 2006/079934 to search for substances which inhibit the formation of VSC starting from their precursors in the presence of cystathionine-beta-lyase. As such substances, in particular, molecules are mentioned in this document which are structurally similar to the precursors of the VSC, so that the mechanism of action of these substances presumably lies in a competitive blocking of the active center of cystathionine-beta-lyase.
Ein Vorteil bei dem Einsatz von Substanzen, die gezielt die Enzymaktivität der Cystathionin-Beta- Lyase inhibieren, besteht darin, dass eine gezieltere Bekämpfung der Geruchsursache erfolgen kann und vorzugsweise weiterhin auf den Einsatz antibakteriell wirksamer Substanzen gegebenenfalls weitgehend verzichtet werden oder deren Einsatz zumindest eingeschränkt werden kann.An advantage of the use of substances that specifically inhibit the enzyme activity of cystathionine beta-lyase, is that a more targeted control of the cause of the odor can occur and preferably continue to be largely dispensed with the use of antibacterial active substances, or at least limited their use can.
Besondere Aufgabe der vorliegenden Erfindung war es daher, nach weiteren Substanzen zu suchen, die gezielt die Aktivität der Cystathionin-Beta-Lyase inhibieren und somit vielversprechende D eo- Wirkstoffe darstellen könnten.It was therefore a particular object of the present invention to search for further substances which specifically inhibit the activity of cystathionine-beta-lyase and thus could represent promising dioecolic active substances.
Als Enzym zum Nachweis der inhibitorischen Eigenschaften eignet sich beispielsweise die Cysta- thionin-beta-Lyase aus Staphylococcus. Als Substrat für die Cystathionin-beta-Lyase kann beispielsweise Benzylcystein verwendet werden. Bei der enzymatischen Umsetzung des Benzylcys- teins wird Cystein freigesetzt, das anschießend mit Hilfe von Nachweisreagenzien detektiert werden kann. So bildet etwa Monobromobiman mit Cystein einen fluoreszierenden Komplex aus, der spektrometrisch nachgewiesen werden kann. Durch Inhibitoren wird die Aktivität der Cystathionin-beta-Lyase herabgesetzt und dadurch auch die Menge an nachweisbarem freigesetzten Cystein.As an enzyme for the detection of the inhibitory properties, for example, the cysta- thionine beta-lyase from Staphylococcus is. For example, benzyl cysteine can be used as a substrate for cystathionine beta-lyase. The enzymatic conversion of the benzylic cysteine liberates cysteine, which can subsequently be detected with the aid of detection reagents. For example, monobromobimane forms a fluorescent complex with cysteine, which can be detected spectrometrically. Inhibitors reduce the activity of cystathionine beta-lyase and thereby also the amount of detectable released cysteine.
Überraschenderweise wurde nun gefunden, dass durch Hydroxyzimtsäuren, Derivate von Hydroxy- zimtsäuren sowie durch Pflanzenextrakte, insbesondere durch Mädesüß-Extrakt und Johanniskraut-Extrakt sowie solchen Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, eine sehr wirksame Inhibierung der Cystathionin-Beta-Lyase erreicht werden kann.Surprisingly, it has now been found that hydroxycinnamic acids, derivatives of hydroxycinnamic acids and also plant extracts, in particular meadowsweet extract and St. John's Wort extract, and also extracts which contain hydroxycinnamic acids and / or their derivatives, very effectively inhibit cystathionine-beta-lyase can be achieved.
Ein erster Gegenstand der vorliegenden Erfindung ist daher die Verwendung von mindestens einer Hydroxyzimtsäure und/oder einem Derivat davon und/oder mindestens einem Pflanzenextrakt, ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, zur Inhibierung eines Enzyms, wobei es sich bei dem Enzym vorzugsweise um eine Cystathionin-Beta-Lyase handelt und wobei die Verwendung vorzugsweise in einem kosmetischen Mittel erfolgt. Gegenstand der vorliegenden Erfindung ist daher weiterhin die Verwendung von mindestens einer Hydroxyzimtsäure und/oder einem Derivat davon und/oder mindestens einem Pflanzenextrakt ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, zur Verhinderung oder Behandlung von Körpergeruch, insbesondere im axillaren oder oralen Bereich, wobei die Verwendung vorzugsweise in einem kosmetischen Mittel erfolgt.A first subject of the present invention is therefore the use of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof for inhibition an enzyme, wherein the enzyme is preferably a cystathionine beta-lyase, and preferably used in a cosmetic agent. The present invention therefore furthermore relates to the use of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof for the purpose of prevention or treatment body odor, especially in the axillary or oral area, the use preferably being in a cosmetic agent.
Gegenstand der vorliegenden Erfindung sind weiterhin kosmetische oder pharmazeutische Zusammensetzungen zur Behandlung oder Verhinderung von Körpergeruch oder Mundgeruch enthaltend mindestens eine Hydroxyzimtsäure und/oder ein Derivat davon und/oder mindestens einen Pflanzenextrakt, ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten.The present invention furthermore relates to cosmetic or pharmaceutical compositions for the treatment or prevention of body odor or halitosis containing at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts, the hydroxycinnamic acids and / or their derivatives.
Gegenstand der vorliegenden Erfindung ist daher weiterhin auch die Verwendung von mindestens einer Hydroxyzimtsäure und/oder einem Derivat davon und/oder mindestens einem Pflanzenextrakt ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, zur Herstellung einer kosmetischen oder pharmazeutischen Zusammensetzung zur Behandlung oder Verhinderung von Körpergeruch, insbesondere im axillaren oder oralen Bereich.The present invention therefore further provides for the use of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or their derivatives for the production of a cosmetic or pharmaceutical composition for the treatment or prevention of body odor, in particular in the axillary or oral area.
Bei Hydroxyzimtsäuren handelt es sich erfindungsgemäß um Verbindungen der allgemeinen Formel (I)Hydroxy cinnamic acids are according to the invention compounds of the general formula (I)
Figure imgf000004_0001
wobei R1 und R2 unabhängig voneinander ausgewählt sind aus Wasserstoff, C-|.6-Alkyl, Hydroxy und C-ι-6-Alkoxy.
Figure imgf000004_0001
wherein R1 and R2 are independently selected from hydrogen, C- |. 6- alkyl, hydroxy and C-ι- 6- alkoxy.
In einer erfindungsgemäß bevorzugten Ausführungsform handelt es sich bei der Hydroxyzimtsäure um Kaffeesäure (R1 = H, R2 = OH), Cumarsäure (R1 = H, R2 = H), Ferulasäure (R1 = OCH3, R2 = H) oder Sinapinsäure (R1 = OCH3, R2 = OCH3), wobei Kaffeesäure besonders bevorzugt ist. Bei dem Derivat der Hydroxyzimtsäure handelt es sich in einer bevorzugten Ausführungsform um einen Ester der Hydroxyzimtsäure mit einem Alkohol, wobei es sich bei dem Alkohol in einer bevorzugten Ausführungsform um ein Polyhydroxyverbindung handelt. Weiterhin handelt es sich in einer bevorzugten Ausführungsform bei der Polyhydroxyverbindung um die Chinasäure. Bevorzugt ist der Ester der Hydroxyzimtsäure ausgewählt aus Chlorogensäure (5-0-Kaffeoylchinasäure, (1 S)-3ß-(3,4-Dihydroxycinnamoyloxy)-1a,4a,5a-trihydroxycyclohexancarbonsäure) und einer Di-Kaffeoylchinasäure, insbesondere aus 3,5-Di-O-Kaffeoylchinasäure.In a preferred embodiment according to the invention, the hydroxycinnamic acid is caffeic acid (R 1 = H, R 2 = OH), coumaric acid (R 1 = H, R 2 = H), ferulic acid (R 1 = OCH 3 , R 2 = H) or sinapinic acid (R 1 = OCH 3 , R 2 = OCH 3 ), with caffeic acid being particularly preferred. In a preferred embodiment, the derivative of hydroxycinnamic acid is an ester of hydroxycinnamic acid with an alcohol, wherein in a preferred embodiment the alcohol is a polyhydroxy compound. Furthermore, in a preferred embodiment, the polyhydroxy compound is the quinic acid. Preferably, the ester of hydroxycinnamic acid is selected from chlorogenic acid (5-0-caffeoylquinic acid, (1S) -3β- (3,4-dihydroxycinnamoyloxy) -1a, 4a, 5a-trihydroxycyclohexanecarboxylic acid) and a di-caffeoylquinic acid, especially from 3,5 di-O-caffeoylquinic.
Bei dem Derivat der Hydroxyzimtsäure kann es sich weiterhin auch um eine Hydroxyzimtsäure oder einen Ester der Hydroxyzimtsäure mit einem Alkohol handeln, dadurch gekennzeichnet, dass die Verbindung ein- oder mehrfach, vorzugsweise ein-, zwei oder dreifach, substituiert ist, vorzugsweise durch Substituenten ausgewählt aus der Gruppe bestehend aus C-|.6-Alkyl, Hydroxy, C-^6- Alkoxy, Carboxy und Halogen, insbesondere Fluor, Chlor oder Brom.The derivative of hydroxycinnamic acid may furthermore be a hydroxycinnamic acid or an ester of hydroxycinnamic acid with an alcohol, characterized in that the compound is monosubstituted or polysubstituted, preferably monosubstituted, disubstituted or trisubstituted, preferably by substituents selected from the group consisting of C 1. 6 alkyl, hydroxy, C ^ 6 - alkoxy, carboxy and halogen, especially fluorine, chlorine or bromine.
Bei dem erfindungsgemäß einzusetzenden Pflanzenextrakt, der eine Hydroxyzimtsäure oder ein Derivat davon enthält, handelt es sich in einer bevorzugten Ausführungsform um einen Pflanzenextrakt, der Kaffeesäure enthält. Bei dem Kaffeesäure enthaltenden Extrakt kann es sich hierbei insbesondere um einen Extrakt aus Ipomoea purga, insbesondere aus den Wurzelknollen von Ipomoea purga, Pyrus communis (Birne), insbesondere aus den Früchten von Pyrus communis, Pyrus malus (Apfel), insbesondere aus den Früchten von Pyrus malus, Ocimum basilicum (Basilikum), insbesondere aus den Blättern von Ocimum basilicum, Thymus vulgaris (Thymian), insbesondere aus den Blättern von Thymus vulgaris, Teucrium scorodonia, insbesondere aus den Blättern von Teucrium scorodonia, Verbena officinalis, insbesondere aus den Blättern von Verbena officinalis, Artemisia dracunculus, insbesondere aus den Sprossen von Artemisia dracunculus, Thymus serpyllum, insbesondere aus dem Kraut von Thymus serpyllum, Origanum vulgäre, insbesondere aus dem Kraut von Origanum vulgäre, Melissa officinalis, insbesondere aus dem Kraut von Melissa officinalis, Camellia sinensis, insbesondere aus den Blättern von Camellia sinensis, Gentiana lutea, insbesondere aus den Wurzeln von Gentiana lutea, Stachys officinalis, insbesondere aus dem Kraut von Stachys officinalis, oder Arnica montana, insbesondere aus den Blüten von Arnica montana, handeln.In the plant extract to be used according to the invention, which contains a hydroxycinnamic acid or a derivative thereof, in a preferred embodiment it is a plant extract which contains caffeic acid. The extract containing caffeic acid may in particular be an extract of Ipomoea purga, in particular of the tubers of Ipomoea purga, Pyrus communis (pear), in particular of the fruits of Pyrus communis, Pyrus malus (apple), in particular of the fruits of Pyrus malus, Ocimum basilicum (basil), in particular from the leaves of Ocimum basilicum, Thymus vulgaris (thyme), in particular from the leaves of Thymus vulgaris, Teucrium scorodonia, in particular from the leaves of Teucrium scorodonia, Verbena officinalis, in particular from the leaves of Verbena officinalis, Artemisia dracunculus, in particular from the sprouts of Artemisia dracunculus, Thymus serpyllum, in particular from the herb of Thymus serpyllum, Origanum vulgare, in particular from the herb of Origanum vulgare, Melissa officinalis, in particular from the herb of Melissa officinalis, Camellia sinensis, in particular from the leaves of Camellia sinensis, Gentiana lut ea, in particular from the roots of Gentiana lutea, Stachys officinalis, in particular from the herb of Stachys officinalis, or Arnica montana, in particular from the flowers of Arnica montana act.
In einer weiteren erfindungsgemäß bevorzugten Ausführungsform handelt es sich bei dem erfindungsgemäß einzusetzenden Pflanzenextrakt, der eine Hydroxyzimtsäure oder ein Derivat davon enthält, um einen Pflanzenextrakt, der Chlorogensäure enthält. Bei dem Chlorogensäure enthaltenden Extrakt kann es sich hierbei insbesondere um einen Extrakt aus Kaffee (Coffea arabica), insbesondere aus dem Samen von Coffea arabica, aus Sonnenblume (Helianthus annuus), insbesondere aus dem Samen von Helianthus annuus, aus Damaszener-Rose (Rosa damascena), insbesondere aus den Pollen und Sporen von Rosa damascena, aus Blaubeere (Vaccinium corymbosum), insbesondere aus den Früchten von Vaccinium corymbosum, aus Pyrus malus (Apfel), insbesondere aus den Früchten von Pyrus malus, aus Melissa officinalis, insbesondere aus dem Kraut von Melissa officinalis, aus Camellia sinensis, insbesondere aus den Blättern von Camellia sinensis, aus japanischem Geißblatt (Lonicera japonica), insbesondere aus den Blüten von Lonicera japonica, oder aus dem Gutta-Percha-Baum (Eucommia ulmoides), insbesondere aus den Blättern von Eucommia ulmoides, handeln.In a further embodiment preferred according to the invention, the plant extract to be used according to the invention, which contains a hydroxycinnamic acid or a derivative thereof, is a plant extract which contains chlorogenic acid. The extract containing chlorogenic acid may in particular be an extract from coffee (Coffea arabica), in particular from the seed of Coffea arabica, from sunflower (Helianthus annuus), in particular from the seed of Helianthus annuus, from Damascus rose (Rosa damascena ), in particular from the pollen and spores of Rosa damascena, from blueberry (Vaccinium corymbosum), in particular from the fruits of Vaccinium corymbosum, from Pyrus malus (apple), in particular from the fruits of Pyrus malus, from Melissa officinalis, in particular from the herb from Melissa officinalis, from Camellia sinensis, in particular from the leaves of Camellia sinensis, from Japanese honeysuckle (Lonicera japonica), in particular from the flowers of Lonicera japonica, or from the Gutta percha tree (Eucommia ulmoides), in particular from the leaves of Eucommia ulmoides, act.
In einer besonders bevorzugten Ausführungsform ist der erfindungsgemäß einzusetzende Pflanzenextrakt ausgewählt aus Extrakten von Lonicera japonica-Blüten, Arnica montana-Blüten und Eucommia ulmoides-Blättern sowie Mischungen davon. Denn diese Extrakte zeigten trotz eines relativ geringen Gehalts an Hydroxyzimtsäuren bzw. deren Derivaten dennoch einen außerordentlich starken inhibitorischen Effekt auf die Cystathionin-Beta-Lyase, so dass davon auszugehen ist, dass die in diesen Extrakten enthaltenen weiteren Komponenten in Kombination mit den Zimtsäuren einen synergistischen Effekt bewirken. In einer weiteren besonders bevorzugten Ausführungsform ist der erfindungsgemäß einzusetzende Pflanzenextrakt ausgewählt aus Extrakten von Mädesüß (Filipendula ulmaria, Spiraea ulmaria; unter anderem auch unter den Namen „Wiesenkönigin" oder „Waldbart" bekannt) und Johanniskraut (Hypericum perforatum).In a particularly preferred embodiment, the plant extract to be used according to the invention is selected from extracts of Lonicera japonica flowers, Arnica montana flowers and Eucommia ulmoides leaves, and mixtures thereof. Because these extracts showed despite a relatively low content of hydroxycinnamic acids or their derivatives nevertheless an extremely strong inhibitory effect on the cystathionine beta-lyase, so that it can be assumed that the components contained in these extracts in combination with the cinnamic acids a synergistic Effect effect. In a further particularly preferred embodiment, the plant extract to be used according to the invention is selected from extracts of meadowsweet (Filipendula ulmaria, Spiraea ulmaria, also known by the names "meadow queen" or "Waldbart") and St. John's wort (Hypericum perforatum).
Ein erfindungsgemäß bevorzugt verwendeter Mädesüß-Extrakt wird durch Extraktion der Blüten und/oder der Blätter mit einem Wasser/Ethanol-Gemisch, einem Wasser/C2-C6-Polyol-Gemisch oder mindestens einem C2-C6-PoIyOl erhalten. Zur Extraktion bevorzugte C2-C6-Polyole sind ausgewählt aus Ethylenglycol, 1 ,2-Propylenglycol, 1 ,3-Butylenglycol, 1 ,2-Butylenglycol, 1 ,4-Butylen- glycol, Dipropylenglycol und Glycerin. Mädesüß-Extrakte auf Basis von Wasser/1 ,2-Propylenglycol im Verhältnis 1 :10 bis 10:1 haben sich als erfindungsgemäß besonders geeignet erwiesen. Ein erfindungsgemäß bevorzugt verwendeter Johanniskraut-Extrakt wird durch Extraktion der Blüten und der Blätter mit einem Wasser/Ethanol-Gemisch, einem Wasser/C2-C6-Polyol-Gemisch oder mindestens einem C2-C6-PoIyOl erhalten. Zur Extraktion bevorzugte C2-C6-Polyole sind ausgewählt aus Ethylenglycol, 1 ,2-Propylenglycol, 1 ,3-Butylenglycol, 1 ,2-Butylenglycol, 1 ,4-Butylen- glycol, Dipropylenglycol und Glycerin. Johanniskraut-Extrakte auf Basis von Wasser/1 ,2-Propylen- glycol im Verhältnis 1 :5 bis 5:1 haben sich als erfindungsgemäß besonders geeignet erwiesen. Als Extraktionsmittel zur Herstellung der übrigen genannten Pflanzenextrakte können beispielsweise Wasser, Alkohole sowie deren Mischungen, Öle und sonstige geeignete Lösungsmittel verwendet werden. Als Alkohole kommen beispielsweise niedere Alkohole wie Ethanol und Isopropa- nol, insbesondere aber auch mehrwertige Alkohole wie Ethylenglycol, 1 ,2-Propylenglycol, Butylen- glycol, Dipropylenglycol und Glycerin in Frage, und zwar sowohl als alleiniges Extraktionsmittel als auch in Mischung mit Wasser. So haben sich beispielsweise Pflanzenextrakte auf Basis von Wasser/Propylenglycol im Verhältnis 1 :10 bis 10:1 als besonders geeignet erwiesen. Die Extraktion kann beispielsweise in Form von Wasserdampfdestillation durchgeführt werden. Gegebenenfalls kann auch eine Kohlendioxidextraktion erfolgen.A meadowsweet extract preferably used according to the invention is obtained by extraction of the flowers and / or the leaves with a water / ethanol mixture, a water / C 2 -C 6 -polyol mixture or at least one C 2 -C 6 -polyIl. Preferred C 2 -C 6 polyols for extraction are selected from ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, dipropylene glycol and glycerol. Meadowsweet extracts based on water / 1, 2-propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable according to the invention. A St. John's Wort extract preferably used according to the invention is obtained by extraction of the flowers and the leaves with a water / ethanol mixture, a water / C 2 -C 6 -polyol mixture or at least one C 2 -C 6 -polyIl. Preferred C 2 -C 6 polyols for extraction are selected from ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, dipropylene glycol and glycerol. St. John's wort extracts based on water / 1,2-propylene glycol in a ratio of 1: 5 to 5: 1 have proven to be particularly suitable according to the invention. As extractant for the preparation of the other plant extracts mentioned, for example, water, alcohols and mixtures thereof, oils and other suitable solvents can be used. Suitable alcohols include, for example, lower alcohols such as ethanol and isopropanol, but especially also polyhydric alcohols such as ethylene glycol, 1,2-propylene glycol, butylene glycol, dipropylene glycol and glycerol, both as the sole extractant and in admixture with water. For example, plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven particularly suitable. The extraction can be carried out, for example, in the form of steam distillation. Optionally, a carbon dioxide extraction can take place.
Die Pflanzenextrakte können erfindungsgemäß sowohl in reiner als auch in verdünnter Form eingesetzt werden. Sofern sie in verdünnter Form eingesetzt werden, enthalten sie üblicherweise ca. 2 - 80 Gew.-% Trockenmasse und als Lösungsmittel das bei ihrer Gewinnung eingesetzte Extraktionsmittel oder Extraktionsmittelgemisch. Je nach Wahl der Extraktionsmittel kann es bevorzugt sein, den Pflanzenextrakt durch Zugabe eines Lösungsvermittlers zu stabilisieren. Als Lösungsvermittler geeignet sind z. B. Ethoxylierungsprodukte von gegebenenfalls gehärteten pflanzlichen und tierischen Ölen. Bevorzugte Lösungsvermittler sind ethoxylierte Mono-, Di- und Triglyceride von C8-22- Fettsäuren mit 4 bis 50 Ethylenoxid-Einheiten, z. B. hydriertes ethoxyliertes Castoröl, ethoxylierte Fettalkohole, Olivenölethoxylat, Mandelölethoxylat, Nerzölethoxylat, Polyoxyethylenglycolcapryl-/- /caprinsäureglyceride, Polyoxyethylenglycerinmonolaurat und Polyoxyethylenglycolkokosfettsäure- glyceride.The plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% dry matter and as a solvent used in their extraction agent or extractant mixture. Depending on the choice of extractants, it may be preferable to stabilize the plant extract by adding a solubilizer. Suitable solubilizers are, for. B. Ethoxylation products of optionally hydrogenated vegetable and animal oils. Preferred solubilizing agents are ethoxylated mono-, di- and triglycerides of C 8 - 22 - fatty acids having from 4 to 50 ethylene oxide units, for example. Hydrogenated ethoxylated castor oil, ethoxylated fatty alcohols, olive oil ethoxylate, almond oil ethoxylate, mink oil ethoxylate, polyoxyethylene glycol capryl - / - / capric acid glycerides, polyoxyethylene glycerol monolaurate, and polyoxyethylene glycol coconut fatty acid glycerides.
Die Pflanzenextrakte können, in einer erfindungsgemäß bevorzugten Ausführungsform, auch auf Träger aufgebracht werden, insbesondere um besser in Produkte eingearbeitet werden zu können. Erfindungsgemäß geeignete Träger sind beispielsweise Maltodextrin, Talk und Silica. Die Pflanzenextrakte sind kommerziell beispielsweise von Cosmetochem (Deutschland), Cognis (Deutschland), Symrise (Deutschland) oder Rahn (Deutschland) erhältlich.The plant extracts can, in a preferred embodiment according to the invention, also be applied to carriers, in particular in order to be better able to be incorporated into products. Suitable carriers according to the invention are, for example, maltodextrin, talc and silica. The plant extracts are commercially available, for example, from Cosmetochem (Germany), Cognis (Germany), Symrise (Germany) or Rahn (Germany).
Hydroxyzimtsäuren und/oder ihre Derivaten sowie Pflanzenextrakte ausgewählt aus Mädesüß- Extrakt, Johanniskraut-Extrakt sowie Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, sind in erfindungsgemäßen Mitteln vorzugsweise in einer Gesamtmenge von bis zu 20 Gew.-%, besonders bevorzugt in einer Gesamtmenge von 0,001 bis 10 Gew.-%, insbesondere von 0,01 bis 5 Gew.-%, vor allem von 0,1 bis 2 Gew.-%, enthalten.Hydroxy cinnamic acids and / or their derivatives and plant extracts selected from meadowsweet extract, St. John's wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof are preferably present in agents according to the invention in a total amount of up to 20% by weight, more preferably in one Total amount of 0.001 to 10 wt .-%, in particular from 0.01 to 5 wt .-%, especially from 0.1 to 2 wt .-%, contain.
Bei der erfindungsgemäßen kosmetischen oder pharmazeutischen Zusammensetzung kann es sich um jede beliebige Darreichungsform handeln, beispielsweise um eine feste oder flüssige Seife, eine Lotion, ein Spray, eine Creme, ein Gel, eine Emulsion, eine Reinigungsflüssigkeit oder Reinigungsmilch, einen Stick, ein Deodorant, ein Antitranspirant oder eine Salbe und sie kann auch in jeder der beschriebenen oder sonstigen Darreichungsformen enthalten sein, beispielsweise auch in einem Pflaster, insbesondere in einem Gel-Reservoir- oder Matrixpflaster. In einer erfindungsgemäß besonders bevorzugten Ausführungsform handelt es sich bei der kosmetischen oder pharmazeutischen Zusammensetzung um ein Deodorant und/oder Antitranspirant. Das Deodorant und/oder Antitranspirant liegt hierbei vorzugsweise als Puder, in Stiftform, als Syndet, Waschlotion, Aerosolspray, Pumpspray, flüssige oder gelförmige Roll-on-Applikation, Creme, Schaum, flüssige oder feste Seife, Gel oder als getränktes flexibles Substrat vor. Als Applikatoren können entsprechend je nach Anwendungsform beispielsweise Stifthülse, Roll-on, Pumpe, Tube, Tiegel, Spender, Tuch, Aerosoldose oder Flasche verwendet werden. Als Applikationsort kommt die Haut jedes Körperbereichs in Frage, insbesondere die Gesichtshaut, die Kopfhaut, die Haut an den Füßen und Händen. In einer besonders bevorzugten Ausführungsform handelt es sich bei dem Applikationsort um die Haut im axillaren Bereich. In einer weiteren besonders bevorzugten Ausführungsform handelt es sich bei dem Applikationsort um den oralen Bereich.The cosmetic or pharmaceutical composition according to the invention may be any dosage form, for example a solid or liquid soap, a lotion, a spray, a cream, a gel, an emulsion, a cleaning liquid or cleansing milk, a stick, a deodorant, an antiperspirant or an ointment, and it may also be included in any of the described or other dosage forms, for example, in a patch, especially in a gel reservoir or matrix patch. In a particularly preferred embodiment according to the invention, the cosmetic or pharmaceutical composition is a deodorant and / or antiperspirant. The deodorant and / or antiperspirant is preferably present as a powder, in stick form, as a syndet, washing lotion, aerosol spray, pump spray, liquid or gel roll-on application, cream, foam, liquid or solid soap, gel or impregnated as a flexible substrate. As applicators, for example, depending on the application form, for example, pen barrel, roll-on, pump, tube, crucible, dispenser, cloth, aerosol can or bottle can be used. The site of application is the skin of each area of the body, in particular the facial skin, the scalp, the skin on the feet and hands. In a particularly preferred embodiment, the site of application is the skin in the axillary area. In a further particularly preferred embodiment, the site of application is the oral area.
Die erfindungsgemäße kosmetische oder pharmazeutische Zusammensetzung kann auch weitere Bestandteile als die zuvor genannten enthalten. In einer bevorzugten Ausführungsform enthält sie mindestens eine der im Folgenden aufgezählten Substanzen. Sie kann auch jede beliebige Kombination der im Folgenden aufgezählten Bestandteile enthalten.The cosmetic or pharmaceutical composition according to the invention may also contain further constituents than those mentioned above. In a preferred embodiment, it contains at least one of the substances enumerated below. It may also contain any combination of the ingredients listed below.
Als erfindungsgemäß besonders vorteilhaft haben sich insbesondere kosmetische oder pharmazeutische Zusammensetzungen herausgestellt, die Mischungen von Hydroxyzimtsäuren und/oder ihren Derivaten und/oder von Pflanzenextrakten ausgewählt aus Mädesüß-Extrakt, Johanniskraut- Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, und mindestens einer im axillaren Bereich präbiotisch wirksamen Substanz (wie in WO2005/011716 oder WO2005/092279 offenbart), insbesondere ausgewählt aus Pflanzenextrakten aus Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp., Ribes sp., Hibiscus spec, Malva spec, Vitis spec, Daucus spec, Commiphora spec, Simmondsia spec oder Calendula spec, Glycerinmonoalkyl- ether, insbesondere α-Monoalkylglycerinether mit einem verzweigten oder linearen gesättigten oder ungesättigten, gegebenenfalls hydroxylierten C6-C22-Alkylrest, besonders bevorzugt 1-(2- Ethylhexyl)glycerinether, Isopropylmyristat oder Ethylmyristat oder Mischungen davon enthalten. Durch die Kombination von einerseits Inhibitoren der Cystathionin-beta-Lyase und andererseits im axillaren Bereich präbiotisch wirksamen Substanzen, wird zum einen durch die Blockierung der Cystathionin-beta-Lyase die Geruchsbildung herabgesetzt und gleichzeitig gezielt das Verhältnis zwischen geruchsbildenden und geruchsneutralen Bakterien zugunsten der geruchsneutralen Bakterien verschoben, so dass eine äußerst effektive Bekämpfung von Körpergeruch erzielt werden kann.Cosmetic or pharmaceutical compositions which have shown mixtures of hydroxycinnamic acids and / or their derivatives and / or of plant extracts selected from meadowsweet extract, St. John's wort extract and extracts which contain hydroxycinnamic acids and / or their derivatives, and in particular have turned out to be particularly advantageous a substance prebiotically active in the axillary area (as disclosed in WO2005 / 011716 or WO2005 / 092279), in particular selected from plant extracts from Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp., Ribes sp., Hibiscus Spec, Malva spec, Vitis spec, Daucus spec, Commiphora spec, Simmondsia spec or Calendula spec, glycerol monoalkyl, especially α-monoalkyl glycerol ether with a branched or linear saturated or unsaturated, optionally hydroxylated C 6 -C 22 alkyl, more preferably 1 - (2- Ethylhexyl) glycerol ether, isopropyl myristate or ethyl myristate or mixtures thereof. The combination of on the one hand inhibitors of cystathionine beta-lyase and on the other hand in the axillary prebiotic active substances, on the one hand by the blocking of cystathionine beta-lyase, the formation of odor and simultaneously targeted the relationship between odor-forming and odorless bacteria in favor of odorless bacteria shifted so that a highly effective fight against body odor can be achieved.
Weiterhin haben sich als erfindungsgemäß besonders vorteilhaft kosmetische oder pharmazeutische Zusammensetzungen herausgestellt, die Mischungen von Hydroxyzimtsäuren und/oder ihren Derivaten und/oder von Pflanzenextrakten ausgewählt aus Mädesüß-Extrakt, Johanniskraut- Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, und mindestens einem weiteren Deodorant-Wirkstoff, insbesondere einer antimikrobiell wirksamen Substanz, vorzugsweise einem aromatischen Alkohol, und in einer bevorzugten Ausführungsform zusätzlich mindestens einer der zuvor genannten im axillaren Bereich präbiotisch wirksamen Substanzen enthalten.Furthermore, cosmetic or pharmaceutical compositions which have been found to comprise mixtures of hydroxycinnamic acids and / or their derivatives and / or of plant extracts selected from meadowsweet extract, St. John's wort extract and extracts which contain hydroxycinnamic acids and / or derivatives thereof, and at least a further deodorant active ingredient, in particular an antimicrobially active substance, preferably an aromatic alcohol, and in a preferred embodiment, additionally at least one of the aforementioned substances which are prebiotically active in the axillary area.
Bei der kombinierten Verwendung von Inhibitoren der Cystathionin-beta-Lyase und antimikrobiell wirksamen Deo-Wirkstoffen wird sowohl die Anzahl der geruchsbildenden Bakterien reduziert als auch deren Geruchsbildungskapazität reduziert. Durch die zusätzliche Anwesenheit einer präbiotisch wirksamen Substanz wird weiterhin das Verhältnis zwischen geruchsbildenden Bakterien und geruchsneutralen Bakterien zugunsten der geruchsneutralen Bakterien verschoben, so dass hierdurch eine noch effektivere Körpergeruchsbekämpfung möglich ist. Aufgrund des kombinierten Effekts von antimikrobiell wirksamen Substanzen einerseits und präbiotisch wirksamen Substanzen andererseits sind die erwünschten Bakterien anschließend in noch stärkerem Maße dazu in der Lage, sich auf der Haut zu verbreiten, als dies bei Vorliegen eines rein präbiotischen Effekts der Fall wäre. Die verbleibenden unerwünschten, weil Geruchsverursachenden, Bakterien werden durch die Inhibitoren der Cystathionin-beta-Lyase wirksam an der Geruchsbildung gehindert. Erfindungsgemäß als weitere Deodorant-Wirkstoffe geeignet sind insbesondere Duftstoffe, Geruchsabsorber, desodorierend wirkende Ionenaustauscher, antimikrobielle oder keimhemmende Stoffe, weitere enzymhemmende Stoffe, Antioxidantien und Geruchsadsorbentien. Als Geruchsabsorber geeignet sind insbesondere Silicate. Diese unterstützen auch gleichzeitig die rheologischen Eigenschaften der erfindungsgemäßen Zusammensetzung in vorteilhafter Weise. Zu den erfindungsgemäß besonders bevorzugt als Geruchsabsorber eingesetzten Silicaten zählen vor allem Schichtsilicate und unter diesen insbesondere Montmorillonit, Kaolinit, Illit, Beidellit, Nontronit, Saponit, Hectorit, Bentonit, Smectit und Talkum. Weitere bevorzugte Geruchsabsorber sind beispielsweise Zeolithe, Zinkricinoleat, Cyclodextrine, bestimmte Metalloxide, wie z. B. Aluminiumoxid, sowie Chlorophyll.The combined use of inhibitors of cystathionine beta-lyase and antimicrobial deodorant agents both reduce the number of odor-causing bacteria and reduce their odor-causing capacity. Due to the additional presence of a prebiotically active substance, the ratio between odor-causing bacteria and odor-neutral bacteria is further shifted in favor of the odor-neutral bacteria, so that an even more effective body odor control is possible as a result. Due to the combined effect of antimicrobial substances on the one hand and prebiotically active substances on the other hand, the desired bacteria are then more able to spread on the skin than would be the case in the presence of a purely prebiotic effect. The remaining undesirable, because odor-causing, bacteria are effectively hindered by the inhibitors of cystathionine beta-lyase in the formation of odors. Fragrances, odor absorbers, deodorizing ion exchangers, antimicrobial or germ-inhibiting substances, further enzyme-inhibiting substances, antioxidants and odor adsorbents are particularly suitable according to the invention as further deodorant active substances. Particularly suitable as odor absorbers are silicates. These also simultaneously support the rheological properties of the composition according to the invention in an advantageous manner. The silicates used particularly preferably according to the invention as odor absorbers include, in particular, layered silicates and, among these, in particular montmorillonite, kaolinite, illite, beidellite, nontronite, saponite, hectorite, bentonite, smectite and talcum. Other preferred odor absorbers are, for example, zeolites, Zinkricinoleat, cyclodextrins, certain metal oxides, such as. As alumina, and chlorophyll.
Als keimhemmende oder antimikrobielle Wirkstoffe erfindungsgemäß bevorzugt sind insbesondere Organohalogenverbindungen sowie -halogenide, quartäre Ammoniumverbindungen, eine Reihe von Pflanzenextrakten und Zinkverbindungen. Bevorzugt einsetzbar sind Triclosan (Irgasan® DP 300), Triethylcitrat, Chlorhexidin, Chlorhexidingluconat, 3,4,4'-Trichlorcarbanilid, Bromchlorophen, Dichlorophen, Chlorothymol, Chloroxylenol, Hexachlorophen, Dichloro-m-xylenol, Dequaliniumchlo- rid, Domiphenbromid, Ammoniumphenolsulfonat, Benzalkoniumhalogenide, Benzalkoniumcetyl- phosphat, Benzalkoniumsaccharinate, Benzethoniumchlorid, Cetylpyridiniumchlorid, Laurylpyridi- niumchlorid, Laurylisoquinoliniumbromid und Methylbenzethoniumchlorid. Weiterhin sind Phenol, Dinatriumdihydroxyethylsulfosuccinylundecylenat, Natriumbicarbonat, Zinklactat, Natriumphenol- sulfonat, Zinkphenolsulfonat, Ketoglutarsäure, Bisabolol, Terpenalkohole wie z. B. Farnesol, Chlorophyllin-Kupfer-Komplexe, Carbonsäureester des Mono-, Di- und Triglycerins (z. B. Glycerin- monolaurat, Diglycerinmonocaprinat), Lantibiotika sowie bestimmte Pflanzenextrakte (z. B. grüner Tee und die Bestandteile des Lindenblütenöls und des Kamillenöls) einsetzbar. Als weitere enzymhemmende Stoffe bevorzugt sind Inhibitoren für weitere Enzyme der axillaren Keimflora, die bei der Entstehung von Körpergeruch involviert sind. Hierbei handelt es sich vorzugsweise um Inhibitoren von Lipasen, Arylsulfatasen (s. WO 01/99376), ß-Glucoronidasen (s. WO 03/039505), 5-α-Reduktasen und Aminoacylasen.Preferred antimicrobial or antimicrobial agents according to the invention are in particular organohalogen compounds and halides, quaternary ammonium compounds, a number of plant extracts and zinc compounds. Triclosan (Irgasan® DP 300), triethyl citrate, chlorhexidine, chlorhexidine gluconate, 3,4,4'-trichlorocarbanilide, bromochlorophene, dichlorophen, chlorothymol, chloroxylenol, hexachlorophene, dichloro-m-xylenol, dequalinium chloride, domiphenbromide, ammonium phenolsulfonate, benzalkonium halides, benzalkonium cetyl phosphate, benzalkonium saccharinates, Benzethonium chloride, cetylpyridinium chloride, laurylpyridinium chloride, laurylisoquinolinium bromide and methylbenzethonium chloride. Furthermore, phenol, disodium dihydroxyethylsulfosuccinyl undecylenate, sodium bicarbonate, zinc lactate, sodium phenol sulfonate, zinc phenolsulfonate, ketoglutaric acid, bisabolol, terpene alcohols such. As farnesol, chlorophyllin copper complexes, carboxylic acid esters of mono-, di- and triglycerol (eg., Glycerin monolaurate, diglycerol monocaprinate), lantibiotics and certain plant extracts (eg., Green tea and the components of lime blossom oil and chamomile oil ) can be used. Preferred further enzyme-inhibiting substances are inhibitors for further enzymes of the axillary germ flora, which are involved in the development of body odor. These are preferably inhibitors of lipases, arylsulfatases (see WO 01/99376), β-glucuronidases (see WO 03/039505), 5-α-reductases and aminoacylases.
Weitere antibakteriell wirksame Deodorant-Wirkstoffe sind Glycoglycerolipide, Sphingolipide (Ceramide), Sterine und andere Wirkstoffe, die die Bakterienadhäsion an der Haut inhibieren, z. B. Glycosidasen, Lipasen, Proteasen, Kohlenhydrate, Di- und Oligosaccharidfettsäureester sowie alkylierte Mono- und Oligosaccharide.Other antibacterial deodorant active ingredients are glycoglycerolipids, sphingolipids (ceramides), sterols and other agents that inhibit bacterial adhesion to the skin, e.g. As glycosidases, lipases, proteases, carbohydrates, di- and Oligosaccharidfettsäureester and alkylated mono- and oligosaccharides.
Weiterhin geeignet als Deodorant-Wirkstoff sind wasserlösliche Polyole, ausgewählt aus wasserlöslichen Diolen, Triolen und höherwertigen Alkoholen sowie Polyethylenglycolen. Unter den Diolen eignen sich C2-Ci2-DbIe, insbesondere 1 ,2-Propylenglycol, Butylenglycole wie z. B. 1 ,2-Butylen- glycol, 1 ,3-Butylenglycol und 1 ,4-Butylenglycol, Pentandiole, z. B. 1 ,2-Pentandiol, sowie Hexan- diole, z. B. 1 ,6-Hexandiol. Weiterhin bevorzugt geeignet sind Glycerin und technische Oligoglyce- ringemische mit einem Eigenkondensationsgrad von 1 ,5 bis 10 wie etwa technische Diglycerin- gemische mit einem Diglyceringehalt von 40 bis 50 Gew.-% oder Triglycerin, weiterhin 1 ,2,6- Hexantriol sowie Polyethylenglycole (PEG) mit einem durchschnittlichen Molekulargewicht von 100 bis 1.000 Dalton, beispielsweise PEG-400, PEG-600 oder PEG-1000. Weitere geeignete höher- wertige Alkohole sind die C4-, C5- und C6-Monosaccharide und die entsprechenden Zuckeralkohole, z. B. Mannit oder Sorbit.Also suitable as a deodorant active ingredient are water-soluble polyols selected from water-soluble diols, triols and higher-grade alcohols and also polyethylene glycols. Among the diols are C 2 -Ci 2 -DbIe, in particular 1, 2-propylene glycol, butylene glycols such. B. 1, 2-butylene glycol, 1, 3-butylene glycol and 1, 4-butylene glycol, pentanediols, z. B. 1, 2-pentanediol, and hexanediols, z. B. 1, 6-hexanediol. Further preferred are glycerol and technical Oligoglyce- ringemische with an intrinsic degree of condensation of 1, 5 to 10 such as technical Diglycerin mixtures having a Diglycerine content of 40 to 50 wt .-% or triglycerol, further 1, 2,6-hexanetriol and polyethylene glycols ( PEG) having an average molecular weight of 100 to 1000 daltons, for example PEG-400, PEG-600 or PEG-1000. Further suitable higher-value alcohols are the C 4 , C 5 and C 6 monosaccharides and the corresponding sugar alcohols, eg. Mannitol or sorbitol.
In einer bevorzugten Ausführungsform wird als weiterer Deodorant-Wirkstoff ein aromatischer Alkohol eingesetzt. Bei dem aromatischen Alkohol handelt es sich erfindungsgemäß vorzugsweise um eine Verbindung der allgemeinen FormelIn a preferred embodiment, an aromatic alcohol is used as further deodorant active ingredient. The aromatic alcohol according to the invention is preferably a compound of the general formula
R5 R3 R1 O -)— (- C-)-( c )-(-C-)- OHR 5 R 3 R 1 O -) - (- C -) - (c) - (- C -) - OH
Re R' R^
Figure imgf000009_0001
wobeiR e R ' R ^
Figure imgf000009_0001
in which
R1 - R6 = unabhängig voneinander stehen für ein Wasserstoffatom, eine lineare oder verzweigte sowie gegebenenfalls substituierte C-|.10-Alkylgruppe oder eine lineare oder verzweigte sowie gegebenenfalls substituierte C2-i0-Alkenylgruppe, wobei die Substituenten jeweils vorzugsweise ausgewählt sind aus Hydroxy und Ci_6-Alkoxy,R 1 - R 6 = independently of one another represent a hydrogen atom, a linear or branched and optionally substituted C 1-. 10 alkyl group or a linear or branched and optionally substituted C 2 -i 0 alkenyl group, wherein the substituents are each preferably selected from hydroxy and CI_ 6 alkoxy,
R7 - R11 = unabhängig voneinander stehen für ein Wasserstoffatom, ein Halogenatom, insbesondere Chlor, oder eine lineare oder verzweigte sowie gegebenenfalls substituierte C-Mo-Alkylgruppe, wobei die Substituenten vorzugsweise ausgewählt sind aus Hydroxy und Ci_6-Alkoxy, insbesondere Methoxy, m = 0 oder 1 ist, n, o, p = unabhängig voneinander ganze Zahlen von 0 bis 10 sein können, wobei mindestens einer der Werte von n, o, p ≠ 0 ist.R 7 - R 11 = independently a hydrogen atom, a halogen atom, especially chlorine, or a linear or branched and optionally substituted C M o-alkyl group, wherein the substituents are preferably selected from hydroxy and CI_ 6 alkoxy, especially methoxy , m = 0 or 1, n, o, p = can independently be integers from 0 to 10, with at least one of the values of n, o, p ≠ 0.
Erfindungsgemäß bevorzugte aromatische Alkohole der zuvor genannten Struktur sind ausgewählt aus Phenoxyethanol, Phenoxyisopropanol (3-Phenoxy-propan-2-ol), Anisalkohol, 2-Methyl-5- phenyl-pentan-1-ol, 1 ,1-Dimethyl-3-phenyl-propan-1-ol, Benzylalkohol, 2-Phenylethan-1-ol, 3- Phenylpropan-1-ol, 4-Phenylbutan-1-ol, 5-Phenylpentan-1-ol, 2-Benzylheptan-1-ol, 2,2-Dimethyl-3- phenylpropan-1-ol, 2,2-Dimethyl-3-(3'-methylphenyl)-propan-1-ol, 2-Ethyl-3-phenylpropan-1-ol, 2- Ethyl-3-(3'-methylphenyl)-propan-1-ol, 3-(3'-Chlorphenyl)-2-ethylpropan-1-ol, 3-(2'-Chlorphenyl)-2- ethylpropan-1-ol, 3-(4'-Chlorphenyl)-2-ethylpropan-1-ol, 3-(3',4'-Dichlorphenyl)-2-ethylpropan-1-ol, 2-Ethyl-3-(2'-methylphenyl)-propan-1-ol, 2-Ethyl-3-(4'-methylphenyl)-propan-1-ol, 3-(3',4'-Dimethyl- phenyl)-2-ethylpropan-1-ol, 2-Ethyl-3-(4'-methoxyphenyl)-propan-1-ol, 3-(3',4'-Dimethoxyphenyl)-2- ethylpropan-1-ol, 2-Allyl-3-phenylpropan-1-ol und 2-n-Pentyl-3-phenylpropan-1-ol. Antioxidative Stoffe können der oxidativen Zersetzung der Schweißkomponenten entgegenwirken und auf diese Weise die Geruchsentwicklung hemmen. Bevorzugte Antioxidantien sind Imidazol und Imidazolderivate (z. B. Urocaninsäure), Peptide, wie z. B. D,L-Carnosin, D-Carnosin, L-Car- nosin und deren Derivate (z. B. Anserin), Carotinoide, Carotine (z. B. α-Carotin, ß-Carotin, Lycopin) und deren Derivate, Liponsäure und deren Derivate (z. B. Dihydroliponsäure), Aurothioglucose, Propylthiouracil und weitere Thioverbindungen (z. B. Thioglycerin, Thiosorbitol, Thioglycolsäure, Thioredoxin, Glutathion, Cystein, Cystin, Cystamin und deren Glycosyl-, N-Acetyl-, Methyl-, Ethyl-, Propyl-, Amyl-, Butyl-, Lauryl-, Palmitoyl-, Oleyl-, γ-Linoleyl-, Cholesteryl- und Glycerylester) sowie deren Salze, Dilaurylthiodipropionat, Distearylthiodipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide, Lipide, Nukleotide, Nukleoside und Salze) sowie Sulfoximinverbindun- gen (z. B. Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-, Hepta- thioninsulfoximin) in sehr geringen verträglichen Dosierungen (z. B. pmol/kg bis μmol/kg), ferner Metallchelatoren (z. B. α-Hydroxyfettsäuren, EDTA, EGTA, Lactoferrin), Huminsäuren, Gallensäure, Gallenextrakte, Catechine, Bilirubin, Biliverdin und deren Derivate, ungesättigte Fettsäuren und deren Derivate (z. B. γ-Linolensäure, Linolsäure, Arachidonsäure, Ölsäure), Folsäure und deren Derivate, Hydrochinon und dessen Derivate (z. B. Arbutin), Ubichinon und Ubichinol sowie deren Derivate, Vitamin C und dessen Derivate (z. B. Ascorbylpalmitat, stearat, -dipalmitat, -acetat, Mg-Ascorbylphosphate, Natrium- und Magnesiumascorbat, Dinatriumascorbylphosphat und -sulfat, Kaliumascorbyltocopherylphosphat, Chitosanascorbat), Isoascorbinsäure und deren Derivate, Tocopherole und deren Derivate (z. B. Tocopherylacetat, -linoleat, -oleat und -succinat, Tocophe- reth-5, Tocophereth-10, Tocophereth-12, Tocophereth-18, Tocophereth-50, Tocophersolan), Vitamin A und Derivate (z. B. Vitamin-A-Palmitat), das Coniferylbenzoat des Benzoeharzes, Rutin, Rutinsäure und deren Derivate, Dinatriumrutinyldisulfat, Zimtsäure und deren Derivate, Kojisäure, Chitosanglycolat und -salicylat, Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguajakharz- säure, Nordihydroguajaretsäure, Trihydroxybutyrophenon, Harnsäure und deren Derivate, Mannose und deren Derivate, Selen und Selen-Derivate (z. B. Selenmethionin), Stilbene und Stilben-Derivate (z. B. Stilbenoxid, trans-Stilbenoxid). Erfindungsgemäß können geeignete Derivate (Salze, Ester, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) sowie Mischungen dieser genannten Wirkstoffe oder wasserfreie Pflanzenextrakte, die diese Antioxidantien enthalten, eingesetzt werden.Aromatic alcohols of the aforementioned structure which are preferred according to the invention are selected from phenoxyethanol, phenoxyisopropanol (3-phenoxy-propan-2-ol), anisalcohol, 2-methyl-5-phenyl-pentan-1-ol, 1,1-dimethyl-3 phenyl-propan-1-ol, benzyl alcohol, 2-phenylethan-1-ol, 3-phenylpropan-1-ol, 4-phenylbutan-1-ol, 5-phenylpentan-1-ol, 2-benzylheptan-1-ol, 2,2-Dimethyl-3-phenylpropan-1-ol, 2,2-dimethyl-3- (3'-methylphenyl) -propan-1-ol, 2-ethyl-3-phenylpropan-1-ol, 2-ethyl -3- (3'-methylphenyl) -propan-1-ol, 3- (3'-chlorophenyl) -2-ethyl-propan-1-ol, 3- (2'-chlorophenyl) -2-ethyl-propan-1-ol, 3- (4'-Chlorophenyl) -2-ethyl-propan-1-ol, 3- (3 ', 4'-dichlorophenyl) -2-ethyl-propan-1-ol, 2-ethyl-3- (2'-methyl-phenyl) - propan-1-ol, 2-ethyl-3- (4'-methylphenyl) -propan-1-ol, 3- (3 ', 4'-dimethylphenyl) -2-ethyl-propan-1-ol, 2-ethyl -3- (4'-methoxyphenyl) -propan-1-ol, 3- (3 ', 4'-dimethoxyphenyl) -2-ethyl-propan-1-ol, 2-allyl-3-phenyl-propan-1-ol and 2- n-pentyl-3-phenyl-propan-1-ol. Antioxidant substances can counteract the oxidative decomposition of the welding components and in this way inhibit odor development. Preferred antioxidants are imidazole and imidazole derivatives (eg urocaninic acid), peptides, such as e.g. B. D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg, anserine), carotenoids, carotenes (eg, α-carotene, β-carotene, lycopene) and their derivatives, Lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thio compounds (eg thioglycerol, thiosorbitol, thioglycollic acid, thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl) , Ethyl, propyl, amyl, butyl, lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides , Lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (eg buthionine sulfoximines, homocysteine sulfoximine, buthione sulfones, penta, hexa, heptothionine sulfoximine) in very low compatible dosages (eg pmol / kg to μmol / kg), metal chelators (eg α-hydroxy fatty acids, EDTA, EGTA, Lactoferr in), humic acids, bile acids, bile extracts, catechins, bilirubin, biliverdin and their derivatives, unsaturated fatty acids and their derivatives (e.g. B. γ-linolenic acid, linoleic acid, arachidonic acid, oleic acid), folic acid and their derivatives, hydroquinone and its derivatives (eg arbutin), ubiquinone and ubiquinol and their derivatives, vitamin C and its derivatives (eg ascorbyl palmitate, stearate, dipalmitate, acetate, Mg ascorbyl phosphates, sodium and magnesium ascorbate , Disodium ascorbyl phosphate and sulfate, potassium ascorbyl tocopheryl phosphate, chitosan ascorbate), isoascorbic acid and its derivatives, tocopherols and their derivatives (for example tocopheryl acetate, linoleate, oleate and succinate, tocopheryl-5, tocophereth-10, tocophereth-12, Tocophereth-18, tocophereth-50, tocopherol), vitamin A and derivatives (e.g., vitamin A palmitate), the benzylic resin coniferyl benzoate, rutin, rutinic acid and derivatives thereof, disodium rubinyldisulfate, cinnamic acid and its derivatives, kojic acid, chitosan glycollate, and salicylate, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiacic acid, nordihydroguiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, selenium and selenium derivative e (eg selenium methionine), stilbenes and stilbene derivatives (e.g. Stilbene oxide, trans-stilbene oxide). Suitable derivatives (salts, esters, sugars, nucleotides, nucleosides, peptides and lipids) and mixtures of these active substances or anhydrous plant extracts containing these antioxidants can be used according to the invention.
Als lipophile, öllösliche Antioxidantien aus dieser Gruppe sind Tocopherol und dessen Derivate, insbesondere Tocopherylacetat, und Carotinoide sowie Butylhydroxytoluol und Butylhydroxyanisol bevorzugt.Preferred lipophilic, oil-soluble antioxidants from this group are tocopherol and its derivatives, in particular tocopheryl acetate, and carotenoids, as well as butylhydroxytoluene and butylhydroxyanisole.
Eine erfindungsgemäß bevorzugte Zusammensetzung enthält mindestens einen der zuvor genannten zusätzlichen Deodorant-Wirkstoffen, wobei die Gesamtmenge an zusätzlichen Deodorant- Wirkstoffen vorzugsweise 0,1 - 10 Gew.-%, bevorzugt 0,2 - 7 Gew.-%, besonders bevorzugt 0,3 - 5 Gew.-% und insbesondere 0,4 - 1 ,0 Gew.-% beträgt.A composition which is preferred according to the invention contains at least one of the abovementioned additional deodorant active ingredients, the total amount of additional deodorant active substances preferably being 0.1-10% by weight, preferably 0.2-7% by weight, particularly preferably 0.3 - 5 wt .-% and in particular 0.4 - 1, 0 wt .-% is.
Weiterhin haben sich als erfindungsgemäß besonders vorteilhaft kosmetische oder pharmazeutische Zusammensetzungen herausgestellt, die Mischungen aus mindestens einer Hydroxyzimt- säure und/oder einem Derivat davon und/oder mindestens einem Pflanzen extra kt ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, und mindestens einem Antitranspirant-Wirkstoff (schweißhemmenden Wirkstoff), vorzugsweise weiterhin in Kombination mit mindestens einer präbiotisch wirksamen Substanz und/oder einem weiteren Deodorant-Wirkstoff enthalten.Furthermore, cosmetic or pharmaceutical compositions which have been found to comprise mixtures of at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one extra-selected plant selected from meadowsweet extract, St. John's wort extract and extracts, the hydroxycinnamic acids and or contain derivatives thereof, and at least one antiperspirant active ingredient (antiperspirant active ingredient), preferably further in combination with at least one prebiotically active substance and / or another deodorant active ingredient.
Als Antitranspirant-Wirkstoffe eignen sich erfindungsgemäß vor allem wasserlösliche adstringieren- de oder einweißkoagulierende metallische Salze, insbesondere anorganische und organische Salze des Aluminiums, Zirkoniums, Zinks und Titans sowie beliebige Mischungen dieser Salze. Erfindungsgemäß bevorzugte Antitranspirant-Wirkstoffe sind ausgewählt aus den Aluminiumchlorhydraten, insbesondere den Aluminiumchlorhydraten mit der allgemeinen Formel [AI2(OH)5CI ■ 2-3 H2O]n, die in nicht-aktivierter oder in aktivierter (depolymerisierter) Form vorliegen können, weiterhin Aluminiumsesquichlorhydrat, Aluminiumchlorhydrex-Propylenglycol (PG) oder -Polyethylengly- col (PEG), Aluminiumsesquichlorhydrex-PG oder -PEG, Aluminium-PG-dichlorhydrex oder Alumi- nium-PEG-dichlorhydrex, Aluminiumhydroxid, weiterhin ausgewählt aus den Aluminiumzirconium- chlorhydraten, wie Aluminiumzirconiumtrichlorhydrat, Aluminiumzirconiumtetrachlorhydrat, Alumi- niumzirconiumpentachlorhydrat, Aluminiumzirconiumoctachlorhydrat, den Aluminium-Zirkonium- Chlorohydrat-Glycin-Komplexen wie Aluminiumzirconiumtrichlorhydrexglycin, Aluminiumzirconium- tetrachlorhydrexglycin, Aluminiumzirconiumpentachlorhydrexglycin, Aluminiumzirconiumoctachlor- hydrexglycin, Kaliumaluminiumsulfat (KAI(SO4)2 ■ 12 H2O, Alaun), Aluminiumundecylenoylkollagen- aminosäure, Natriumaluminiumlactat + Aluminiumsulfat, Natriumaluminiumchlorhydroxylactat, Aluminiumbromhydrat, Aluminiumchlorid, den Komplexen von Zink- und Natriumsalzen, den Komplexen von Lanthan und Cer, den Aluminiumsalzen von Lipoaminosäuren, Aluminiumsulfat, Alumini- umlactat, Aluminiumchlorhydroxyallantoinat, Natrium-Aluminium-Chlorhydroxylactat, Zinkchlorid, Zinksulfocarbolat, Zinksulfat und Zirkoniumchlorohydrat. Erfindungsgemäß wird unter Wasserlöslichkeit eine Löslichkeit von wenigstens 5 Gew.-% bei 20 0C verstanden, das heißt, dass Mengen von wenigstens 5 g des Antitranspirant-Wirkstoffs in 95 g Wasser bei 20 0C löslich sind. Die Anti- transpirant-Wirkstoffe können als wässrige Lösungen eingesetzt werden.Suitable antiperspirant active substances according to the invention are, in particular, water-soluble astringent or protein coagulating metallic salts, in particular inorganic and organic salts of aluminum, zirconium, zinc and titanium, and any desired mixtures of these salts. According to the invention preferred antiperspirant active substances are selected from aluminum chlorohydrates, especially aluminum chlorohydrates having the general formula [Al 2 (OH) 5 CI 2-3 ■ H 2 O] n, which may be present in non-activated or activated in (depolymerized) Form , furthermore aluminum sesquichlorohydrate, aluminum chlorohydrex-propylene glycol (PG) or polyethylene glycol (PEG), aluminum sesquichlorohydrex PG or PEG, aluminum PG-dichlorohydrex or aluminum PEG-dichlorhydrex, aluminum hydroxide, furthermore selected from the aluminum zirconium chlorohydrates, such as aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, alumina niumzirconiumpentachlorhydrat, Aluminiumzirconiumoctachlorhydrat, the aluminum-zirconium chlorohydrate glycine complexes, such as Aluminiumzirconiumtrichlorhydrexglycin, Aluminiumzirconium- tetrachlorhydrexglycin, Aluminiumzirconiumpentachlorhydrexglycin, Aluminiumzirconiumoctachlor- hydrexglycin, potassium aluminum sulfate (KAI (SO 4) 2 ■ 12 H 2 O, alum), amino acid Aluminiumundecylenoylkollagen-, Natriumaluminiumlactat + Aluminum sulfate, sodium aluminum chlorohydroxylactate, aluminum bromohydrate, aluminum chloride, the complexes of zinc and sodium salts, the complexes of lanthanum and cerium, the aluminum salts of lipoamino acids, aluminum sulfate, aluminum lactate, aluminum chlorohydrate, sodium aluminum chlorohydroxactate, zinc chloride, zinc sulfocarbolate, zinc sulfate and zirconium chlorohydrate. A solubility of at least 5 wt .-% at 20 0 C is understood according to the invention, solubility in water, that is, amounts of at least 5 g of the antiperspirant active ingredient in 95 g of water are soluble at 20 0 C. The antiperspirant active ingredients can be used as aqueous solutions.
In einer besonders bevorzugten Ausführungsform enthält die erfindungsgemäße Zusammensetzung als Antitranspirant ein adstringierendes Aluminiumsalz, insbesondere Aluminiumchlorohydrat, das beispielsweise pulverförmig als Micro Dry® Ultrafine oder Micro Dry® SUF von Reheis, in Form einer wässrigen Lösung als Locron® L von Clariant, als Chlorhydrol® sowie in aktivierter Form als Reach® 103 oder Reach® 501 von Reheis vertrieben wird. Unter der Bezeichnung Reach® 301 wird ein Aluminiumsesquichlorohydrat von Reheis angeboten, das ebenfalls besonders bevorzugt ist. Auch die Verwendung von Aluminium-Zirkonium-Tetrachlorohydrex-Glycin-Komplexen, die beispielsweise von Reheis unter der Bezeichnung Rezal® 36G oder Reach® 908 im Handel sind, kann erfindungsgemäß besonders bevorzugt sein.In a particularly preferred embodiment, the inventive composition as antiperspirant comprises an astringent aluminum salt, especially aluminum chlorohydrate, for example, in powder form as Micro Dry ® Ultrafine or Micro Dry ® SUF from Reheis, in the form of an aqueous solution as Locron ® L from Clariant, as Chlorhydrol ® and in activated form as Reach® 103 or Reach® 501 from Reheis. Under the name Reach® 301 an aluminum sesquichlorohydrate from Reheis is offered, which is likewise particularly preferred. The use of aluminum zirconium tetrachlorohydrex glycine complexes, which are, for example, by Reheis under the name Rezal ® 36G or Reach ® 908 commercially, may be particularly preferred according to the invention.
Der schweißhemmende Wirkstoff ist in den erfindungsgemäßen Zusammensetzungen in einer Menge von 0,01 - 40 Gew.-%, vorzugsweise 2 - 30 Gew.-% und besonders bevorzugt 5 - 25 Gew.-% enthalten.The antiperspirant active is contained in the compositions according to the invention in an amount of 0.01-40% by weight, preferably 2-30% by weight and more preferably 5-25% by weight.
Eine erfindungsgemäße Zusammensetzung kann neben den zuvor genannten erfindungsgemäß einsetzbaren Pflanzenextrakten auch weitere und/oder andere Pflanzenextrakte enthalten. Diese weiteren und/oder anderen Pflanzenextrakte können beispielsweise durch Extraktion der gesamten Pflanze, aber auch ausschließlich durch Extraktion aus Blüten und/oder Blättern und/oder Samen und/oder anderen Pflanzenteilen hergestellt werden. Erfindungsgemäß sind vor allem die Extrakte aus dem Meristem, also dem teilungsfähigen Bildungsgewebe der Pflanzen, und die Extrakte aus speziellen Pflanzen wie Grünem Tee, Hamamelis, Kamille, Stiefmütterchen, Paeonie, Aloe Vera, Rosskastanie, Salbei, Weidenrinde, Zimtbaum (cinnamon tree), Chrysanthemen, Eichenrinde, Brennessel, Hopfen, Klettenwurzel, Schachtelhalm, Weißdorn, Lindenblüten, Mandeln, Fichtennadeln, Sandelholz, Wacholder, Kokosnuß, Kiwi, Guave, Limette, Mango, Aprikose, Weizen, Melone, Orange, Grapefruit, Avocado, Rosmarin, Birke, Buchensprossen, Wiesenschaumkraut, Schafgarbe, Quendel, Thymian, Melisse, Hauhechel, Eibisch (Althaea), Veilchen, Blättern der Schwarzen Johannisbeere, Huflattich, Fünffingerkraut, Ginseng, Ingwerwurzel und Süßkartoffel als weiterer Pflanzenextrakt bevorzugt. Vorteilhaft eingesetzt werden können auch Algenextrakte. Die erfindungsgemäß verwendeten Algenextrakte stammen aus Grünalgen, Braunalgen, Rotalgen oder Blaualgen (Cyanobakterien). Die zur Extraktion eingesetzten Algen können sowohl natürlichen Ursprungs als auch durch biotechnologische Prozesse gewonnen und gewünschtenfalls gegenüber der natürlichen Form verändert sein. Die Veränderung der Organismen kann gentechnisch, durch Züchtung oder durch die Kultivation in mit ausgewählten Nährstoffen angereicherten Medien erfolgen. Bevorzugte Algenextrakte stammen aus Seetang, Blaualgen, aus der Grünalge Codium tomentosum sowie aus der Braunalge Fucus vesiculosus. Ein besonders bevorzugter Algenextrakt stammt aus Blaualgen der Species Spirulina, die in einem Magnesium-angereicherten Medium kultiviert wurden.A composition according to the invention may also contain other and / or other plant extracts in addition to the abovementioned plant extracts which can be used according to the invention. These further and / or other plant extracts can be prepared for example by extraction of the entire plant, but also exclusively by extraction from flowers and / or leaves and / or seeds and / or other parts of plants. According to the invention, especially the extracts from the meristem, so the divisible educated tissue of the plants, and the extracts of special plants such as green tea, witch hazel, chamomile, pansy, Paeonie, aloe vera, horse chestnut, sage, willow bark, cinnamon tree (cinnamon tree), Chrysanthemums, Oak bark, Stinging nettle, Hops, Burdock root, Horsetail, Hawthorn, Lime blossom, Almonds, Spruce needles, Sandalwood, Juniper, Coconut, Kiwi, Guava, Lime, Mango, Apricot, Wheat, Melon, Orange, Grapefruit, Avocado, Rosemary, Birch, Beech shoots, meadowfoam, yarrow, quenelle, thyme, lemon balm, toadstool, marshmallow (Althaea), violets, blackcurrant leaves, coltsfoot, Fünffingerkraut, ginseng, ginger root and sweet potato are preferred as another plant extract. Algae extracts can also be used to advantage. The Algae extracts used according to the invention are derived from green algae, brown algae, red algae or blue-green algae (cyanobacteria). The algae used for extraction can be obtained both from natural sources as well as by biotechnological processes and, if desired, be modified from the natural form. The alteration of the organisms may be by genetic engineering, by breeding or by cultivation in media enriched with selected nutrients. Preferred algae extracts are from seaweed, blue-green algae, from the green alga Codium tomentosum and from the brown algae Fucus vesiculosus. A particularly preferred algae extract is derived from blue-green algae of the species Spirulina, which were cultured in a magnesium-enriched medium.
Als weiterer Pflanzenextrakt besonders bevorzugt sind die Extrakte aus Spirulina, Grünem Tee, Aloe Vera, Meristem, Hamamelis, Aprikose, Guave, Süßkartoffel, Limette, Mango, Kiwi, Gurke, Malve, Eibisch und Veilchen. Die erfindungsgemäßen Mittel können als zusätzlichen Pflanzenextrakt auch Mischungen aus mehreren, insbesondere aus zwei, verschiedenen Pflanzenextrakten enthalten.Particularly preferred as a further plant extract are the extracts of spirulina, green tea, aloe vera, meristem, witch hazel, apricot, guava, sweet potato, lime, mango, kiwi, cucumber, mallow, marshmallow and violet. The compositions according to the invention may also contain mixtures of several, in particular two, different plant extracts as additional plant extract.
Die kosmetischen oder pharmazeutischen Zusammensetzungen und insbesondere die erfindungsgemäß bevorzugten Deodorant- oder Antitranspirant-Zusammensetzungen, können weiterhin Fettstoffe enthalten. Unter Fettstoffen sind Fettsäuren, Fettalkohole, natürliche und synthetische kosmetische Ölkomponenten sowie natürliche und synthetische Wachse zu verstehen, die sowohl in fester Form als auch flüssig in wässriger oder öliger Dispersion vorliegen können. Als Fettsäuren können eingesetzt werden lineare und/oder verzweigte, gesättigte und/oder ungesättigte C8-3o-Fettsäuren. Bevorzugt sind Cio-22-Fettsäuren. Beispiele sind Capronsäure, Capryl- säure, 2-Ethylhexansäure, Caprinsäure, Laurinsäure, Isotridecansäure, Myristinsäure, Palmitin- säure, Palmitoleinsäure, Stearinsäure, Isostearinsäure, Ölsäure, Elaidinsäure, Petroselinsäure, Linolsäure, Linolensäure, Elaeostearinsäure, Arachidonsäure, Gadoleinsäure, Behensäure und Erucasäure sowie deren technische Mischungen. Besonders bevorzugt ist der Einsatz von Stearinsäure. Die eingesetzten Fettsäuren können eine oder mehrere Hydroxygruppen tragen. Bevorzugte Beispiele hierfür sind die α-Hydroxy-C8-C-|8-Carbonsäuren sowie 12-Hydroxystearinsäure. Die Einsatzmenge beträgt dabei 0,1 - 15 Gew.-%, bevorzugt 0,5 - 10 Gew.-%, besonders bevorzugt 1 - 5 Gew.-%, jeweils bezogen auf die gesamte Zusammensetzung.The cosmetic or pharmaceutical compositions, and in particular the inventively preferred deodorant or antiperspirant compositions, may further contain fatty substances. Fatty substances are to be understood as meaning fatty acids, fatty alcohols, natural and synthetic cosmetic oil components as well as natural and synthetic waxes, which can be in solid or liquid form in aqueous or oily dispersion. As fatty acids can be used linear and / or branched, saturated and / or unsaturated C 8 - 3 o fatty acids. Ciol- 22- fatty acids are preferred. Examples are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidonic acid, gadoleic acid, behenic acid and erucic acid, and their technical mixtures. Particularly preferred is the use of stearic acid. The fatty acids used can carry one or more hydroxyl groups. Preferred examples of these are the α-hydroxy-C 8 -C 8 -carboxylic acids and 12-hydroxystearic acid. The amount used is 0.1 to 15 wt .-%, preferably 0.5 to 10 wt .-%, particularly preferably 1 to 5 wt .-%, each based on the total composition.
Als Fettalkohole können eingesetzt werden gesättigte, ein- oder mehrfach ungesättigte, verzweigte oder unverzweigte Fettalkohole mit 6 - 30, bevorzugt 10 - 22 und ganz besonders bevorzugt 12 - 22 Kohlenstoffatomen. Einsetzbar im Sinne der Erfindung sind z.B. Decanol, Octanol, Octenol, Dodecenol, Decenol, Octadienol, Dodecadienol, Decadienol, Oleylalkohol, Erucaalkohol, Ricinol- alkohol, Stearylalkohol, Isostearylalkohol, Cetylalkohol, Laurylalkohol, Myristylalkohol, Arachidyl- alkohol, Caprylalkohol, Caprinalkohol, Linoleylalkohol, Linolenylalkohol und Behenylalkohol, sowie deren Guerbetalkohole.As fatty alcohols it is possible to use saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 6 to 30, preferably 10 to 22 and very particularly preferably 12 to 22 carbon atoms. Applicable according to the invention are e.g. Decanol, octanol, dodecadienol, decadienol, oleyl alcohol, eruca alcohol, ricinoleic alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol, and the like Guerbet.
Für Stiftformulierungen werden häufig Wachse verwendet. Als natürliche oder synthetische Wachse können erfindungsgemäß eingesetzt werden feste Paraffine oder Isoparaffine, Pflanzenwachse wie Candelillawachs, Carnaubawachs, Espartograswachs, Japanwachs, Korkwachs, Zuckerrohrwachs, Ouricurywachs, Kesterwachs, Montanwachs, Sonnenblumenwachs, Fruchtwachse und tierische Wachse, wie z. B. Bienenwachse und andere Insektenwachse, Walrat, Schellackwachs, Wollwachs und Bürzelfett, weiterhin Mineralwachse, wie z. B. Ceresin und Ozo- kerit oder die petrochemischen Wachse, wie z. B. Petrolatum, Paraffinwachse, Microwachse aus Polyethylen oder Polypropylen und Polyethylenglycolwachse. Es kann vorteilhaft sein, hydrierte oder gehärtete Wachse einzusetzen. Weiterhin sind auch chemisch modifizierte Wachse, insbesondere die Hartwachse, z. B. Montanesterwachse, Sasolwachse und hydrierte Jojobawachse, einsetzbar.For pen formulations waxes are often used. As natural or synthetic waxes it is possible according to the invention to use solid paraffins or isoparaffins, plant waxes such as candelilla wax, carnauba wax, esparto grass wax, Japan wax, cork wax, Sugarcane wax, ouricury wax, Kester wax, montan wax, sunflower wax, fruit waxes and animal waxes, such as. B. beeswax and other insect waxes, spermaceti, shellac wax, wool wax and raffia fat, continue to mineral waxes such. Ceresin and Ozokerit or the petrochemical waxes such. As petrolatum, paraffin waxes, Microwachse of polyethylene or polypropylene and polyethylene glycol waxes. It may be advantageous to use hydrogenated or hardened waxes. Furthermore, chemically modified waxes, especially the hard waxes, z. As montan ester waxes, Sasol waxes and hydrogenated jojoba waxes, can be used.
Weiterhin geeignet sind die Mono-, Di- und Triglyceride gesättigter und gegebenenfalls hydroxy- lierter Ci6-3o-Fettsäuren, wie z. B. gehärtete Triglyceridfette (hydriertes Palmöl, hydriertes Kokosöl, hydriertes Rizinusöl (Cutina® HR)), Glycerylmonostearat (Cutina® MD), Glyceryltribehenat oder Glyceryltri-12-hydroxystearat, weiterhin synthetische Vollester aus Fettsäuren und Glycolen (z. B. Syncrowachs®) oder Polyolen mit 2 - 6 C-Atomen, Fettsäuremonoalkanolamide mit einem C12_22- Acylrest und einem C2^-Alkanolrest, Ester aus gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkancarbonsäuren einer Kettenlänge von 1 bis 80 C-Atomen und gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkoholen einer Kettenlänge von 1 bis 80 C-Atomen, darunter z. B. synthetische Fettsäure-Fettalkoholester wie Stearylstearat oder Cetylpalmitat, Ester aus aromatischen Carbonsäuren, Dicarbonsäuren bzw. Hydroxycarbon- säuren (z. B. 12-Hydroxystearinsäure) und gesättigten und/oder ungesättigten, verzweigten und/ oder unverzweigten Alkoholen einer Kettenlänge von 1 bis 80 C-Atomen, Lactide langkettiger Hydroxycarbonsäuren und Vollester aus Fettalkoholen und Di- und Tricarbonsäuren, z. B. Dicetyl- succinat oder Dicetyl-/stearyladipat, sowie Mischungen dieser Substanzen, sofern die einzelnen Wachskomponenten oder ihre Mischung bei Raumtemperatur fest sind.Also suitable are the mono-, di- and triglycerides of saturated and optionally hydroxylated Ci 6 - 3 o-fatty acids, such as. B. hydrogenated triglyceride fats (hydrogenated palm oil, hydrogenated coconut oil, hydrogenated castor oil (Cutina ® HR)), glyceryl monostearate (Cutina ® MD), glyceryl tribehenate or glyceryl tri-12-hydroxystearate, further synthetic Vollester of fatty acids and glycols (eg. B. Syncrowachs ®) or polyols having 2 - 6 carbon atoms, fatty acid monoalkanolamides with a C 12 _ 22 - acyl group and a C 2 ^ alkanol, esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 1 to 80 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 1 to 80 carbon atoms, including z. Example, synthetic fatty acid fatty alcohol esters such as stearyl stearate or cetyl palmitate, esters of aromatic carboxylic acids, dicarboxylic acids or hydroxycarboxylic acids (eg., 12-hydroxystearic acid) and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 1 to 80 C-atoms, lactides of long-chain hydroxycarboxylic acids and full esters of fatty alcohols and di- and tricarboxylic acids, eg. As dicetyl succinate or dicetyl / stearyl adipate, and mixtures of these substances, provided that the individual wax components or their mixture are solid at room temperature.
Besonders bevorzugt ist, die Wachskomponenten zu wählen aus der Gruppe der Ester aus gesättigten, unverzweigten Alkancarbonsäuren einer Kettenlänge von 14 bis 44 C-Atomen und gesättigten, unverzweigten Alkoholen einer Kettenlänge von 14 bis 44 C-Atomen, sofern die Wachskomponente oder die Gesamtheit der Wachskomponenten bei Raumtemperatur fest sind. Insbesondere vorteilhaft können die Wachskomponenten aus der Gruppe der Ci6-36-Alkylstearate, der C-ιo-40-Alkylstearate, der C2-4o-Alkylisostearate, der C20-40-Dialkylester von Dimersäuren, der Ci8- 38-Alkylhydroxystearoylstearate, der C20-40-Alkylerucate gewählt werden, ferner sind C30-50-Alkyl- bienenwachs sowie Cetearylbehenat einsetzbar. Auch Silikonwachse, zum Beispiel Stearyltri- methylsilan/Stearylalkohol sind gegebenenfalls vorteilhaft. Besonders bevorzugte Wachskomponenten sind die Ester aus gesättigten, einwertigen C20-C60-Alkoholen und gesättigten C8-C30-Mono- carbonsäuren, insbesondere ein C20-C40-Alkylstearat bevorzugt, das unter dem Namen Kesterwachs® K82H von der Firma Koster Keunen Inc. erhältlich ist. Das Wachs oder die Wachskomponenten sollten bei 25° C fest sein, jedoch im Bereich von 35 - 95°C schmelzen, wobei ein Bereich von 45 - 85 0C bevorzugt ist.It is particularly preferred to choose the wax components from the group of esters of saturated, unbranched alkanecarboxylic acids having a chain length of 14 to 44 carbon atoms and saturated, unbranched alcohols of a chain length of 14 to 44 carbon atoms, provided the wax component or the entirety of the wax components are solid at room temperature. Particularly advantageously, the wax components from the group of Ci 6 can - 36 alkyl stearates, C-40 ιo- alkyl stearates, C 2-4 o-Alkylisostearate, the C 20 - 40 dialkyl esters of dimer acids, of the C 8-38 - Alkylhydroxystearoylstearates, the C 20 - 40 -Alkylerucate be selected, also C 30 - 50 -alkyl beeswax and Cetearylbehenat be used. Silicone waxes, for example stearyltrimethylsilane / stearyl alcohol, may also be advantageous. Particularly preferred wax components are the esters of saturated, monohydric C 20 -C 60 alcohols, and saturated C 8 -C 30 mono-carboxylic acids, in particular a C 20 -C 40 alkyl preferred, under the name ® Kesterwachs K82H by the company Koster Keunen Inc. is available. The wax or the wax components should be solid at 25 ° C, but in the range of 35 - 95 ° C to melt, with a range from 45 to 85 0 C is preferred.
Natürliche, chemisch modifizierte und synthetische Wachse können alleine oder in Kombination eingesetzt werden. Die Wachskomponenten sind in einer Menge von 0,1 bis 40 Gew.-%, bezogen auf die Gesamtzusammensetzung, vorzugsweise 1 bis 30 Gew.-% und insbesondere 5 - 25 Gew.-% enthalten. Die erfindungsgemäßen Zusammensetzungen können weiterhin wenigstens ein unpolares oder polares flüssiges Öl, das natürlich oder synthetisch sein kann, enthalten. Die polare Ölkomponente kann ausgewählt sein aus pflanzlichen Ölen, z. B. Sonnenblumenöl, Olivenöl, Sojaöl, Rapsöl, Mandelöl, Jojobaöl und den flüssigen Anteilen des Kokosöls sowie synthetischen Triglyceridölen, aus Esterölen, das heißt den Estern von C6-3o-Fettsäuren mit C2-3o-Fettalkoholen, aus Dicarbon- säureestern wie Di-n-butyladipat, Di-(2-ethylhexyl)-adipat und Di-(2-ethylhexyl)-succinat sowie Diolestern wie Ethylenglycoldioleat und Propylenglycoldi(2-ethylhexanoat), aus symmetrischen, unsymmetrischen oder cyclischen Estern der Kohlensäure mit Fettalkoholen, beispielsweise beschrieben in der DE-OS 197 56 454, Glycerincarbonat oder Dicaprylylcarbonat (Cetiol® CC), aus Mono,- Di- und Trifettsäureestern von gesättigten und/oder ungesättigten linearen und/oder verzweigten Fettsäuren mit Glycerin, aus verzweigten Alkanolen, z. B. Guerbet-Alkoholen mit einer einzigen Verzweigung am Kohlenstoffatom 2 wie 2-Hexyldecanol, 2-Octyldodecanol, Isotridecanol und Isohexadecanol, aus Alkandiolen, z. B. den aus Epoxyalkanen mit 12 - 24 C-Atomen durch Ringöffnung mit Wasser erhältlichen vicinalen Diolen, aus Etheralkoholen, z. B. den Monoalkyl- ethern des Glycerins, des Ethylenglycols, des 1 ,2-Propylenglycols oder des 1 ,2-Butandiols, aus Dialkylethern mit jeweils 12 - 24 C-Atomen, z. B. den Alkyl-methylethern oder Di-n-alkylethern mit jeweils insgesamt 12 - 24 C-Atomen, insbesondere Di-n-octylether (Cetiol®OE ex Cognis), sowie aus Anlagerungsprodukten von Ethylenoxid und/oder Propylenoxid an ein- oder mehrwertige C3.2o- Alkanole wie Butanol und Glycerin, z. B. PPG-3-Myristylether (Witconol® APM), PPG-14-Butylether (Ucon Fluid® AP), PPG-15-Stearylether (Arlamol® E), PPG-9-Butylether (Breox® B25) und PPG-10- Butandiol (Macol® 57). Die unpolare Ölkomponente kann ausgewählt sein aus flüssigen Paraffinölen, Isoparaffinölen, z. B. Isohexadecan und Isoeicosan, aus hydrogenierten Polyalkenen, insbesondere Poly-1-decenen (im Handel erhätlich als Nexbase 2004, 2006 oder 2008 FG (Fortum, Belgien)), aus synthetischen Kohlenwasserstoffen, z. B. 1 ,3-Di-(2-ethyl-hexyl)-cyclohexan (Cetiol® S), sowie aus flüchtigen und nichtflüchtigen Siliconölen, die cyclisch, wie z. B. Decamethylcyclo- pentasiloxan und Dodecamethylcyclohexasiloxan, oder linear sein können, z. B. lineares Dimethyl- polysiloxan, im Handel erhältlich z. B. unter der Bezeichnung Dow Corning® 190, 200, 244, 245, 344 oder 345 und Baysilon® 350 M.Natural, chemically modified and synthetic waxes may be used alone or in combination. The wax components are present in an amount of from 0.1 to 40% by weight, based on the total composition, preferably from 1 to 30% by weight and in particular from 5 to 25% by weight. The compositions of the invention may further contain at least one nonpolar or polar liquid oil, which may be natural or synthetic. The polar oil component may be selected from vegetable oils, e.g. B. sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil and the liquid portions of coconut oil and synthetic triglyceride oils, from ester oils, that is the esters of C 6 - 3 o-fatty acids with C 2 - 3 o-fatty alcohols, from dicarboxylic acid esters such as di-n-butyl adipate, di (2-ethylhexyl) adipate and di (2-ethylhexyl) succinate and diol esters such as ethylene glycol dioleate and propylene glycol di (2-ethylhexanoate), from symmetrical, unsymmetrical or cyclic esters of carbonic acid with fatty alcohols , for example described in DE-OS 197 56 454, glycerol carbonate or dicaprylyl carbonate (Cetiol ® CC), from mono, - di- and trifatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerol, branched alkanols, eg. B. Guerbet alcohols having a single branch on the carbon atom 2 such as 2-hexyldecanol, 2-octyldodecanol, isotridecanol and isohexadecanol, from alkanediols, eg. B. from Epoxyalkanen with 12 - 24 carbon atoms by ring opening with water available vicinal diols, from ether alcohols, eg. As the monoalkyl ethers of glycerol, ethylene glycol, 1, 2-propylene glycol or 1, 2-butanediol, from dialkyl ethers each having 12 - 24 carbon atoms, z. Example, the alkyl methyl ethers or di-n-alkyl ethers, each having a total of 12 to 24 carbon atoms, in particular di-n-octyl ether (Cetiol ® OE ex Cognis), as well as adducts of ethylene oxide and / or propylene oxide to mono- or polyvalent C 3 . 2 o-alkanols such as butanol and glycerol, z. PPG-3 myristyl ether (Witconol APM ®), PPG-14 butyl ether (Ucon Fluid ® AP) PPG-15 stearyl ether (Arlamol ® E), PPG-9-butyl ether (Breox B25 ®) and PPG-10 - butanediol (Macol ® 57). The non-polar oil component may be selected from liquid paraffin oils, isoparaffin oils, e.g. Isohexadecane and isoeicosane, from hydrogenated polyalkenes, especially poly-1-decenes (commercially available as Nexbase 2004, 2006 or 2008 FG (Fortum, Belgium)), from synthetic hydrocarbons, e.g. B. 1, 3-di- (2-ethyl-hexyl) -cyclohexane (Cetiol ® S), as well as volatile and nonvolatile silicone oils, the cyclic, such as. B. decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane, or may be linear, for. As linear dimethyl polysiloxane, commercially available for. Example under the name Dow Corning ® 190, 200, 244, 245, 344 or 345 and Baysilon ® 350 M.
Die erfindungsgemäßen Zusammensetzungen können weiterhin wenigstens einen wasserlöslichen Alkohol enthalten. Unter Wasserlöslichkeit versteht man erfindungsgemäß, dass sich wenigstens 5 Gew.-% des Alkohols bei 20 0C klar lösen oder aber - im Falle langkettiger oder polymerer Alkohole - durch Erwärmen der Lösung auf 50 0C bis 60 0C in Lösung gebracht werden können. Geeignet sind je nach Darreichungsform einwertige Alkohole wie z. B. Ethanol, Propanol oder Isopropa- nol. Weiterhin geeignet sind wasserlösliche Polyole. Hierzu zählen wasserlösliche Diole, Triole und höherwertige Alkohole sowie Polyethylenglycole. Unter den Diolen eignen sich C2-Ci2-DbIe, insbesondere 1 ,2-Propylenglycol, Butylenglycole wie z. B. 1 ,2-Butylenglycol, 1 ,3-Butylenglycol und 1 ,4-Butylenglycol, Hexandiole wie z. B. 1 ,6-Hexandiol. Weiterhin bevorzugt geeignet sind Glycerin und insbesondere Diglycerin und Triglycerin, 1 ,2,6-Hexantriol sowie die Dipropylenglycol und die Polyethylenglycole (PEG) PEG-400, PEG-600, PEG-1000, PEG-1550, PEG-3000 und PEG-4000. Die Menge des Alkohols oder des Alkohol-Gemisches in den erfindungsgemäßen Zusammensetzungen beträgt 1 - 98 oder 1 - 70 Gew.-% und vorzugsweise 5 - 40 oder 5 - 55 Gew.-%, bezogen auf die gesamte Zusammensetzung. Erfindungsgemäß kann sowohl ein Alkohol als auch ein Gemisch mehrerer Alkohole eingesetzt werden.The compositions of the invention may further contain at least one water-soluble alcohol. Water solubility is understood according to the invention that at least 5 wt .-% of the alcohol at 20 0 C clear dissolve or - in the case of long-chain or polymeric alcohols - by heating the solution to 50 0 C to 60 0 C can be brought into solution. Suitable depending on the dosage form monohydric alcohols such. For example, ethanol, propanol or isopropanol. Also suitable are water-soluble polyols. These include water-soluble diols, triols and higher alcohols and polyethylene glycols. Among the diols are C 2 -Ci 2 -DbIe, in particular 1, 2-propylene glycol, butylene glycols such. For example, 1, 2-butylene glycol, 1, 3-butylene glycol and 1, 4-butylene glycol, hexanediols such as. B. 1, 6-hexanediol. Also preferred are glycerol and in particular diglycerol and triglycerol, 1, 2,6-hexanetriol and the dipropylene glycol and the polyethylene glycols (PEG) PEG-400, PEG-600, PEG-1000, PEG-1550, PEG-3000 and PEG-4000. The amount of the alcohol or the alcohol mixture in the compositions according to the invention is 1-98 or 1-70% by weight and preferably 5-40 or 5-55% by weight, based on the total composition. According to the invention, both an alcohol and a mixture of several alcohols can be used.
Die erfindungsgemäßen Zusammensetzungen können im Wesentlichen wasserfrei sein, das heißt maximal 5 Gew.-%, bevorzugt maximal 1 Gew.-% Wasser enthalten. In wasserhaltigen Darreichungsformen beträgt der Wassergehalt 5 - 98 Gew.-%, bevorzugt 10 - 90 und besonders bevorzugt 15 - 85 Gew.-%, bezogen auf die gesamte Zusammensetzung.The compositions of the invention may be substantially anhydrous, that is containing a maximum of 5 wt .-%, preferably at most 1 wt .-% water. In water-containing administration forms, the water content is 5 to 98% by weight, preferably 10 to 90 and particularly preferably 15 to 85% by weight, based on the total composition.
Die erfindungsgemäßen Zusammensetzungen können weiterhin wenigstens ein hydrophil modifiziertes Silicon enthalten. Sie ermöglichen die Formulierung hochtransparenter Zusammensetzungen, reduzieren die Klebrigkeit und hinterlassen ein frisches Hautgefühl. Unter hydrophil modifizierten Siliconen werden erfindungsgemäß Polyorganosiloxane mit hydrophilen Substituenten verstanden, welche die Wasserlöslichkeit der Silicone bedingen. Erfindungsgemäß wird unter Wasserlöslichkeit verstanden, dass sich wenigstens 2 Gew.-% des mit hydrophilen Gruppen modifizierten Silicons in Wasser bei 20 0C lösen. Entsprechende hydrophile Substituenten sind beispielsweise Hydroxy-, Polyethylenglycol- oder Polyethylenglycol/Polypropylenglycol-Seitenketten sowie ethoxy- lierte Ester-Seitenketten. Erfindungsgemäß bevorzugt geeignet sind hydrophil modifizierte Silicon- Copolyole, insbesondere Dimethicone-Copolyole, die beispielsweise von Wacker-Chemie unter der Bezeichnung Belsil® DMC 6031 , Belsil® DMC 6032, Belsil® DMC 6038 oder Belsil® DMC 3071 VP bzw. von Dow Corning unter der Bezeichnung DC 2501 im Handel sind. Besonders bevorzugt geeignet ist die Verwendung von Belsil® DMC 6038, da es die Formulierung hochtransparenter Zusammensetzungen ermöglicht, die beim Verbraucher eine höhere Akzeptanz erreichen. Als hydrophiles Silikonderivat kann des Weiteren etwa auch ABIL EM97 von Degussa/Goldschmidt eingesetzt werden. Erfindungsgemäß kann auch ein beliebiges Gemisch der genannten Silicone eingesetzt werden.The compositions of the invention may further comprise at least one hydrophilic modified silicone. They allow the formulation of highly transparent compositions, reduce the stickiness and leave a fresh feeling on the skin. Hydrophilically modified silicones are understood according to the invention to mean polyorganosiloxanes having hydrophilic substituents which cause the water solubility of the silicones. According to the invention is understood to mean water-solubility that solve at least 2 wt .-% of the modified silicone with hydrophilic groups in water at 20 0 C. Corresponding hydrophilic substituents are, for example, hydroxy, polyethylene glycol or polyethylene glycol / polypropylene glycol side chains and ethoxylated ester side chains. According to the invention are preferably suitable hydrophilic modified silicone copolyols, in particular dimethicone copolyols, for example, by Wacker-Chemie under the name Belsil ® DMC 6031, Belsil ® DMC 6032, Belsil ® DMC 6038 or Belsil ® DMC 3071 VP or Dow Corning under the name DC 2501 are commercially available. Particularly preferably suitable is the use of Belsil® ® DMC 6038, as it allows the formulation of highly transparent compositions that achieve higher consumer acceptance. Furthermore, ABIL EM97 from Degussa / Goldschmidt can also be used as the hydrophilic silicone derivative. According to the invention, it is also possible to use any desired mixture of the silicones mentioned.
Die Menge des hydrophil modifizierten Silicons oder des Alkohol-Gemisches in den erfindungsgemäßen Zusammensetzungen beträgt 0,5 - 10 Gew.-%, bevorzugt 1 - 8 Gew.-% und besonders bevorzugt 2 - 6 Gew.-%, bezogen auf das Gesamtgewicht der Zusammensetzung. Die erfindungsgemäßen Zusammensetzungen können weiterhin Emulgatoren und/oder Tenside enthalten. In einer besonders bevorzugten Ausführungsform handelte sich hierbei um Anlagerungsprodukte von 10 - 50 Mol Ethylenoxid an lineare oder verzweigte Fettalkohole mit 16 - 22 C- Atomen, an Fettsäuren mit 12 - 22 C-Atomen, an Fettsäurealkanolamide, an Fettsäuremonoglyce- ride, an Sorbitan-Fettsäuremonoester, an Fettsäurealkanolamide, an Fettsäureglyceride, z.B. an gehärtetes Rizinusöl, an Methylglucosidmonofettsäureester und Gemische davon. Grundsätzlich können jedoch auch beliebige andere Emulgatoren und/oder Tenside verwendet werden. Erfindungsgemäß verwendbare Emulgatoren in diesem Sinne sind beispielsweise Anlagerungsprodukte von 4 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare oder verzweigte C8-C22-Fettalkohole, an C12-C22-Fettsäuren und an C8-C15-Alkylphenole, C12-C22-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an C3-C6-Polyole, insbesondere an Glycerin, Ethylenoxid- und Polyglycerin-Anlagerungsprodukte an Methylglucosid-Fett- säureester, Fettsäurealkanolamide und Fettsäureglucamide, C8-C22-Alkylmono- und -oligoglycosi- de und deren ethoxylierte Analoga, wobei Oligomerisierungsgrade von 1 ,1 bis 5, insbesondere 1 ,2 bis 2,0, und Glucose als Zuckerkomponente bevorzugt sind, Gemische aus Alkyl-(oligo)-glucosiden und Fettalkoholen, z. B. das im Handel erhältliche Produkt Montanov®68, Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und gehärtetes Rizinusöl, Partialester von Polyolen mit 3-6 Kohlenstoffatomen mit gesättigten C8-C22-Fettsäuren, Sterole (Sterine). Als Sterole wird eine Gruppe von Steroiden verstanden, die am C-Atom 3 des Steroid-Gerüstes eine Hydroxylgruppe tragen und sowohl aus tierischem Gewebe (Zoosterole) wie auch aus pflanzlichen Fetten (Phyto- sterole) isoliert werden. Beispiele für Zoosterole sind das Cholesterol und das Lanosterol. Beispiele geeigneter Phytosterole sind Beta-Sitosterol, Stigmasterol, Campesterol und Ergosterol. Auch aus Pilzen und Hefen werden Sterole, die sogenannten Mykosterole, isoliert; Phospholipide, vor allem die Glucose-Phospolipide, die z. B. als Lecithine bzw. Phosphatidylcholine aus z. B. Eidotter oder Pflanzensamen (z. B. Sojabohnen) gewonnen werden, Fettsäureester von Zuckern und Zuckeralkoholen wie Sorbit, Polyglycerine und Polyglycerinderivate, bevorzugt Polyglyceryl-2-dipolyhydro- xystearat (Handelsprodukt Dehymuls® PGPH) und Polyglyceryl-3-diisostearat (Handelsprodukt Lameform® TGI), lineare und verzweigte C8-C30-Fettsäuren und deren Na-, K-, Ammonium-, Ca-, Mg- und Zn - Salze.The amount of the hydrophilic modified silicone or the alcohol mixture in the compositions according to the invention is 0.5-10% by weight, preferably 1-8% by weight and more preferably 2-6% by weight, based on the total weight of the Composition. The compositions of the invention may further contain emulsifiers and / or surfactants. In a particularly preferred embodiment, adducts of 10 to 50 moles of ethylene oxide to linear or branched fatty alcohols having 16 to 22 carbon atoms, to fatty acids containing 12 to 22 carbon atoms, to fatty acid alkanolamides, to fatty acid monoglycerides, to sorbitan Fatty acid monoesters, fatty acid alkanolamides, fatty acid glycerides, eg hydrogenated castor oil, methylglucoside mono-fatty acid esters and mixtures thereof. In principle, however, any other emulsifiers and / or surfactants can be used. Emulsifiers which can be used according to the invention in this sense are, for example, addition products of from 4 to 30 mol of ethylene oxide and / or from 0 to 5 mol of propylene oxide to linear or branched C 8 -C 22 fatty alcohols, C 12 -C 22 fatty acids and C 8 -C 15 alkylphenols, C 12 -C 22 fatty acid mono- and diesters of addition products of from 1 to 30 moles of ethylene oxide onto C 3 -C 6 -polyols, in particular of glycerol, ethylene oxide and polyglycerol addition products of methyl glucoside fatty acid esters, fatty acid alkanolamides and fatty acid glucamides, C 8 -C 22 alkyl mono- and oligoglycosides and their ethoxylated analogs, wherein degrees of oligomerization of 1, 1 to 5, in particular 1, 2 to 2.0, and glucose are preferred as the sugar component, mixtures of alkyl (oligo) glucosides and fatty alcohols, for. As the commercially available product Montanov ® 68, addition products of 5 to 60 moles of ethylene oxide with castor oil and hydrogenated castor oil, partial esters of polyols having 3-6 carbon atoms with saturated C 8 -C 22 fatty acids, sterols (sterols). Sterols are understood to mean a group of steroids which have a hydroxyl group at C atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are beta-sitosterol, stigmasterol, campesterol and ergosterol. From fungi and yeasts sterols, the so-called mycosterols, isolated; Phospholipids, especially the glucose phospholipids, the z. B. as lecithins or phosphatidylcholines from z. Example, egg yolk or plant seeds (eg., Soybean) are obtained, fatty acid ester of sugars and sugar alcohols such as sorbitol, polyglycerols and polyglycerol, preferably Polyglyceryl-2-dipolyhydro- xystearat (commercial product Dehymuls ® PGPH) and polyglyceryl-3-diisostearate (commercial product Lameform ® TGI), linear and branched C 8 -C 30 fatty acids and their Na, K, ammonium, Ca, Mg and Zn salts.
Die erfindungsgemäßen Mittel enthalten die Emulgatoren bevorzugt in Mengen von 0,1 bis 25 Gew.-%, insbesondere 0,5 - 15 Gew.-%, bezogen auf das gesamte Mittel. In einer anderen, ebenfalls bevorzugten Ausführungsform ist mindestens ein ionischer Emulgator, ausgewählt aus anionischen, zwitterionischen, ampholytischen und kationischen Emulgatoren, enthalten. Bevorzugte anionische Emulgatoren sind Alkylsulfate, Alkylpolyglycolethersulfate und Ethercarbonsäuren mit 10 bis 18 C-Atomen in der Alkylgruppe und bis zu 12 Glycolethergruppen im Molekül, Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 18 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremono-alkylpolyoxyethylester mit 8 bis 18 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen, Monoglyceridsulfate, Alkyl- und Alkenyletherphosphate sowie Eiweißfettsäurekondensate. Zwitterionische Emulgatoren tragen im Molekül mindestens eine quartäre Ammoniumgruppe und mindestens eine -COO" - oder -SO3 " -Gruppe. Besonders geeignete zwitterionische Emulgatoren sind die sogenannten Betaine wie die N-Alkyl-N,N-dimethylammoni- um-glycinate, N-Acyl-aminopropyl-N,N-dimethylammoniumglycinate und 2-Alkyl-3-carboxymethyl- 3-hydroxyethyl-imidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe sowie das Kokosacylaminoethylhydroxyethylcarboxymethylglycinat.The agents according to the invention preferably contain the emulsifiers in amounts of 0.1 to 25% by weight, in particular 0.5 to 15% by weight, based on the total agent. In another, likewise preferred embodiment, at least one ionic emulsifier selected from anionic, zwitterionic, ampholytic and cationic emulsifiers is contained. Preferred anionic emulsifiers are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups, monoglyceride sulfates, alkyl and Alkenyletherphosphate and protein fatty acid condensates. Zwitterionic emulsifiers carry in the molecule at least one quaternary ammonium group and at least one -COO " - or -SO 3 " group. Particularly suitable zwitterionic emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, N-acylaminopropyl-N, N-dimethylammonium glycinates and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines in each case 8 to 18 C atoms in the alkyl or acyl group and the Kokosacylaminoethylhydroxyethylcarboxymethylglycinat.
Ampholytische Emulgatoren enthalten außer einer C8 - C24-Alkyl- oder -Acylgruppe mindestens eine freie Aminogruppe und mindestens eine -COOH- oder -SO3H-Gruppe im Molekül und können innere Salze ausbilden. Beispiele für geeignete ampholytische Emulgatoren sind N-Alkylglycine, N- Alkylaminopropionsäuren, N-Alkylaminobuttersäuren, N-Alkyliminodipropionsäuren, N-Hydroxy- ethyl-N-alkylamidopropylglycine, N-Alkyltaurine, N-Alkylsarcosine, 2-Alkylaminopropionsäuren und Alkylaminoessigsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe. Die ionischen Emulgatoren sind in einer Menge von 0,01 bis 5 Gew.-%, bevorzugt von 0,05 bis 3 Gew.-% und besonders bevorzugt von 0,1 bis 1 Gew.-%, bezogen auf das gesamte Mittel, enthalten.Ampholytic emulsifiers contain, in addition to a C 8 -C 24 -alkyl or -acyl group, at least one free amino group and at least one -COOH or -SO 3 H group in the molecule and can form internal salts. Examples of suitable ampholytic emulsifiers are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxy- ethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group. The ionic emulsifiers are contained in an amount of 0.01 to 5 wt .-%, preferably from 0.05 to 3 wt .-% and particularly preferably from 0.1 to 1 wt .-%, based on the total agent ,
Weiterhin können die erfindungsgemäßen Zusammensetzungen mindestens ein Proteinhydrolysat oder dessen Derivat enthalten. Erfindungsgemäß können sowohl pflanzliche als auch tierische Proteinhydrolysate eingesetzt werden. Tierische Proteinhydrolysate sind z. B. Elastin-, Collagen-, Keratin-, Seiden- und Milcheiweiß-Proteinhydrolysate, die auch in Form von Salzen vorliegen können. Erfindungsgemäß bevorzugt sind pflanzliche Proteinhydrolysate, z. B. Soja-, Weizen-, Mandel-, Erbsen-, Kartoffel- und Reisproteinhydrolysate.Furthermore, the compositions according to the invention may contain at least one protein hydrolyzate or its derivative. Both vegetable and animal protein hydrolysates can be used according to the invention. Animal protein hydrolysates are z. B. elastin, collagen, keratin, silk and milk protein protein hydrolysates, which may also be in the form of salts. Vegetable protein hydrolysates, eg. Soy, wheat, almonds, peas, potato and rice protein hydrolysates.
An Stelle der Proteinhydrolysate können zum einen anderweitig erhaltene Aminosäuregemische, zum anderen auch einzelne Aminosäuren sowie deren physiologisch verträgliche Salze eingesetzt werden. Zu den erfindungsgemäß bevorzugten Aminosäuren gehören Glycin, Serin, Threonin, Cystein, Asparagin, Glutamin, Pyroglutaminsäure, Alanin, VaNn, Leucin, Isoleucin, Prolin, Tryptophan, Phenylalanin, Methionin, Asparaginsäure, Glutaminsäure, Lysin, Arginin und Histidin sowie die Zinksalze und die Säureadditionssalze der genannten Aminosäuren. Ebenfalls möglich ist der Einsatz von Derivaten der Proteinhydrolysate, z. B. in Form ihrer Fettsäure-Kondensationsprodukte. Erfindungsgemäß einsetzbar sind auch kationisierte Proteinhydrolysate, wobei das zugrunde liegende Proteinhydrolysat vom Tier, von der Pflanze, von marinen Lebensformen oder von biotechnologisch gewonnenen Proteinhydrolysaten, stammen kann.Instead of the protein hydrolysates, amino acid mixtures obtained on the one hand and, on the other hand, individual amino acids and their physiologically tolerated salts can also be used. The inventively preferred amino acids include glycine, serine, threonine, cysteine, asparagine, glutamine, pyroglutamic acid, alanine, VaNn, leucine, isoleucine, proline, tryptophan, phenylalanine, methionine, aspartic acid, glutamic acid, lysine, arginine and histidine, and the zinc salts and Acid addition salts of said amino acids. Also possible is the use of derivatives of protein hydrolysates, z. In the form of their fatty acid condensation products. Cationized protein hydrolysates can also be used according to the invention, it being possible for the underlying protein hydrolyzate to originate from the animal, from the plant, from marine life forms or from biotechnologically obtained protein hydrolysates.
In den erfindungsgemäßen Zusammensetzungen sind die Proteinhydrolysate und deren Derivate beziehungsweise die Aminosäuren und deren Derivate in Mengen bis zu 10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1 bis 5 Gew.-%, insbesondere 0,1 bis 3 Gew.-%, sind besonders bevorzugt.In the compositions according to the invention are the protein hydrolysates and their derivatives or the amino acids and their derivatives in amounts of up to 10 wt .-%, based on the total agent included. Amounts of 0.1 to 5 wt .-%, in particular 0.1 to 3 wt .-%, are particularly preferred.
Weiterhin können die erfindungsgemäßen Zusammensetzungen mindestens ein Mono-, Oligo- oder Polysaccharid oder deren Derivate enthalten. Erfindungsgemäß geeignete Monosaccharide sind z. B. Glucose, Fructose, Galactose, Arabinose, Ribose, Xylose, Lyxose, Allose, Altrose, Man- nose, Gulose, Idose und Talose, die Desoxyzucker Fucose und Rhamnose sowie Aminozucker wie z. B. Glucosamin oder Galactosamin. Bevorzugt sind Glucose, Fructose, Galactose, Arabinose und Fucose; Glucose ist besonders bevorzugt. Erfindungsgemäß geeignete Oligosaccharide sind aus zwei bis zehn Monosaccharideinheiten zusammengesetzt, z. B. Saccharose, Lactose oder Treha- lose. Ein besonders bevorzugtes Oligosaccharid ist Saccharose. Ebenfalls besonders bevorzugt ist die Verwendung von Honig, der überwiegend Glucose und Saccharose enthält. Erfindungsgemäß geeignete Polysaccharide sind aus mehr als zehn Monosaccharideinheiten zusammengesetzt. Bevorzugte Polysaccharide sind die aus α-D-Glucose-Einheiten aufgebauten Stärken sowie Stärkeabbauprodukte wie Amylose, Amylopektin und Dextrine. Erfindungsgemäß besonders vorteilhaft sind chemisch und/oder thermisch modifizierte Stärken, z. B. Hydroxypropylstärkephosphat, Dihydroxypropyldistärkephosphat oder die Handelsprodukte Dry Flo®. Weiterhin bevorzugt sind Dextrane sowie ihre Derivate, z. B. Dextransulfat. Ebenfalls bevorzugt sind nichtionische Cellulose- Derivate, wie Methylcellulose, Hydroxypropylcellulose oder Hydroxyethylcellulose, sowie kationische Cellulose-Derivate, z. B. die Handelsprodukte Celquat® und Polymer JR®, und bevorzugt CeI- quat® H 100, Celquat® L 200 und Polymer JR® 400 (Polyquaternium-10) sowie Polyquaternium-24. Weitere bevorzugte Beispiele sind Polysaccharide aus Fucose-Einheiten, z. B. das Handelsprodukt Fucogel®. Besonders bevorzugt sind die aus Aminozuckereinheiten aufgebauten Polysaccharide, insbesondere Chitine und ihre deacetylierten Derivate, die Chitosane, und Mucopolysaccharide. Zu den erfindungsgemäß bevorzugten Mucopolysacchariden gehören Hyaluronsäure und ihre Derivate, z. B. Natriumhyaluronat oder Dimethylsilanolhyaluronat, sowie Chondroitin und seine Derivate, z. B. Chondroitinsulfat.Furthermore, the compositions according to the invention may contain at least one mono-, oligo- or polysaccharide or derivatives thereof. According to the invention suitable monosaccharides are z. As glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, man- nose, gulose, idose and talose, the deoxy sugars fucose and rhamnose and amino sugars such. As glucosamine or galactosamine. Preferred are glucose, fructose, galactose, arabinose and fucose; Glucose is particularly preferred. According to the invention suitable oligosaccharides are composed of two to ten monosaccharide units, for. For example, sucrose, lactose or trehalose. A particularly preferred oligosaccharide is sucrose. Also particularly preferred is the use of honey, which contains predominantly glucose and sucrose. Polysaccharides which are suitable according to the invention are composed of more than ten monosaccharide units. Preferred polysaccharides are the starches made from α-D-glucose units and starch degradation products such as amylose, amylopectin and dextrins. Particularly advantageous according to the invention are chemically and / or thermally modified starches, for. Hydroxypropyl starch phosphate, dihydroxypropyldistarch phosphate or the commercial products Dry Flo® . Further preferred Dextrans and their derivatives, eg. B. dextran sulfate. Also preferred are nonionic cellulose derivatives such as methylcellulose, hydroxypropylcellulose or hydroxyethylcellulose, as well as cationic cellulose derivatives, e.g. , The commercial products Celquat ® and Polymer JR ®, and preferably CEI quat ® H 100, Celquat L 200 and Polymer JR ® ® 400 (Polyquaternium-10) as well as Polyquaternium-24th Further preferred examples are polysaccharides from fucose units, e.g. B. the commercial product Fucogel ® . Particularly preferred are the polysaccharides composed of amino sugar units, in particular chitins and their deacetylated derivatives, the chitosans, and mucopolysaccharides. The inventively preferred mucopolysaccharides include hyaluronic acid and its derivatives, e.g. As sodium hyaluronate or Dimethylsilanolhyaluronat, and chondroitin and its derivatives, for. B. chondroitin sulfate.
In einer vorteilhaften Ausführungsform enthalten die erfindungsgemäßen Zusammensetzungen mindestens ein filmbildendes, emulsionsstabilisierendes, verdickendes oder adhäsives Polymer, ausgewählt aus natürlichen und synthetischen Polymeren, die kationisch, anionisch, amphoter geladen oder nichtionisch sein können. Erfindungsgemäß bevorzugt sind kationische, anionische sowie nichtionische Polymere.In an advantageous embodiment, the compositions according to the invention comprise at least one film-forming, emulsion-stabilizing, thickening or adhesive polymer selected from natural and synthetic polymers which may be cationic, anionic, amphoteric or nonionic. Cationic, anionic and nonionic polymers are preferred according to the invention.
Bevorzugte anionische Polymere, die die Wirkung des erfindungsgemäß verwendeten Wirkstoffs unterstützen können, enthalten Carboxylat- und/oder Sulfonatgruppen und als Monomere zum Beispiel Acrylsäure, Methacrylsäure, Crotonsäure, Maleinsäureanhydrid und 2-Acrylamido-2-methyl- propansulfonsäure. Dabei können die sauren Gruppen ganz oder teilweise als Natrium-, Kalium-, Ammonium-, Mono- oder Triethanolammonium-Salz vorliegen. Bevorzugte Monomere sind 2-Acryl- amido-2-methylpropansulfonsäure und Acrylsäure. Ganz besonders bevorzugte anionische Polymere enthalten als alleiniges Monomer oder als Comonomer 2-Acrylamido-2-methylpropansulfon- säure, wobei die Sulfonsäuregruppe ganz oder teilweise in Salzform vorliegen kann. Innerhalb dieser Ausführungsform ist es bevorzugt, Copolymere aus mindestens einem anionischen Monomer und mindestens einem nichtionischen Monomer einzusetzen. Bezüglich der anionischen Monomere wird auf die oben aufgeführten Substanzen verwiesen. Bevorzugte nichtionogene Monomere sind Acrylamid, Methacrylamid, Acrylsäureester, Methacrylsäureester, Vinylpyrrolidon, Vinylether und Vinylester. Bevorzugte anionische Copolymere sind Acrylsäure-Acrylamid-Copoly- mere sowie insbesondere Polyacrylamidcopolymere mit Sulfonsäuregruppen-haltigen Monomeren. Ein besonders bevorzugtes anionisches Copolymer besteht aus 70 bis 55 Mol-% Acrylamid und 30 bis 45 Mol-% 2-Acrylamido-2-methylpropansulfonsäure, wobei die Sulfonsäuregruppen ganz oder teilweise als Natrium-, Kalium-, Ammonium-, Mono- oder Triethanolammonium-Salz vorliegen. Dieses Copolymer kann auch vernetzt vorliegen, wobei als Vernetzungsagentien bevorzugt poly- olefinisch ungesättigte Verbindungen wie Tetraallyloxyethan, Allylsucrose, Allylpentaerythrit und Methylen-bisacrylamid zum Einsatz kommen. Ein solches Polymer ist in dem Handelsprodukt Sepigel®305 der Firma SEPPIC enthalten. Die Verwendung dieses Compounds hat sich im Rahmen der erfindungsgemäßen Lehre als besonders vorteilhaft erwiesen. Auch die unter der Bezeichnung Simulgel®600 als Compound mit Isohexadecan und Polysorbat-80 vertriebenen Natriumacryloyldimethyltaurat-Copolymere haben sich als erfindungsgemäß besonders wirksam erwiesen.Preferred anionic polymers which can support the action of the active ingredient used according to the invention comprise carboxylate and / or sulfonate groups and as monomers, for example, acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. The acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid. Very particularly preferred anionic polymers contain, as the sole monomer or comonomer, 2-acrylamido-2-methylpropanesulfonic acid, it being possible for the sulfonic acid group to be wholly or partly in salt form. Within this embodiment, it is preferred to use copolymers of at least one anionic monomer and at least one nonionic monomer. With regard to the anionic monomers, reference is made to the substances listed above. Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters. Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with monomers containing sulfonic acid groups. A particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid groups are wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt present. This copolymer can also be present in crosslinked form, with crosslinking agents preferably used being poly-olefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide. Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC. The use of this compound has proven to be particularly advantageous in the context of the teaching of the invention. Also sold under the name Simulgel ® 600 as a compound with isohexadecane and polysorbate-80 Sodium acryloyldimethyltaurate copolymers have proven to be particularly effective according to the invention.
Weitere bevorzugte anionische Homo- und Copolymere sind unvernetzte und vernetzte Polyacryl- säuren. Dabei können Allylether von Pentaerythrit, von Sucrose und von Propylen bevorzugte Ver- netzungsagentien sein. Solche Verbindungen sind zum Beispiel die Handelsprodukte Carbopol®. Ein besonders bevorzugtes anionisches Copolymer enthält als Monomer zu 80 - 98 % eine ungesättigte, gewünschtenfalls substituierte C3.6-Carbonsäure oder ihr Anhydrid sowie zu 2 - 20 % gewünschtenfalls substituierte Acrylsäureester von gesättigten Cio-30-Carbonsäuren, wobei das Copolymer mit den vorgenannten Vernetzungsagentien vernetzt sein kann. Entsprechende Handelsprodukte sind Pemulen® und die Carbopol®-Typen 954, 980, 1342 und ETD 2020 (ex Noveon). Geeignete nichtionische Polymere sind beispielsweise Polyvinylalkohole, die teilverseift sein können, z. B. die Handelsprodukte Mowiol® sowie Vinylpyrrolidon/Vinylester-Copolymere und PoIy- vinylpyrrolidone, die z. B. unter dem Warenzeichen Luviskol® (BASF) vertrieben werden. Die erfindungsgemäßen Zusammensetzungen können weiterhin mindestens eine α-Hydroxycar- bonsäure oder α-Ketocarbonsäure oder deren Ester-, Lacton- oder Salzform enthalten. Geeignete α-Hydroxycarbonsäuren oder α-Ketocarbonsäuren sind ausgewählt aus Milchsäure, Weinsäure, Citronensäure, 2-Hydroxybutansäure, 2,3-Dihydroxypropansäure, 2-Hydroxypentansäure, 2-Hydro- xyhexansäure, 2-Hydroxyheptansäure, 2-Hydroxyoctansäure, 2-Hydroxydecansäure, 2-Hydroxydo- decansäure, 2-Hydroxytetradecansäure, 2-Hydroxyhexadecansäure, 2-Hydroxyoctadecansäure, Mandelsäure, 4-Hydroxymandelsäure, Äpfelsäure, Erythrarsäure, Threarsäure, Glucarsäure, Galactarsäure, Mannarsäure, Gularsäure, 2-Hydroxy-2-methylbernsteinsäure, Gluconsäure, Brenz- traubensäure, Glucuronsäure und Galacturonsäure. Die Ester der genannten Säuren sind ausgewählt aus den Methyl-, Ethyl-, Propyl-, Isopropyl-, Butyl-, Amyl-, Pentyl-, Hexyl-, 2-Ethylhexyl-, Octyl-, Decyl-, Dodecyl- und Hexadecylestern. Die α-Hydroxycarbonsäuren oder α-Ketocarbonsäuren oder ihre Derivate sind in Mengen von 0,1 - 10 Gew.-%, bevorzugt 0,5 - 5 Gew.-%, jeweils bezogen auf die gesamte Zusammensetzung, enthalten.Further preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example the commercial products Carbopol ®. A particularly preferred anionic copolymer contains as monomer 80-98% of an unsaturated, optionally substituted C 3 . 6- carboxylic acid or its anhydride and to 2 - 20%, if desired, substituted acrylic acid esters of saturated Cio 30 carboxylic acids, wherein the copolymer can be crosslinked with the aforementioned crosslinking agents. Corresponding commercial products are Pemulen ® and Carbopol ® grades 954, 980, 1342 and ETD 2020 (ex Noveon). Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for. As the commercial products Mowiol ® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidone z. B. under the trademark Luviskol ® (BASF) are sold. The compositions of the invention may further contain at least one α-hydroxycarboxylic acid or α-ketocarboxylic acid or their ester, lactone or salt form. Suitable α-hydroxycarboxylic acids or α-ketocarboxylic acids are selected from lactic acid, tartaric acid, citric acid, 2-hydroxybutanoic acid, 2,3-dihydroxypropanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxydecanoic acid, 2 Hydroxydodecanoic acid, 2-hydroxytetradecanoic acid, 2-hydroxyhexadecanoic acid, 2-hydroxyoctadecanoic acid, mandelic acid, 4-hydroxymandelic acid, malic acid, erythraric acid, threaric acid, glucaric acid, galactaric acid, mannaric acid, gularic acid, 2-hydroxy-2-methylsuccinic acid, gluconic acid, pyruvic acid , Glucuronic acid and galacturonic acid. The esters of said acids are selected from the methyl, ethyl, propyl, isopropyl, butyl, amyl, pentyl, hexyl, 2-ethylhexyl, octyl, decyl, dodecyl and hexadecyl esters. The α-hydroxycarboxylic acids or α-ketocarboxylic acids or their derivatives are present in amounts of from 0.1 to 10% by weight, preferably 0.5 to 5% by weight, in each case based on the total composition.
Die erfindungsgemäßen Mittel können weitere Wirk-, Hilfs- und Zusatzstoffe enthalten, z. B. Vitamine, Provitamine und Vitaminvorstufen aus den Gruppen A, C, E und F, insbesondere 3,4-Dide- hydroretinol (Vitamin A2), ß-Carotin (Provitamin des Vitamin A1), Ascorbinsäure (Vitamin C), sowie die Palmitinsäureester, Glucoside oder Phosphate der Ascorbinsäure, Tocopherole, insbesondere α-Tocopherol sowie seine Ester, z. B. das Acetat, das Nicotinat, das Phosphat und das Succinat; weiterhin Vitamin F, worunter essentielle Fettsäuren, besonders Linolsäure, Linolensäure und Ara- chidonsäure, verstanden werden; einen Ester von Retinol (Vitamin A1) mit einer C2--i8-Carbonsäure, insbesondere Retinylacetat oder Retinylpalmitat; Vitamine, Provitamine oder Vitaminvorstufen der Vitamin B-Gruppe oder deren Derivate sowie Derivate von 2-Furanon, insbesondere Vitamin B1 (Thiamin), Vitamin B2 (Riboflavin), Vitamin B3 (Nicotinsäure und/oder Nicotinsäureamid), Vitamin B5 (Pantothensäure und/oder Panthenol), Vitamin B6 (Pyridoxin, Pyridoxamin und/oder Pyridoxal) und/oder Vitamin B7 (Biotin), Allantoin, Ceramide und Pseudoceramide, Triterpene, insbesondere Triterpensäuren wie Ursolsäure, Rosmarinsäure, Betulinsäure, Boswelliasäure und Bryonolsäure, monomere Catechine, besonders Catechin und Epicatechin, Leukoanthocyanidine, Catechinpoly- mere (Catechin-Gerbstoffe) sowie Gallotannine, Verdickungsmittel, z. B. Gelatine, Pflanzengumme wie Agar-Agar, Guar-Gum, Alginate, Xanthan-Gum, Gummi arabicum, Karaya-Gummi oder Johannisbrotkernmehl, natürliche und synthetische Tone und Schichtsilikate, z. B. Bentonit, Hectorit, Montmorillonit oder Laponite®, vollsynthetische Hydrokolloide wie z. B. Polyvinylalkohol, und außerdem Ca-, Mg- oder Zn-Seifen von Fettsäuren, Pflanzenglycoside, Strukturanten wie Maleinsäure und Milchsäure, Dimethylisosorbid, alpha-, beta- sowie gamma-Cyclodextrine, insbesondere zur Stabilisierung von Retinol, Lösungsmittel, Quell- und Penetrationsstoffe wie Ethanol, Isopropa- nol, Ethylenglycol, Propylenglycol, Propylenglycolmonoethylether, Glycerin und Diethylenglycol, Carbonate, Hydrogencarbonate, Guanidine, Harnstoffe sowie primäre, sekundäre und tertiäre Phosphate, Parfümöle, Pigmente sowie Farbstoffe zum Anfärben des Mittels, Substanzen zur Einstellung des pH-Wertes, z. B. α- und ß-Hydroxycarbonsäuren, Komplexbildner wie EDTA, NTA, ß- Alanindiessigsäure und Phosphonsäuren, Trübungsmittel wie Latex, Styrol/PVP- und Styrol/Acryl- amid-Copolymere, Treibmittel wie Propan-Butan-Gemische, N2O, Dimethylether, CO2 und Luft, MMP-1-inhibierende Substanzen, insbesondere ausgewählt aus Photolyase und/oder T4 Endo- nuclease V, Propylgallat, Precocenen, 6-Hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran und 3,4-Dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran, organische, mineralische und/oder modifizierte mineralische Lichtschutzfilter, insbesondere UVA-Filter und/oder UVB-Filter. Erfindungsgemäße Deodorant- oder Antitranspirant-Stifte können in gelierter Form, auf wasserfreier Wachsbasis und auf Basis von W/O-Emulsionen und O/W-Emulsionen vorliegen. Gelstifte können auf der Basis von Fettsäureseifen, Dibenzylidensorbitol, N-Acylaminosäureamiden, 12- Hydroxystearinsäure und anderen Gelbildnern hergestellt werden. Aerosolsprays, Pumpsprays, Roll on-Applikationen und Cremes können als Wasser-in-ÖI-Emulsion, ÖI-in-Wasser-Emulsion, Siliconöl-in-Wasser-Emulsion, Wasser-in-ÖI-Mikroemulsion, ÖI-in-Wasser-Mikroemulsion, Silicon- öl-in-Wasser-Mikroemulsion, wasserfreie Suspension, alkoholische und hydroalkoholische Lösung, wässriges Gel und als Öl vorliegen. Alle genannten Zusammensetzungen können verdickt sein, z. B. auf der Basis von Fettsäureseifen, Dibenzylidensorbitol, N-Acylaminosäureamiden, 12-Hydroxy- stearinsäure, Polyacrylaten vom Carbomer- und Carbopol-Typ, Polyacrylamiden und Polysacchariden, die chemisch und/oder physikalisch modifiziert sein können, sowie auf Basis von Fettalkoholen in Kombination mit gehärteten Triglyceriden, insbesondere in Kombination mit hydriertem Rizinusöl (Cutina® HR). Die Emulsionen und Mikroemulsionen können transparent, translucent oder opak sein.The compositions of the invention may contain other active ingredients, auxiliaries and additives, for. B. vitamins, provitamins and vitamin precursors from groups A, C, E and F, in particular 3,4-dide hydroretinol (vitamin A 2 ), ß-carotene (provitamin of vitamin A 1 ), ascorbic acid (vitamin C), and the palmitic acid esters, glucosides or phosphates of ascorbic acid, tocopherols, in particular α-tocopherol and its esters, for. The acetate, the nicotinate, the phosphate and the succinate; also vitamin F, which is understood as meaning essential fatty acids, especially linoleic acid, linolenic acid and arachidonic acid; an ester of retinol (vitamin A 1 ) with a C 2 - 8 carboxylic acid, especially retinyl acetate or retinyl palmitate; Vitamins, provitamins or vitamin precursors of the vitamin B group or derivatives thereof and derivatives of 2-furanone, in particular vitamin B 1 (thiamine), vitamin B 2 (riboflavin), vitamin B 3 (nicotinic acid and / or nicotinic acid amide), vitamin B 5 ( Pantothenic acid and / or panthenol), vitamin B 6 (pyridoxine, pyridoxamine and / or pyridoxal) and / or vitamin B 7 (biotin), allantoin, ceramides and pseudoceramides, triterpenes, in particular Triterpenic acids such as ursolic acid, rosmarinic acid, betulinic acid, boswellic acid and bryonic acid, monomeric catechins, especially catechin and epicatechin, leucoanthocyanidins, catechin polymers (catechin tannins) and gallotannins, thickeners, eg. As gelatin, plant matter such as agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum or locust bean gum, natural and synthetic clays and phyllosilicates, z. As bentonite, hectorite, montmorillonite or Laponite ® , fully synthetic hydrocolloids such. As polyvinyl alcohol, and also Ca, Mg or Zn soaps of fatty acids, vegetable glycosides, structurants such as maleic acid and lactic acid, dimethyl isosorbide, alpha, beta and gamma cyclodextrins, especially for the stabilization of retinol, solvents, swelling and penetrating agents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerol and diethylene glycol, carbonates, bicarbonates, guanidines, ureas and primary, secondary and tertiary phosphates, perfume oils, pigments and dyes for dyeing the agent, substances for adjusting the pH, z. B. α- and ß-hydroxycarboxylic acids, complexing agents such as EDTA, NTA, ß-Alanindiessigsäure and phosphonic acids, opacifiers such as latex, styrene / PVP and styrene / acrylic amide copolymers, propellants such as propane-butane mixtures, N 2 O, Dimethyl ether, CO 2 and air, MMP-1-inhibiting substances, in particular selected from photolyase and / or T4 endonuclease V, propyl gallate, precocenes, 6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) - benzopyran and 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) -benzopyran, organic, mineral and / or modified mineral sunscreen filters, in particular UVA filters and / or UVB filters. Deodorant or antiperspirant sticks according to the invention may be in gelled form, on anhydrous wax base and based on W / O emulsions and O / W emulsions. Gel sticks can be prepared on the basis of fatty acid soaps, dibenzylidene sorbitol, N-acyl amino acid amides, 12-hydroxystearic acid and other gelling agents. Aerosol sprays, pump sprays, roll on applications and creams can be used as water in oil emulsion, oil in water emulsion, silicone oil in water emulsion, water in oil microemulsion, oil in water. Microemulsion, silicone oil-in-water microemulsion, anhydrous suspension, alcoholic and hydroalcoholic solution, aqueous gel and as an oil. All of the above compositions may be thickened, e.g. B. on the basis of fatty acid soaps, Dibenzylidensorbitol, N-Acylaminosäureamiden, 12-hydroxy stearic acid, carbomeric and carbopol type polyacrylates, polyacrylamides and polysaccharides, which may be chemically and / or physically modified, and based on fatty alcohols in combination with hardened triglycerides, especially in combination with hydrogenated castor oil (Cutina® HR). The emulsions and microemulsions may be transparent, translucent or opaque.
Flüssige und gelförmige Darreichungsformen der erfindungsgemäßen Zusammensetzungen können Verdickungsmittel enthalten, z. B. Celluloseether, wie Hydroxypropylcellulose, Hydroxy- ethylcellulose und Methylhydroxypropylcellulose, verdickende Polymere auf Basis von Polyacrylaten, die gewünschtenfalls vernetzt sein können, z. B. die Carbopoltypen oder Pemulen®-Pro- dukte, oder auf Basis von Polyacrylamiden oder sulfonsäuregruppenhaltigen Polyacrylaten, z. B Sepigel® 305 oder Simulgel® EG, weiterhin anorganische Verdicker, z. B. Bentonite und Hectorite (Laponite®).Liquid and gelatin dosage forms of the compositions of the invention may contain thickening agents, e.g. As cellulose ethers such as hydroxypropyl cellulose, hydroxy ethyl cellulose and methyl hydroxypropyl cellulose, thickening polymers based on polyacrylates, which may be crosslinked, if desired, for. As the Carbopol types or Pemulen ® products, or based on polyacrylamides or sulfonic acid-containing polyacrylates, eg. B Sepigel ® 305 or Simulgel® ® EG, also inorganic thickeners such. B. Bentonite and Hectorite (Laponite ®).
Die erfindungsgemäßen Zusammensetzungen können weitere kosmetisch und dermatologisch wirksame Stoffe enthalten, wie beispielsweise entzündungshemmende Substanzen, Feststoffe, ausgewählt aus Kieselsäuren, z. B. Aerosil®-Typen, Kieselgelen, Siliciumdioxid, Tonen, z. B. Bentonite oder Kaolin, Magnesiumaluminiumsilikaten, z. B. Talkum, Bornitrid, Titandioxid, das gewünschtenfalls beschichtet sein kann, gegebenenfalls modifizierten Stärken und Stärkederivaten, Cellulosepulvern und Polymerpulvern, desweiteren Pflanzenextrakte, Proteinhydrolysate, Vitamine, Parfümöle, Sebostatika, Anti-Akne-Wirkstoffe sowie Keratolytika.The compositions of the invention may contain other cosmetically and dermatologically active substances, such as anti-inflammatory substances, solids selected from silicic acids, eg. As Aerosil ® types, silica gels, silica, clays, z. B. bentonite or kaolin, magnesium aluminum silicates, z. Talc, boron nitride, titanium dioxide, which may if desired be coated, optionally modified starches and starch derivatives, cellulose powders and polymer powders, furthermore plant extracts, protein hydrolysates, vitamins, perfume oils, sebostatics, anti-acne agents and keratolytics.
Die erfindungsgemäßen Zusammensetzungen können, soweit sie flüssig vorliegen, auf flexible und saugfähige Träger aufgebracht und als Deodorant- oder Antitranspirant-Tücher oder Schwämm- chen angeboten werden. Als flexible und saugfähige Träger im Sinne der Erfindung eignen sich z. B. Träger aus Textilfasern, Kollagen oder polymeren Schaumstoffen. Als Textilfasern können sowohl Naturfasern wie Cellulose (Baumwolle, Leinen), Seide, Wolle, Regeneratcellulose (Viskose, Rayon), Cellulosederivate als auch synthetische Fasern wie z.B. Polyester, Polyacrylnitril, Polyamid- oder Polyolefinfasern oder Mischungen solcher Fasern gewebt oder ungewebt verwendet werden. Diese Fasern können zu saugfähigen Wattepads, Vliesstoffen oder zu Geweben oder Gewirken verarbeitet sein. Auch flexible und saugfähige polymere Schaumstoffe, z. B. Polyurethanschäume und Polyamidschäume sind geeignete Substrate. Das Substrat kann eine, zwei, drei sowie mehr als drei Lagen aufweisen, wobei die einzelnen Lagen aus gleichen oder unterschiedlichen Materialien bestehhen können. Jede Substratschicht kann eine homogene oder eine inhomogene Struktur mit beispielsweise verschiedenen Zonen unterschiedlicher Dichte aufweisen. Als saugfähig im Sinne der Erfindung sind solche Trägersubstrate anzusehen, die bei 20° C wenigstens 10 Gew.-%, bezogen auf das Trockengewicht, an Wasser adsorptiv bzw. kapillar binden können. Bevorzugt eignen sich aber solche Träger, die wenigstens 100 Gew.-% Wasser adsorptiv und kapillar binden können.The compositions according to the invention can, insofar as they are in liquid form, be applied to flexible and absorbent carriers and be offered as deodorant or antiperspirant wipes or sponges. As a flexible and absorbent carrier in the context of the invention, z. As carriers of textile fibers, collagen or polymeric foams. Textile fibers may be both natural fibers such as cellulose (cotton, linen), silk, wool, regenerated cellulose (viscose, rayon), cellulose derivatives and synthetic fibers such as e.g. Polyester, polyacrylonitrile, polyamide or polyolefin fibers or mixtures of such fibers woven or unwoven be used. These fibers may be made into absorbent cotton pads, nonwovens or woven or knitted fabrics. Also flexible and absorbent polymeric foams, eg. As polyurethane foams and polyamide foams are suitable substrates. The substrate may have one, two, three and more than three layers, wherein the individual layers may consist of the same or different materials. Each substrate layer may have a homogeneous or an inhomogeneous structure with, for example, different zones of different densities. Absorbent for the purposes of the invention are those support substrates which, at 20 ° C., can bind at least 10% by weight, based on the dry weight, of water adsorptively or capillary. Preferably, however, are those carriers which can bind at least 100 wt .-% water adsorptive and capillary.
Die Ausrüstung der Trägersubstrate erfolgt in der Weise, daß man die saugfähigen, flexiblen Trägersubstrate, bevorzugt aus Textilfasern, Kollagen oder polymeren Schaumstoffen mit den erfindungsgemäßen Zusammensetzungen behandelt bzw. ausrüstet und gegebenenfalls trocknet. Dabei kann die Behandlung (Ausrüstung) der Trägersubstrate nach beliebigen Verfahren, z. B. durch Aufsprühen, Tauchen und Abquetschen, Durchtränken oder einfach durch Einspritzen der erfindungsgemäßen Zusammensetzung in die Trägersubstrate erfolgen.The equipment of the carrier substrates is carried out in such a way that the absorbent, flexible carrier substrates, preferably from textile fibers, collagen or polymeric foams treated with the compositions according to the invention and optionally dried. In this case, the treatment (equipment) of the carrier substrates by any method, for. B. by spraying, dipping and squeezing, soaking or simply by injecting the composition of the invention into the carrier substrates.
Erfindungsgemäß bevorzugt ist weiterhin die Darreichungsform als Aerosol, wobei die kosmetische Zusammensetzung ein Treibmittel, vorzugsweise ausgewählt aus Propan, Butan, Isobutan, Pentan, Isopentan, Dimethylether, Fluorkohlenwasserstoffen und Fluorchlorkohlenwasserstoffen enthält. Ebenso kann ein komprimiertes Treibmittel wie Luft, Stickstoff oder Kohlendioxid verwendet werden. Ebenso können Mischungen der genannten Treibmittel eingesetzt werden. In einer bevorzugten Ausführungsform liegen die erfindungsgemäßen Zusammensetzungen in Form einer flüssigen oder festen ÖI-in-Wasser-Emulsion, Wasser-in-ÖI-Emulsion, Mehrfach-Emul- sion, Mikroemulsion, PIT-Emulsion oder Pickering-Emulsion, eines Hydrogels, eines Lipogels, einer ein- oder mehrphasigen Lösung, eines Schaumes, eines Puders oder einer Mischung mit mindestens einem als medizinischen Klebstoff geeigneten Polymer vor. Die Mittel können auch in wasserfreier Form, wie beispielsweise einem Öl oder einem Balsam, dargereicht werden. Hierbei kann der Träger ein pflanzliches oder tierisches Öl, ein Mineralöl, ein synthetisches Öl oder eine Mischung solcher Öle sein.Also preferred according to the invention is the dosage form as an aerosol, the cosmetic composition containing a propellant, preferably selected from propane, butane, isobutane, pentane, isopentane, dimethyl ether, fluorohydrocarbons and chlorofluorocarbons. Likewise, a compressed propellant such as air, nitrogen or carbon dioxide can be used. Likewise, mixtures of the stated blowing agents can be used. In a preferred embodiment, the compositions according to the invention are in the form of a liquid or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsifier. sion, microemulsion, PIT emulsion or Pickering emulsion, a hydrogel, a lipogel, a mono- or multiphase solution, a foam, a powder or a mixture with at least one polymer suitable as a medical adhesive. The agents may also be presented in anhydrous form, such as an oil or a balm. Here, the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
In einer besonderen Ausführungsform der erfindungsgemäßen Mittel liegen die Mittel als Mikroemulsion vor. Unter Mikroemulsionen werden im Rahmen der Erfindung neben den thermodyna- misch stabilen Mikroemulsionen auch die so genannten "PIT'-Emulsionen verstanden. Bei diesen Emulsionen handelt es sich um Systeme mit den 3 Komponenten Wasser, Öl und Emulgator, die bei Raumtemperatur als ÖI-in-Wasser-Emulsion vorliegen. Beim Erwärmen dieser Systeme bilden sich in einem bestimmten Temperaturbereich (als Phaseninversiontemperatur oder "PIT" bezeichnet) Mikroemulsionen aus, die sich bei weiterer Erwärmung in Wasser-in-ÖI(W/O)-Emulsionen umwandeln. Bei anschließendem Abkühlen werden wieder O/W-Emulsionen gebildet, die aber auch bei Raumtemperatur als Mikroemulsionen oder als sehr feinteilige Emulsionen mit einem mittleren Teilchendurchmesser unter 400 nm und insbesondere von etwa 100-300 nm, vorliegen. Erfindungsgemäß können solche Mikro- oder "PIT'-Emulsionen bevorzugt sein, die einen mittleren Teilchendurchmesser von etwa 200 nm aufweisen.In a particular embodiment of the agents according to the invention, the agents are present as microemulsions. In the context of the invention, microemulsions are understood as meaning, in addition to the thermodynamically stable microemulsions, also the so-called "PIT" emulsions These emulsions are systems containing the three components water, oil and emulsifier, which are oil-in at room temperature When these systems are heated, microemulsions are formed in a certain temperature range (referred to as phase inversion temperature or "PIT"), which on further heating convert to water-in-oil (W / O) emulsions O / W emulsions are again formed, but are also present at room temperature as microemulsions or as very finely divided emulsions having an average particle diameter of less than 400 nm and in particular of approximately 100 to 300 nm. Emulsions having an average particle diameter of about 200 nm may be preferred.
Weiterer bevorzugter Gegenstand der vorliegenden Erfindung sind Mittel zur oralen Pflege, worunter Mund-, Zahn- und/oder Zahnprothesenpflegemittel zu verstehen sind, die mindestens eine Hydroxyzimtsäure und/oder ein Derivat davon und/oder mindestens einen Pflanzenextrakt ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, enthalten.A further preferred subject of the present invention are compositions for oral care, which are to be understood as oral, dental and / or dental prosthesis care compositions containing at least one hydroxycinnamic acid and / or a derivative thereof and / or at least one plant extract selected from meadowsweet extract, St. John's wort Extract and extracts containing Hydroxyzimtsäuren and / or their derivatives contain.
Die erfindungsgemäßen Mund-, Zahn- und/oder Zahnprothesenpflegemittel können beispielsweise als Mundwasser, Gel, flüssige Zahnputzlotion, steife Zahnpaste, Kaugummi, Gebissreiniger oder Prothesenhaftcreme vorliegen. Hierzu ist es erforderlich, die erfindungsgemäßen Wirkstoffe in einen geeigneten Träger einzuarbeiten.The oral, dental and / or dental prosthesis care agents according to the invention can be present, for example, as a mouthwash, gel, liquid toothbrush lotion, stiff toothpaste, chewing gum, denture cleaner or denture adhesive cream. For this purpose, it is necessary to incorporate the active compounds according to the invention in a suitable carrier.
Als Träger können z.B. auch pulverförmige Zubereitungen oder wässrig-alkoholische Lösungen dienen, die als Mundwässer 0 bis 15 Gew.-% Ethanol, 1 bis 1 ,5 Gew.-% Aromaöle und 0,01 bis 0,5 Gew.-% Süßstoffe oder als Mundwasser-Konzentrate 15 bis 60 Gew.-% Ethanol, 0,05 bis 5 Gew.- % Aromaöle, 0,1 bis 3 Gew.-% Süßstoffe sowie ggf. weitere Hilfsstoffe enthalten können und vor Gebrauch mit Wasser verdünnt werden. Die Konzentration der Komponenten muss dabei so hoch gewählt werden, dass nach Verdünnung die genannten Konzentrationsuntergrenzen bei der Anwendung nicht unterschritten werden.As carriers, e.g. also pulverulent preparations or aqueous-alcoholic solutions serve as mouthwash 0 to 15 wt .-% ethanol, 1 to 1, 5 wt .-% flavor oils and 0.01 to 0.5 wt .-% sweeteners or as mouthwash concentrates From 15 to 60% by weight of ethanol, from 0.05 to 5% by weight of flavoring oils, from 0.1 to 3% by weight of sweeteners and, if appropriate, further auxiliaries may be included and diluted with water before use. The concentration of the components must be so high that, after dilution, the specified lower concentration limits are not undershot during use.
Als Träger können aber auch Gele sowie mehr oder weniger fließfähige Pasten dienen, die aus flexiblen Kunststoffbehältern oder Tuben ausgedrückt und mit Hilfe einer Zahnbürste auf die Zähne aufgetragen werden. Solche Produkte enthalten höhere Mengen an Feuchthaltemitteln und Bindemitteln oder Konsistenzreglern und Polierkomponenten. Darüber hinaus sind auch in diesen Zubereitungen Aromaöle, Süßstoffe und Wasser enthalten. Als Feuchthaltemittel können dabei z.B. Glycerin, Sorbit, Xylit, Propylenglycole, Polyethylenglycole oder Gemische dieser Polyole, insbesondere solche Polyethenylenglycole mit Molekulargewichten von 200 bis 800 (von 400 - 2000 ) verwendet werden enthalten sein. Bevorzugt ist als Feuchthaltemittel Sorbit in einer Menge von 25 - 40 Gew.-% enthalten.However, gels and more or less flowable pastes, which are expressed from flexible plastic containers or tubes and applied to the teeth with the aid of a toothbrush, can also serve as the carrier. Such products contain higher levels of humectants and binders or consistency regulators and polishing components. In addition, aromatic oils, sweeteners and water are also contained in these preparations. For example, glycerol, sorbitol, xylitol, propylene glycols, polyethylene glycols or mixtures of these polyols, in particular those polyethyleneglycols having molecular weights of from 200 to 800 (from 400 to 2000), may be present as humectants. Preferably, sorbitol is contained as humectant in an amount of 25-40 wt .-%.
Als Antizahnstein-Wirkstoffe und als Demineralisierungs-Inhibitoren können kondensierten Phosphate in Form ihrer Alkalisalze, bevorzugt in Form ihrer Natrium- oder Kaliumsalze enthalten sein. Die wäßrigen Lösungen dieser Phosphate reagieren aufgrund hydrolytischer Effekte alkalisch. Durch Säurezusatz wird der pH-Wert der erfindungsgemäßen Mund-, Zahn- und/oder Zahnprothesen pflege mitte I auf die bevorzugten Werte von 7,5 - 9 eingestellt.As anticalculus agents and as demineralization inhibitors, condensed phosphates may be present in the form of their alkali metal salts, preferably in the form of their sodium or potassium salts. The aqueous solutions of these phosphates react alkaline due to hydrolytic effects. By addition of acid, the pH of the oral, dental and / or dental care of the present invention centering care I to the preferred values of 7.5 to 9 set.
Es können auch Gemische verschiedener kondensierter Phosphate oder auch hydratisierte Salze der kondensierten Phosphate eingesetzt werden. Die spezifizierten Mengen von 2 - 12 Gew.-% beziehen sich jedoch auf die wasserfreien Salze. Bevorzugt ist als kondensiertes Phosphat ein Natrium- oder Kalium-tripolyphosphat in einer Menge von 5 - 10 Gew.-% der Zusammensetzung enthalten.It is also possible to use mixtures of different condensed phosphates or else hydrated salts of the condensed phosphates. The specified amounts of 2-12% by weight, however, refer to the anhydrous salts. Preferably, the condensed phosphate is a sodium or potassium tripolyphosphate in an amount of 5-10% by weight of the composition.
Ein bevorzugt enthaltener Wirkstoff ist eine karieshemmende Fluorverbindung, bevorzugt aus der Gruppe der Fluoride oder Monofluorophosphate in einer Menge von 0,1 - 0,5 Gew.-% Fluor. Geeignete Fluorverbindungen sind z.B. Natriummonofluorophosphat (Na2PO3F), Kaliummonofluo- rophosphat, Natrium- oder Kaliumfluorid, Zinnfluorid oder das Fluorid einer organischen Aminoverbindung.A preferred active ingredient is a caries-inhibiting fluorine compound, preferably from the group of fluorides or monofluorophosphates in an amount of 0.1 to 0.5 wt .-% fluorine. Suitable fluorine compounds are, for example, sodium monofluorophosphate (Na 2 PO 3 F), potassium monofluorophosphate, sodium or potassium fluoride, tin fluoride or the fluoride of an organic amino compound.
Als Bindemittel und Konsistenzregler dienen z.B. natürliche und synthetische wasserlösliche Polymere wie Carragheen, Traganth, Guar, Stärke und deren nichtionogene Derivate wie z.B. Hydroxy- propylguar, Hydroxyethylstärke, Celluloseether wie z.B. Hydroxyethylcellulose oder Methylhydroxy- propylcellulose. Auch Agar-Agar, Xanthan-Gum, Pektine, wasserlösliche Carboxyvinylpolymere (z.B. Carbopol®-Typen), Polyvinylalkohol, Polyvinylpyrrolidon, höhermolekulare Polyethylenglycole (Molekulargewicht 103 bis 106 D). Weitere Stoffe, die sich zur Viskositätskontrolle eignen, sind Schichtsilikate, wie z.B. Montmorillonit-Tone, kolloidale Verdickungskieselsäuren, z.B. Aerogel- Kieselsäure oder pyrogene Kieselsäuren.Examples of suitable binders and consistency regulators are natural and synthetic water-soluble polymers such as carrageenan, tragacanth, guar, starch and their nonionic derivatives such as, for example, hydroxypropylguar, hydroxyethyl starch, cellulose ethers such as hydroxyethylcellulose or methylhydroxypropylcellulose. Also, agar-agar, xanthan gum, pectins, water-soluble carboxyvinyl polymers (for example Carbopol ® types), polyvinyl alcohol, polyvinyl pyrrolidone, high molecular weight polyethylene glycols (molecular weight 10 3 to 10 6 D). Further substances which are suitable for viscosity control are phyllosilicates, such as, for example, montmorillonite clays, colloidal thickening silicas, for example airgel silicic acid or pyrogenic silicic acids.
Als Polierkomponenten können alle hierfür bekannten Poliermittel, bevorzugt aber Fällungs- und Gelkieselsäuren, Aluminiumhydroxid, Aluminiumsilicat, Aluminiumoxid, Aluminiumoxidtrihydrat, unlösliches Natriummetaphosphat, Calciumpyrophosphat, Calciumhydrogenphosphat, Dicalcium- phosphat, Kreide, Hydroxylapatit, Hydrotalcite, Talkum, Magnesiumaluminiumsilicat (Veegum®), Calciumsulfat, Magnesiumcarbonat, Magnesiumoxid, Natriumaluminiumsilikate, z.B. Zeolith A oder organische Polymere, z.B. Polymethacrylat, eingesetzt werden. Die Poliermittel werden vorzugsweise in kleineren Mengen von z.B. 1 - 10 Gew.-% verwendet.As polishing components may all heretofore known polishing agent, but preferably precipitated and gel silicas, aluminum hydroxide, aluminum silicate, alumina, alumina trihydrate, insoluble sodium metaphosphate, calcium pyrophosphate, calcium hydrogen phosphate, dicalcium phosphate, chalk, hydroxyapatite, hydrotalcites, talc, magnesium aluminum silicate (Veegum ®), calcium sulfate, Magnesium carbonate, magnesium oxide, sodium aluminum silicates, such as zeolite A or organic polymers, such as polymethacrylate, are used. The polishing agents are preferably used in smaller amounts of eg 1-10% by weight.
Die erfindungsgemäßen Zahn- und/oder Mundpflegeprodukte können durch Zugabe von Aromaölen und Süßungsmitteln in ihren organoleptischen Eigenschaften verbessert werden. Als Aromaöle kommen alle für Mund-, Zahn- und/oder Zahnprothesenpflegemittel gebräuchlichen natürlichen und synthetischen Aromen in Frage. Natürliche Aromen können sowohl in Form der aus den Drogen isolierten etherischen Öle als auch der aus diesen isolierten Einzelkomponenten verwendet werden. Bevorzugt sollte wenigstens ein Aromaöl aus der Gruppe Pfefferminzöl, Krauseminzöl, Anisöl, Kümmelöl, Eukalyptusöl, Fenchelöl, Zimtöl, Geraniumöl, Salbeiöl, Thymianöl, Majoranöl, Basilikumöl, Citrusöl, Gaultheriaöl oder eine oder mehrere daraus isolierte synthetisch erzeugten Komponenten dieser Öle enthalten sein. Die wichtigsten Komponenten der genannten Öle sind z.B. Menthol, Carvon, Anethol, Cineol, Eugenol, Zimtaldehyd, Geraniol, Citronellol, Linalool, Salven, Thymol, Terpinen, Terpinol, Methylchavicol und Methylsalicylat. Weitere geeignete Aromen sind z.B. Menthylacetat, Vanillin, Jonone, Linalylacetat, Rhodinol und Piperiton. Als Süßungsmittel eignen sich entweder natürliche Zucker wie Sucrose, Maltose, Lactose und Fructose oder synthetische Süßstoffe wie z.B. Saccharin-Natriumsalz, Natriumcyclamat oder Aspartam. Als Tenside sind dabei insbesondere Alkyl- und/oder Alkenyl-(oligo)-glycoside einsetzbar. Ihre Herstellung und Verwendung als oberflächenaktive Stoffe sind beispielsweise aus US-A-3 839 318, US-A-3 707 535, US-A-3 547 828, DE-A- 19 43 689, DE-A-20 36 472 und DE-A-30 01 064 sowie EP-A-77 167 bekannt. Bezüglich des Glycosidrestes gilt, daß sowohl Monoglycoside (x = 1 ), bei denen ein Pentose- oder Hexoserest glycosidisch an einen primären Alkohol mit 4 bis 16 C- Atomen gebunden ist, als auch oligomere Glycoside mit einem Oligomerisationsgrad x bis 10 geeignet sind. Der Oligomerisationsgrad ist dabei ein statistischer Mittelwert, dem eine für solche technischen Produkte übliche Homologenverteilung zugrunde liegt. Bevorzugt eignet sich als Alkyl- und/oder Alkenyl-(oligo)-glycosid ein Alkyl- und/oder Alkenyl-(oligo)-glucosid der Formel RO(C6H10O)x-H, in der R eine Alkyl- und/oder Alkenyl-gruppe mit 8 bis 14 C-Atomen ist und x einen Mittelwert von 1 bis 4 hat. Besonders bevorzugt sind Alkyloligoglucoside auf Basis von gehärtetem C-12/14-Kokosalkohol mit einem DP von 1 bis 3. Das Alkyl- und/oder Alkenyl-glycosid-Tensid kann sehr sparsam verwendet werden, wobei bereits Mengen von 0,005 bis 1 Gew.-% ausreichend sind. Außer den genannten Alkylglucosid-Tensiden können auch andere nichtionische, ampholytische und kationische Tenside enthalten sein, als da beispielsweise sind: Fettalkoholpolyglycolethersulfa- te, Monoglyceridsulfate, Monoglyceridethersulfate, Mono- und/oder Dialkylsulfosuccinate, Fett- säureisethionate, Fettsäuresarcosinate, Fettsäuretauride, Fettsäureglutamate, Ethercarbonsäuren, Fettsäureglucamide, Alkylamido-betaine und/oder Proteinfettsäurekondensate, letztere vorzugsweise auf Basis von Weizenproteinen. Insbesondere zur Solubilisierung der meist wasserunlöslichen Aromaöle kann ein nichtionogener Lösungsvermittler aus der Gruppe der oberflächenaktiven Verbindungen erforderlich sein. Besonders geeignet für diesen Zweck sind z.B. oxethylierte Fett- säureglyceride, oxethylierte Fettsäuresorbitanpartialester oder Fettsäurepartialester von Glycerin- oder Sorbitan-Oxethylaten. Lösungsvermittler aus der Gruppe der oxethylierten Fettsäureglyceride umfassen vor allem Anlagerungsprodukte von 20 bis 60 Mol Ethylenoxid an Mono- und Diglyceride von linearen Fettsäuren mit 12 bis 18 C-Atomen oder an Triglyceride von Hydroxyfettsäuren wie Oxystearinsäure oder Ricinolsäure. Weitere geeignete Lösungsvermittler sind oxethylierte Fettsäuresorbitanpartialester; das sind bevorzugt Anlagerungsprodukte von 20 bis 60 Mol Ethylenoxid an Sorbitanmonoester und Sorbitandiester von Fettsäuren mit 12 bis 18 C-Atomen. Ebenfalls geeignete Lösungsvermittler sind Fettsäurepartialester von Glycerin- oder Sorbitan-Oxethylaten; das sind bevorzugt Mono- und Diester von C-i2-C18-Fettsäuren und Anlagerungsprodukten von 20 bis 60 Mol Ethylenoxid an 1 Mol Glycerin oder an 1 Mol Sorbit.The dental and / or oral care products according to the invention can be improved in their organoleptic properties by adding aroma oils and sweeteners. Aromatic oils are all natural and synthetic flavors which are customary for oral, dental and / or dental care products. Natural flavors can be used both in the form of the essential oils isolated from the drugs and those isolated from individual components become. Preferably, at least one aromatic oil from the group of peppermint oil, spearmint oil, aniseed oil, caraway oil, eucalyptus oil, fennel oil, cinnamon oil, geranium oil, sage oil, thyme oil, marjoram oil, basil oil, citrus oil, Gaultheria oil or one or more synthetic components of these oils isolated therefrom should be included. The most important components of the oils mentioned are, for example, menthol, carvone, anethole, cineole, eugenol, cinnamaldehyde, geraniol, citronellol, linalool, salvos, thymol, terpinene, terpinol, methylchavicol and methyl salicylate. Further suitable flavors are, for example, menthyl acetate, vanillin, ionone, linalyl acetate, rhodinol and piperitone. Suitable sweeteners are either natural sugars such as sucrose, maltose, lactose and fructose or synthetic sweeteners such as saccharin sodium salt, sodium cyclamate or aspartame. In particular, alkyl and / or alkenyl (oligo) glycosides can be used as surfactants. Their preparation and use as surfactants are described, for example, in US-A-3,839,318, US-A-3,707,535, US-A-3,547,828, DE-A-19 43 689, DE-A-20 36 472 and US Pat DE-A-30 01 064 and EP-A-77 167 known. With regard to the glycoside radical, monoglycosides (x = 1) in which a pentose or hexose radical is glycosidically bound to a primary alcohol having 4 to 16 carbon atoms, as well as oligomeric glycosides having a degree of oligomerization x to 10, are suitable. The degree of oligomerization is a statistical mean, which is based on a homolog distribution typical for such technical products. As alkyl and / or alkenyl (oligo) glycoside, an alkyl and / or alkenyl (oligo) glucoside of the formula RO (C 6 H 10 O) x -H in which R is an alkyl radical and is preferably suitable / or alkenyl group having 8 to 14 carbon atoms and x has an average of 1 to 4. Particular preference is given to alkyl oligoglucosides based on hydrogenated C 12/14 coconut alcohol having a DP of from 1 to 3. The alkyl and / or alkenyl glycoside surfactant can be used very sparingly, amounts of from 0.005 to 1% by weight already being used. % are sufficient. In addition to the alkyl glucoside surfactants mentioned, other nonionic, ampholytic and cationic surfactants may also be present, for example: fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, monoglyceride ether sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides, fatty acid glutamates, ether carboxylic acids, Fatty acid glucamides, alkylamido-betaines and / or protein fatty acid condensates, the latter preferably based on wheat proteins. In particular, to solubilize the usually water-insoluble aroma oils, a non-ionic solubilizer from the group of surface-active compounds may be required. Particularly suitable for this purpose are, for example, ethoxylated fatty acid glycerides, ethoxylated fatty acid sorbitan partial esters or fatty acid partial esters of glycerol or sorbitan ethoxylates. Solubilizers from the group of ethoxylated Fettsäureglyceride include especially addition products of 20 to 60 moles of ethylene oxide with mono- and diglycerides of linear fatty acids having 12 to 18 carbon atoms or triglycerides of hydroxy fatty acids such as oxystearic acid or ricinoleic acid. Further suitable solubilizers are ethoxylated fatty acid sorbitan partial esters; these are preferably addition products of 20 to 60 moles of ethylene oxide with sorbitan monoesters and sorbitan diesters of fatty acids with 12 to 18 carbon atoms. Also suitable solubilizers are fatty acid partial esters of glycerol or sorbitan ethoxylates; These are preferably mono- and diesters of C 2 -C 18 -fatty acids and adducts of 20 to 60 moles of ethylene oxide with 1 mole of glycerol or with 1 mole of sorbitol.
Die erfindungsgemäßen Mund-, Zahn- und/oder Zahnprothesenpflegemittel enthalten bevorzugt als Lösungsvermittler für gegebenenfalls enthaltene Aromaöle Anlagerungsprodukte von 20 bis 60 Mol Ethylenoxid an gehärtetes oder ungehärtetes Rizinusöl (d.h. an Oxystearinsäure- oder Ricinol- säuretriglycerid), an Glycerinmono- und/oder -distearat oder an Sorbitanmono- und/oder -distearat. Weitere übliche Zusätze für die Mund-, Zahn- und/oder Zahnprothesenpflege mittel sind z.B. Pigmente, z.B. Titandioxid, und/oder Farbstoffe, pH-Stellmittel und Puffersubstanzen wie z.B. Natrium- bicarbonat, Natriumeitrat, Natriumbenzoat, Zitronensäure, Phosphorsäure oder saure Salze, z.B. NaH2PO4, wundheilende und entzündungshemmende Stoffe wie z.B. Allantoin, Harnstoff, Panthenol, Azulen bzw. Kamillenextrakt, weitere gegen Zahnstein wirksame Stoffe wie z.B. Organophos- phonate, z.B. Hydroxyethandiphosphonate oder Azacycloheptandiphosphonat, Konservierungsstoffe wie z.B. Sorbinsäure-Salze, p-Hydroxybenzoesäure-Ester, Plaque-Inhibitoren wie z.B. Hexa- chlorophen, Chlorhexidin, Hexetidin, Triclosan, Bromchlorophen, Phenylsalicylsäureester. In einer besonderen Ausführungsform ist die Zusammensetzung eine Mundspülung, ein Mundwasser, ein Prothesenreiniger oder ein Prothesenhaftmittel. Für erfindungsgemäß bevorzugte Prothesenreiniger, insbesondere Prothesenreinigungstabletten und -pulver, eignen sich neben den schon genannten Inhaltsstoffen für die Mund-, Zahn- und/oder Zahnprothesenpflege zusätzlich noch Per-Verbindungen wie beispielsweise Peroxoborat, Peroxomonosulfat oder Percarbonat. Sie haben den Vorteil, dass sie neben der Bleichwirkung gleichzeitig auch desodorierend und/oder desinfizierend wirken. Der Einsatz solcher Per-Verbindungen in Prothesenreinigern beträgt zwischen 0,01 und 10 Gew.-%, insbesondere zwischen 0,5 und 5 Gew.-%.The oral, dental and / or dental prosthesis care agents according to the invention preferably contain as solubilizer for optionally contained aroma oils addition products of 20 to 60 moles of ethylene oxide to hardened or unhardened castor oil (ie to Oxystearinsäure- or ricinoleic acid triglyceride), glycerol mono- and / or distearate or sorbitan mono- and / or distearate. Further customary additives for oral care, dental care and / or denture care are, for example, pigments, for example titanium dioxide, and / or dyes, pH regulators and buffer substances such as sodium bicarbonate, sodium citrate, sodium benzoate, citric acid, phosphoric acid or acidic salts, eg NaH 2 PO 4 , wound healing and anti-inflammatory substances such as allantoin, urea, panthenol, azulene or camomile extract, other active against tartar substances such as organophosphonates, eg Hydroxyethandiphosphonate or Azacycloheptandiphosphonat, preservatives such as sorbic acid salts, p-hydroxybenzoic acid esters , Plaque inhibitors such as hexachlorophene, chlorhexidine, hexetidine, triclosan, bromochlorophene, phenylsalicylic acid esters. In a particular embodiment, the composition is a mouthwash, a mouthwash, a denture cleanser or a denture adhesive. In addition to the already mentioned ingredients for oral, dental and / or dental prosthesis care, per-compounds such as, for example, peroxoborate, peroxomonosulfate or percarbonate are additionally suitable for prosthesis cleaners according to the invention, in particular prosthesis cleansing tablets and powders. They have the advantage that, in addition to the bleaching effect, they also have a deodorizing and / or disinfecting effect. The use of such per-compounds in prosthesis cleaners is between 0.01 and 10 wt .-%, in particular between 0.5 and 5 wt .-%.
Als weitere Inhaltsstoffe sind auch Enzyme, wie z.B. Proteasen und Carbohydrase, zum Abbau von Proteinen und Kohlenhydraten geeignet. Der pH-Wert kann zwischen pH 4 und pH 12, insbesondere zwischen pH 5 und pH 1 1 liegen.As further ingredients are also enzymes, e.g. Proteases and carbohydrase, suitable for the breakdown of proteins and carbohydrates. The pH can be between pH 4 and pH 12, in particular between pH 5 and pH 1 1.
Für die Prothesenreinigungstabletten sind zusätzlich noch weitere Hilfsstoffe notwendig, wie z. B. Mittel, die einen sprudelnden Effekt hervorrufen, wie z.B. CO2 freisetzende Stoffe wie Natrium- hydrogencarbonat, Füllstoffe, z.B. Natriumsulfat oder Dextrose, Gleitmittel, z.B. Magnesiumstearat, Fließregulierungsmittel, wie beispielsweise kolloidales Siliziumdioxid und Granuliermittel, wie die bereits erwähnten hochmolekularen Polyethylenglycole oder Polyvinylpyrrolidon. Prothesenhaftmittel können als Pulver, Cremes, Folien oder Flüssigkeiten angeboten werden und unterstützen die Haftung der Prothesen.For the prosthesis cleansing tablets, additional auxiliaries are necessary in addition, such. As agents which cause a bubbling effect, such as CO 2 releasing substances such as sodium bicarbonate, fillers, eg sodium sulfate or dextrose, lubricants, for example magnesium stearate, flow control agents such as colloidal silica and granulating agents, such as the already mentioned high molecular weight polyethylene glycols or polyvinylpyrrolidone , Denture adhesives can be offered as powders, creams, foils or liquids and support the adhesion of the prostheses.
Als Wirkstoffe sind natürliche und synthetische Quellstoffe geeignet. Als natürliche Quellstoffe sind neben Alginaten auch Pflanzengummen, wie z.B. Gummi arabicum, Traganth und Karaya-Gummi sowie natürlicher Kautschuk aufzufassen. Insbesondere haben sich Alginate und synthetische Quellstoffe, wie z.B. Natriumcarboxymethylcellulose, hochmolekulare Ethylenoxid-Copolymere, Salze der Poly(vinyl-ether-co-maleinsäure) und Polyacrylamide.As active ingredients natural and synthetic swelling substances are suitable. As natural swelling agents, besides alginates, plant gums, such as e.g. Gum arabic, tragacanth and karaya gum as well as natural rubber. In particular, alginates and synthetic bulking agents, e.g. Sodium carboxymethyl cellulose, high molecular weight ethylene oxide copolymers, salts of poly (vinyl ether-co-maleic acid) and polyacrylamides.
Als Hilfsstoffe für pastöse und flüssige Produkte eignen sich besonders hydrophobe Grundlagen, insbesondere Kohlenwasserstoffe, wie beispielsweise Weißes Vaselin (DAB) oder Paraffinöl. AusführungsbeispieleAs adjuvants for pasty and liquid products are particularly hydrophobic bases, in particular hydrocarbons, such as white Vaseline (DAB) or paraffin oil. embodiments
Die folgenden Beispiele sollen die Erfindung erläutern, ohne sie darauf zu beschränken.The following examples are intended to illustrate the invention without being limited thereto.
Beispiel 1 : AktivitätstestsExample 1: Activity Tests
Substanzen wurden mit einem Fluoreszenz-basierten Test auf ihre hemmende Wirkung gegen die Cystathionin-Beta-Lyase (CBL; E. C. 4.4.1.8.) Aktivität eines Rohextraktes aus einem Staphylo- coccus sp. (Eigenisolat Henkel AG und Co. KGaA) hin getestet. Das während des Tests aus dem Substrat freigesetzte Cystein bildet mit Monobromobiman einen fluoreszierenden Komplex.Substances were tested for their inhibitory effect against cystathionine beta-lyase (CBL; E.C. 4.4.1.8.) By a fluorescence-based assay of a crude extract from Staphylococcus sp. (Self-isolate Henkel AG and Co. KGaA) tested out. The cysteine released from the substrate during the assay forms a fluorescent complex with monobromobimane.
1.1 Herstellung eines Rohextraktes aus Staphylococcus sp.:1.1 Preparation of a crude extract from Staphylococcus sp .:
• Anzucht von Staphylococcus sp. auf CaSo-Agar bei 37°C für ca. 48 h• Cultivation of Staphylococcus sp. on CaSo agar at 37 ° C for about 48 h
• Abschwemmen der Zellen mit Sörensen-Puffer pH 7,0 (~ 10 ml / 6 Platten)• Wash the cells with Sörensen buffer pH 7.0 (~ 10 ml / 6 plates)
• Pelletierung durch Zentrifugation, 3-maliges Waschen mit Sörensenpuffer• Pelleting by centrifugation, washing 3 times with Sörensenpuffer
• Mechanischer Aufschluss der Zellen in Sörensen-Puffer (1 ml / g Zellen) mittels Kugelmühle (Retsch) oder FastPrep Cell Disruptor (MP Biomedicals)Mechanical disruption of the cells in Sörensen buffer (1 ml / g cells) by means of ball mill (Retsch) or FastPrep Cell Disruptor (MP Biomedicals)
• Abzentrifugation der Zelltrümmer• centrifugation of cell debris
• Bestimmung des Proteingehaltes des Rohextraktes mit einem kommerziellen Kit, z.B. Uptima BC-AssayDetermination of the protein content of the crude extract with a commercial kit, e.g. Uptima BC assay
• Lagerung bei -200C• Store at -20 0 C.
1.2 Photometrischer Test auf CBL-Aktivität und Auswertung1.2 Photometric test for CBL activity and evaluation
• Assay:• Assay:
0,25 mM Benzylcystein0.25 mM benzylcysteine
0,1 mM Monobromobiman (Natsch et al., 2004)0.1 mM monobromobimane (Natsch et al., 2004)
50 μl Rohextrakt aus Staphylococcus sp.50 μl of crude extract from Staphylococcus sp.
2.5 μl Inhibitor (für 1 %ige AWK) ad 250 μl auffüllen mit Sörensenpuffer pH 7,5Add 2.5 μl of inhibitor (for 1% AWK) to 250 μl with Sörensen buffer pH 7.5
• Messung der CBL-Aktivität als Zunahme der Fluoreszenz bei 460 nm über 30 min. in einem Fluorimeter (Anregung mit Blaulicht von 390 nm).Measurement of CBL activity as fluorescence increase at 460 nm for 30 min. in a fluorimeter (excitation with blue light of 390 nm).
• Berechnung der spezifischen CBL-Aktivität als Δ Fluoreszenz / min x mg Protein. Alle Messwerte werden zuvor um Blank-Werte korrigiert (Rohextrakt ersetzt durch Puffer).Calculation of specific CBL activity as Δ fluorescence / min x mg protein. All measured values are previously corrected for blank values (raw extract replaced by buffer).
• Vergleich der spezifischen CBL-Aktivitäten mit und ohne Inhibitor (Kontrolle).• Comparison of specific CBL activities with and without inhibitor (control).
1.3. Ergebnisse1.3. Results
Spezifische CBL-Aktivitäten eines Sfapfty/ococcus-Rohextrakts unter Einfluss verschiedenerSpecific CBL activities of a Sfapfty / ococcus crude extract under the influence of various
Inhibitoren relativ zur Kontrolle (Mittelwerte ± SEM, n = 2 - 4 unabhängige Replikate). Inhibitor CBL-RestaktivitatInhibitors relative to the control (mean ± SEM, n = 2 - 4 independent replicates). Inhibitor CBL residual activity
Quelle / Lieferant (AWK in % v/v) (%)Source / Supplier (AWK in% v / v) (%)
Kein Inhibitor (Kontrolle) 100 -No inhibitor (control) 100 -
Arnika-Tinktur #15027; Rahn,Arnica tincture # 15027; Rahn,
Extrakt aus Arnica montana (1 %) 30 ± 2 Frankfurt a. MArnica montana extract (1%) 30 ± 2 Frankfurt a. M
Meadowsweet Extract HG; Rahn,Meadowsweet Extract HG; Rahn,
Extrakt aus Spiraea ulmaria (1 %) 9 ± 1 Frankfurt a. M.Extract from Spiraea ulmaria (1%) 9 ± 1 Frankfurt a. M.
Extrakt aus Hypericum perforatum Hypericum Glycolic Extract; Rahn,Extract of Hypericum perforatum Hypericum Glycolic Extract; Rahn,
18 + 018 + 0
(1 %) Frankfurt a. M.(1%) Frankfurt a. M.
Tee grün Herbasol Tinktur,Green tea Herbasol tincture,
Extrakt aus Camellia sinensis (1 %) 2 ± 0 Cosmetochem, CH-SteinhausenCamellia sinensis extract (1%) 2 ± 0 Cosmetochem, CH-Steinhausen
Gentian Extract PG, #2049; Rahn,Gentian Extract PG, # 2049; Rahn,
Extrakt aus Gentiana lutea (1 %) 10 ± 7 Frankfurt a.M.Extract from Gentiana lutea (1%) 10 ± 7 Frankfurt a.M.
Polyplant ME spezial, Polygon, CHPolyplant ME special, Polygon, CH
Extrakt aus Melissa officinalis (1 %) 3 ± 1 ÖltenExtract of Melissa officinalis (1%) 3 ± 1 oils
Pomactiv wap, GFN-Selco, Wald-Pomactiv wap, GFN-Selco, forest
Extrakt aus Pyrus malus (1 %) 0 ± 0 Michelbach;Extract of Pyrus malus (1%) 0 ± 0 Michelbach;
Extrakt aus Lonicera japonica mit 2400 Actipone Honeysuckle #102906;Extract of Lonicera japonica with 2400 Actipone Honeysuckle # 102906;
22 + 2 ppm Chlorogensäure (1 %) Symrise, Holzminden;22 + 2 ppm chlorogenic acid (1%) Symrise, Holzminden;
Extrakt aus Eucommia ulmoides mit > Eucommia ulmoides leaf extractExtract from Eucommia ulmoides with> Eucommia ulmoides leaf extract
3 ± 1 60% Chlorogensäure (0.1 %) 60%, IMPAG, Offenbach3 ± 1 60% chlorogenic acid (0.1%) 60%, IMPAG, Offenbach
Extrakt aus Eucommia ulmoides mit > Eucommia ulmoides leaf extractExtract from Eucommia ulmoides with> Eucommia ulmoides leaf extract
6 ± 1 80% Chlorogensäure (0.1 %) 80%; IMPAG, Offenbach6 ± 1 80% chlorogenic acid (0.1%) 80%; IMPAG, Offenbach
Chlorogensäure (0.1 %) 11 ± 2 Roth, KarlsruheChlorogenic acid (0.1%) 11 ± 2 Roth, Karlsruhe
Chlorogensäure (0.01 %) 53 ± 4 Roth, KarlsruheChlorogenic acid (0.01%) 53 ± 4 Roth, Karlsruhe
Chlorogensäure (0.001 %) 70 ± 7 Roth, KarlsruheChlorogenic acid (0.001%) 70 ± 7 Roth, Karlsruhe
Kaffeesäure (0.1 %) 1 ± 1 Roth, KarlsruheCaffeic acid (0.1%) 1 ± 1 Roth, Karlsruhe
AWK: Anwendungskonzentration; SEM: Standardfehler des MittelwertesAWK: application concentration; SEM: standard error of the mean value
Weitere Tests haben gezeigt, dass auch ein Überschuss an Deo-Wirkstoffen (10% v/v im Assay), die Wirkung der eingesetzten Substanzen nicht negativ beeinflusst.Further tests have shown that even an excess of deodorant active ingredients (10% v / v in the assay) does not adversely affect the effect of the substances used.
Die Versuchsergebnisse zeigen, dass bereits mit einer sehr geringen Menge an Kaffeesäure eine fast vollständige Inhibierung der Cystathionin-beta-Lyase erreicht werden kann. Ein Vergleich der mit Pflanzenextrakten und reiner Chlorogensäure erzielten Hemmraten zeigt, dass die Wirkung einiger Extrakte nicht alleine auf ihren Chlorogensäuregehalt zurückzuführen sein kann: Bei einem Einsatz von 1 % Lonicera yapon/ca-Extrakt beträgt der Chlorogensäuregehalt im Assay z.B. 0,006%. Vergleichbare Konzentrationen reiner Chlorogensäure wirken deutlich schlechter. Ähnliches gilt beispielsweise auch für die Extrakte aus Arnica montana und Eucommonia ulmoides. Vermutlich sind daher weitere Inhaltsstoffe der Extrakte synergistisch an der Enzym-Inhibition beteiligt.The test results show that even with a very small amount of caffeic acid, an almost complete inhibition of cystathionine beta-lyase can be achieved. A comparison of the inhibition rates achieved with plant extracts and pure chlorogenic acid shows that the effect of some extracts can not be attributed solely to their chlorogenic acid content: For example, when using 1% Lonicera yapon / ca extract, the chlorogenic acid content in the assay is 0.006%. Comparable concentrations of pure chlorogenic acid are significantly worse. The same applies, for example, to the extracts from Arnica montana and Eucommonia ulmoides. Presumably, therefore, further ingredients of the extracts are synergistically involved in enzyme inhibition.
Beispiel 2: Erfindungsgemäße FormulierungsbeispieleExample 2 Formulation Examples According to the Invention
Erfindungsgemäße Antitranspirant-Stifte auf Basis einer ÖI-in-Wasser-Emulsion (Mengenangaben in Gew.-%)Antiperspirant sticks according to the invention based on an oil-in-water emulsion (amounts in% by weight)
Figure imgf000029_0001
Formulierungsbeispiel 8: Erfindungsgemäße Antitranspirant-Emulsion (O/W)
Figure imgf000029_0001
Formulation Example 8: Antiperspirant Emulsion (O / W) According to the Invention
Figure imgf000030_0001
Figure imgf000030_0001
Die Emulsion gemäß Formulierungsbeispiel 8 wies am ersten Tag nach der Herstellung eine Viskosität von 2200 mPas auf, gemessen mit einem Brookfield-Viskosimeter, Spindel RV 4, 20 s"1 , ohne Helipath, bei 20 0C Umgebungstemperatur und 20 0C Probentemperatur; sie wurde in einen Roll-on-Applikator abgefüllt.The emulsion according to Formulation Example 8 had the first day after the preparation has a viscosity of 2200 mPas, measured with a Brookfield viscometer, spindle RV 4, 20 s "1 without Helipath, at 20 0 C ambient temperature and 20 0 C sample temperature; it was filled into a roll-on applicator.
Formulierungsbeispiel 9: erfindungsgemäße Antitranspirant-Emulsion (O/W)Formulation Example 9: Antiperspirant Emulsion (O / W) According to the Invention
Figure imgf000030_0002
Figure imgf000030_0002
Die Emulsion gemäß Formulierungsbeispiel 9 wies am ersten Tag nach der Herstellung eine Viskosität von 1700 mPas auf, gemessen mit einem Brookfield-Viskosimeter, Spindel RV 4, 20 s"1 , ohne Helipath, bei 20 0C Umgebungstemperatur und 20 0C Probentemperatur; sie wurde in einen Roll-on-Applikator abgefüllt. The emulsion according to Formulation Example 9 had the first day after the preparation has a viscosity of 1700 mPas, measured with a Brookfield viscometer, spindle RV 4, 20 s "1 without Helipath, at 20 0 C ambient temperature and 20 0 C sample temperature; it was filled into a roll-on applicator.
Figure imgf000031_0001
Figure imgf000031_0001
Sprühfähige, transluzente Antitranspirant-Mikroemulsionen (Angaben in Gew.-%)
Figure imgf000031_0002
Sprayable, translucent antiperspirant microemulsions (in% by weight)
Figure imgf000031_0002
Figure imgf000032_0001
Figure imgf000032_0001
Seifenhaltige Stifte (Angaben in Gew.-%)
Figure imgf000032_0002
Soap-containing pens (in% by weight)
Figure imgf000032_0002
Figure imgf000033_0001
Figure imgf000033_0001
Wasserfreies Deodorant-Spray (Angaben in Gew.-%)Anhydrous deodorant spray (in% by weight)
Figure imgf000033_0002
Figure imgf000033_0002
Antitranspirant-Spray vom Suspensionstyp (Angaben in Gew.-%)
Figure imgf000033_0003
Figure imgf000034_0001
Suspension type antiperspirant spray (in% by weight)
Figure imgf000033_0003
Figure imgf000034_0001
Antitranspirant-Tücher (Formulierungsbeispiele Nr. 17.1. - 17.4)Antiperspirant wipes (Formulation Examples No. 17.1 - 17.4)
Für die erfindungsgemäße Ausführungsform als Antitranspirant-Tuch wurde ein einlagiges Substrat aus 100 % Viskose mit einem Flächengewicht von 50 g/m2 mit jeweils 75 g der BeispielemulsionenFor the embodiment according to the invention as an antiperspirant cloth, a single-layer substrate of 100% viscose with a weight per unit area of 50 g / m 2 was used , each with 75 g of the example emulsions
11.1 bzw. 11.2 bzw. 2.3 pro Quadratmeter oder mit jeweils 75 g der Beispiellösungen 13.1 bzw.11.1 or 11.2 or 2.3 per square meter or with 75 g each of the sample solutions 13.1 or
13.2 beaufschlagt, in Tücher geeigneter Größe geschnitten und in Sachets verpackt.13.2, cut into cloths of suitable size and packed in sachets.
Figure imgf000034_0002
Figure imgf000034_0002
Figure imgf000034_0003
Figure imgf000034_0003
Figure imgf000035_0001
Figure imgf000035_0001
Beispielzusammensetzung 19.1 enthält eine erfindungsgemäße Antitranspirant-Emulsion mit 9,9 Gew.-% Aluminiumchlorohydrat, bezogen auf das Gewicht der treibgasfreien Emulsion. Mit einer Sprührate von 0,35 g/s versprüht man in der Sekunde 0,035 g des schweißhemmenden Wirkstoffs Aluminiumchlorohydrat auf die Hautoberfläche.Example Composition 19.1 contains an antiperspirant emulsion according to the invention with 9.9% by weight aluminum chlorohydrate, based on the weight of the propellant-free emulsion. With a spray rate of 0.35 g / s, 0.035 g of the antiperspirant active ingredient aluminum chlorohydrate are sprayed onto the skin surface every second.
Beispielzusammensetzung 19.2 enthält eine erfindungsgemäße Antitranspirant-Emulsion mit 17,49 Gew.-% Aluminiumchlorohydrat, bezogen auf das Gewicht der treibgasfreien Emulsion. Mit einer Sprührate von 0,2 g/s versprüht man in der Sekunde 0,035 g des schweißhemmenden Wirkstoffs Aluminiumchlorohydrat auf die Hautoberfläche.Example Composition 19.2 contains an antiperspirant emulsion according to the invention with 17.49% by weight aluminum chlorohydrate, based on the weight of the propellant-free emulsion. At a spray rate of 0.2 g / s, 0.035 g of the antiperspirant active ingredient aluminum chlorohydrate is sprayed onto the skin surface every second.
Flüssige ZahnreinigungsgeleLiquid tooth cleaning gels
Figure imgf000035_0002
Figure imgf000035_0002
Figure imgf000036_0001
Figure imgf000036_0001
Liste der verwendeten Rohstoffe
Figure imgf000036_0002
Figure imgf000037_0001
List of raw materials used
Figure imgf000036_0002
Figure imgf000037_0001

Claims

Patentansprüche claims
1. Nicht-therapeutische, kosmetische Verwendung von mindestens einem Pflanzenextrakt ausgewählt aus Mädesüß-Extrakt (Spiraea ulmaria), Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten und/oder einer Hydroxyzimtsäure und/oder einem Derivat davon zur Verhinderung oder Behandlung von Körpergeruch, insbesondere im axillaren oder oralen Bereich.1. Non-therapeutic, cosmetic use of at least one plant extract selected from meadowsweet extract (Spiraea ulmaria), St. John's wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof and / or a hydroxycinnamic acid and / or a derivative thereof for preventing or Treatment of body odor, especially in the axillary or oral area.
2. Verwendung von mindestens einem Pflanzenextrakt ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten und/oder einer Hydroxyzimtsäure und/oder einem Derivat davon zur Inhibierung der Cysta- thionin-beta-Lyase.2. Use of at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts containing hydroxycinnamic acids and / or derivatives thereof and / or a hydroxycinnamic acid and / or a derivative thereof for inhibiting cystathenol-beta-lyase.
3. Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass der Mädesüß-Extrakt durch Extraktion der Blüten und/oder der Blätter mit einem Wasser/Ethanol-Gemisch, einem Wasser/C2-C6-Polyol-Gemisch oder mindestens einem C2-C6-PoIyOl erhalten ist.3. Use according to claim 1 or 2, characterized in that the meadowsweet extract by extraction of the flowers and / or the leaves with a water / ethanol mixture, a water / C 2 -C 6 polyol mixture or at least a C 2 -C 6 -PoIyOl is obtained.
4. Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass es sich bei der Hydroxyzimtsäure um eine Verbindung der allgemeinen Formel (I)4. Use according to claim 1 or 2, characterized in that the hydroxycinnamic acid is a compound of the general formula (I)
Figure imgf000038_0001
handelt, wobei R1 und R2 unabhängig voneinander ausgewählt sind aus Wasserstoff, C-|.6-Alkyl, Hydroxy und C-|.6-Alkoxy.
Figure imgf000038_0001
where R1 and R2 are independently selected from hydrogen, C- | 6- alkyl, hydroxy and C- |. 6- alkoxy.
5. Verwendung nach Anspruch 4, dadurch gekennzeichnet, dass es sich bei der Hydroxyzimtsäure um Kaffeesäure (R1 = H, R2 = OH) handelt.5. Use according to claim 4, characterized in that the hydroxycinnamic acid is caffeic acid (R 1 = H, R 2 = OH).
6. Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass es sich bei dem Derivat der Hydroxyzimtsäure um einen Ester der Hydroxyzimtsäure mit einem Alkohol handelt.6. Use according to claim 1 or 2, characterized in that it is the derivative of hydroxycinnamic acid is an ester of hydroxycinnamic acid with an alcohol.
7. Verwendung nach Anspruch 6, dadurch gekennzeichnet, dass es sich bei dem Alkohol um eine Polyhydroxyverbindung, insbesondere um die Chinasäure, handelt.7. Use according to claim 6, characterized in that the alcohol is a polyhydroxy compound, in particular the quinic acid.
8. Verwendung nach Anspruch 7, dadurch gekennzeichnet, dass der Ester ausgewählt ist aus Chlorogensäure und Di-Kaffeoylchinasäure. 8. Use according to claim 7, characterized in that the ester is selected from chlorogenic acid and di-caffeoylquinic acid.
9. Verwendung nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass der Pflanzenextrakt, der Hydroxyzimtsäure und/oder ein Derivat davon enthält, ausgewählt ist aus Extrakten von Ipomoea purga, Pyrus communis (Birne), Pyrus malus (Apfel), Ocimum basili- cum (Basilikum), Thymus vulgaris (Thymian), Teucrium scorodonia, Verbena officinalis, Artemi- sia dracunculus, Thymus serpyllum, Origanum vulgäre, Melissa officinalis, Camellia sinensis, Gentiana lutea, Stachys officinalis, Lonicera japonica, Arnica montana, Eucommia ulmoides (Guttapercha), Kaffee (Coffea arabica), Sonnenblume (Helianthus annuus), Damaszener-Rose (Rosa damascena), Blaubeere (Vaccinium corymbosum) und japanischem Geißblatt (Lonicera japonica) und Mischungen davon.9. Use according to one of the preceding claims, characterized in that the plant extract containing hydroxycinnamic acid and / or a derivative thereof is selected from extracts of Ipomoea purga, Pyrus communis (pear), Pyrus malus (apple), Ocimum basilicum (Basil), Thymus vulgaris (thyme), Teucrium scorodonia, Verbena officinalis, Artemisia dracunculus, Thymus serpyllum, Origanum vulgaris, Melissa officinalis, Camellia sinensis, Gentiana lutea, Stachys officinalis, Lonicera japonica, Arnica montana, Eucommia ulmoides (gutta-percha) , Coffee (Coffea arabica), sunflower (Helianthus annuus), damask rose (Rosa damascena), blueberry (Vaccinium corymbosum) and Japanese honeysuckle (Lonicera japonica) and mixtures thereof.
10. Verwendung nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, dass die Verwendung in einem kosmetischen oder pharmazeutischen Mittel, ausgewählt aus Deodorants, Antitranspirantien und Mitteln zur oralen Pflege, erfolgt.10. Use according to any one of claims 1 to 9, characterized in that the use in a cosmetic or pharmaceutical agent selected from deodorants, antiperspirants and oral care products takes place.
11. Kosmetische oder pharmazeutische Zusammensetzung zur Behandlung oder Verhinderung von Körpergeruch oder Mundgeruch, ausgewählt aus Deodorants, Antitranspirantien und Mitteln zur oralen Pflege, enthaltend mindestens einen Pflanzenextrakt, ausgewählt aus Mädesüß-Extrakt, Johanniskraut-Extrakt und Extrakten, die Hydroxyzimtsäuren und/oder deren Derivate enthalten, und/oder eine Hydroxyzimtsäure und/oder ein Derivat davon.11. A cosmetic or pharmaceutical composition for the treatment or prevention of body odor or halitosis selected from deodorants, antiperspirants and oral care compositions containing at least one plant extract selected from meadowsweet extract, St. John's Wort extract and extracts, the hydroxycinnamic acids and / or their derivatives contain, and / or a hydroxycinnamic acid and / or a derivative thereof.
12. Kosmetische oder pharmazeutische Zusammensetzung nach Anspruch 11 , dadurch gekennzeichnet, dass das Deodorant oder Antitranspirant mindestens eine im axillaren Bereich prä- biotisch wirksame Substanz ausgewählt aus Pflanzenextrakten aus Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp., Ribes sp., Hibiscus spec, Malva spec, Vitis spec, Daucus spec, Commiphora spec, Simmondsia spec oder Calendula spec, Glycerinmono- alkylether, insbesondere 1-(2-Ethylhexyl)glycerinether, Isopropylmyristat oder Ethylmyristat oder Mischungen davon enthält.12. Cosmetic or pharmaceutical composition according to claim 11, characterized in that the deodorant or antiperspirant at least one biologically active substance in the axillary region selected from plant extracts of Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp ., Ribes sp., Hibiscus spec., Malva spec., Vitis spec., Daucus spec., Commiphora spec., Simmondsia spec or Calendula spec, glycerol monoalkyl ethers, especially 1- (2-ethylhexyl) glycerol ethers, isopropyl myristate or ethyl myristate or mixtures thereof.
13. Kosmetische oder pharmazeutische Zusammensetzung nach Anspruch 11 oder 12, dadurch gekennzeichnet, dass das Deodorant oder Antitranspirant mindestens einen weiteren Deodorant-Wirkstoff ausgewählt aus Duftstoffen, Geruchsabsorbern, desodorierend wirkenden Ionenaustauschern, antimikrobiellen oder keimhemmenden Stoffen, weiteren enzymhemmenden Stoffen, Antioxidantien und Geruchsadsorbentien enthält.13. Cosmetic or pharmaceutical composition according to claim 11 or 12, characterized in that the deodorant or antiperspirant contains at least one further deodorant active ingredient selected from fragrances, odor absorbers, deodorizing ion exchangers, antimicrobial or germ-inhibiting substances, other enzyme-inhibiting substances, antioxidants and odor adsorbents.
14. Kosmetische oder pharmazeutische Zusammensetzung nach Anspruch 13, dadurch gekennzeichnet, dass es sich bei dem antimikrobiellen Wirkstoff um einen aromatischen Alkohol der allgemeinen Formel
Figure imgf000040_0001
handelt, wobei R1 - R6 = unabhängig voneinander stehen für ein Wasserstoffatom, eine lineare oder verzweigte sowie gegebenenfalls substituierte C-|.10-Alkylgruppe oder eine lineare oder verzweigte sowie gegebenenfalls substituierte C2-io-Alkenylgruppe, wobei die Substituenten jeweils vorzugsweise ausgewählt sind aus Hydroxy und C-|.6-Alkoxy,14. A cosmetic or pharmaceutical composition according to claim 13, characterized in that it is the antimicrobial agent is an aromatic alcohol of the general formula
Figure imgf000040_0001
wherein R 1 - R 6 = independently of one another represent a hydrogen atom, a linear or branched and optionally substituted C-. 10 -alkyl group or a linear or branched and optionally substituted C 2 -io-alkenyl group, wherein the substituents are each preferably selected from hydroxy and C-. 6- alkoxy,
R7 - R11 = unabhängig voneinander stehen für ein Wasserstoffatom, ein Halogenatom, insbesondere Chlor, oder eine lineare oder verzweigte sowie gegebenenfalls substituierte C1.R 7 - R 11 = independently of one another represent a hydrogen atom, a halogen atom, in particular chlorine, or a linear or branched and optionally substituted C 1 .
-ιo-Alkylgruppe, wobei die Substituenten vorzugsweise ausgewählt sind aus Hydroxy und C-^6--ιo-alkyl group, wherein the substituents are preferably selected from hydroxy and C- ^ 6 -
Alkoxy, insbesondere Methoxy, m = 0 oder 1 ist, n, o, p = unabhängig voneinander ganze Zahlen von 0 bis 10 sein können, wobei mindestens einer der Werte von n, o, p ≠ 0 ist.Alkoxy, in particular methoxy, m = 0 or 1, n, o, p = can independently be integers from 0 to 10, wherein at least one of the values of n, o, p ≠ 0.
15. Kosmetische oder pharmazeutische Zusammensetzung nach einem der Ansprüche 1 1 bis 14, dadurch gekennzeichnet, dass das Deodorant oder Antitranspirant mindestens einen schweißhemmenden Wirkstoff, ausgewählt aus adstringierenden Salzen des Aluminiums, Zirkoniums, Zinks oder Titans, enthält. 15. A cosmetic or pharmaceutical composition according to any one of claims 1 1 to 14, characterized in that the deodorant or antiperspirant contains at least one antiperspirant active ingredient selected from astringent salts of aluminum, zirconium, zinc or titanium.
PCT/EP2009/063412 2008-10-24 2009-10-14 Use of hydroxycinnamic acids and derivatives thereof and/or of plant extracts for treating body odor WO2010046291A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008053034.4 2008-10-24
DE102008053034A DE102008053034A1 (en) 2008-10-24 2008-10-24 Use of hydroxycinnamic acids and their derivatives and / or plant extracts for the treatment of body odor

Publications (2)

Publication Number Publication Date
WO2010046291A2 true WO2010046291A2 (en) 2010-04-29
WO2010046291A3 WO2010046291A3 (en) 2010-07-22

Family

ID=42055035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/063412 WO2010046291A2 (en) 2008-10-24 2009-10-14 Use of hydroxycinnamic acids and derivatives thereof and/or of plant extracts for treating body odor

Country Status (2)

Country Link
DE (1) DE102008053034A1 (en)
WO (1) WO2010046291A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102381974A (en) * 2011-08-31 2012-03-21 河南科技大学 Method for separating and preparing caffeic tannic acid from honeysuckle by utilizing high speed countercurrent chromatography
DE102011086019A1 (en) 2011-11-09 2012-08-02 Henkel Ag & Co. Kgaa Cosmetic product useful for preventing body odor, comprises composition comprising antiperspirant or deodorant active substance, water, and agent for dissolving or suspending active substance, propellant, and aerosol dispensing device
DE102011089430A1 (en) 2011-12-21 2012-08-23 Henkel Ag & Co. Kgaa Use of a specified hydrocarbon, obtained from non-fossil biomass, as a blowing agent for spray products, preferably a cosmetic product, pharmaceutical product, air care product, home care product or a product for the car or paint care
DE102011087980A1 (en) 2011-12-08 2012-09-06 Henkel Kgaa Cosmetic and non-therapeutic use of platycodin e.g. for influencing natural pigmentation process of hair and its follicles in armpit region, for reducing shaving or epilation frequency, and as active substance in topically applied agents
WO2013079349A1 (en) 2011-12-02 2013-06-06 Henkel Ag & Co. Kgaa Cosmetic aerosol spray with lasting freshness effect
DE102011088967A1 (en) 2011-12-19 2013-06-20 Henkel Ag & Co. Kgaa Deodorants and antiperspirants with stabilized antioxidant
DE102011089012A1 (en) 2011-12-19 2013-06-20 Henkel Ag & Co. Kgaa Textile-friendly antiperspirants
DE102011089560A1 (en) 2011-12-22 2013-06-27 Henkel Ag & Co. Kgaa Antiperspirant suspension spray with improved drug release and reduced textile soiling
DE102011089340A1 (en) 2011-12-21 2013-06-27 Henkel Ag & Co. Kgaa PEG-free antiperspirant oil-in-water emulsions with improved feel
DE102012222692A1 (en) 2012-12-11 2013-09-05 Henkel Ag & Co. Kgaa Cosmetic composition useful as antiperspirant and deodorant, comprises 2-benzylheptan-1-ol, and rosemary extract
CN103553922A (en) * 2013-11-06 2014-02-05 天津科技大学 Preparation of macranthoin G in eucommia ulmoides, and application of macranthoin G in neuroprotective medicine
JP2014028778A (en) * 2012-07-31 2014-02-13 Mandom Corp Diketone action inhibitor
DE102012224156A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly nonaerosol antiperspirants with hydroxycarboxylic acids
DE102012224142A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly antiperspirant sprays with methanesulfonic acid
WO2014095688A2 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-sparing, non-aerosol antiperspirants with methanesulphonic acid
DE102012224157A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly antiperspirant sprays with hydroxycarboxylic acids
DE102014217316A1 (en) 2014-08-29 2016-03-03 Henkel Ag & Co. Kgaa Low-electrolyte preparations against body odor
WO2016062487A1 (en) * 2014-10-23 2016-04-28 Henkel Ag & Co. Kgaa Performance-enhanced antiperspirants
CN107519377A (en) * 2017-08-31 2017-12-29 海南蛛王药业有限公司 A kind of inhibiting bacteria and diminishing inflammation composition and preparation method thereof and oral health care product
CN117682954A (en) * 2024-02-04 2024-03-12 云南西草资源开发有限公司 Chlorogenic acid-enriched coffee extract, preparation method and chlorogenic acid-enriched coffee powder

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179430B2 (en) 2012-06-08 2021-11-23 Finzelberg Gmbh & Co. Kg Extracts from mother-of-thyme and the use i'hereof
DE102012223532A1 (en) 2012-12-18 2014-06-18 Beiersdorf Ag Improved protection against body odor
DE102012223553A1 (en) * 2012-12-18 2014-06-18 Beiersdorf Ag Use of aluminum salts against stress sweating
ITUB20160058A1 (en) * 2016-01-19 2017-07-19 Farm S R L C U S Composition of a preparation for the treatment of insect bites with vasoconstrictive, soothing, anti-inflammatory and anti-reddening activity

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1241402A (en) * 1969-04-21 1971-08-04 Colgate Palmolive Co Dental creams
GB1514469A (en) * 1974-08-01 1978-06-14 Beecham Group Ltd Oral hygiene compositions
DE3302694A1 (en) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München ORAL CARE PRODUCTS
DE3809457A1 (en) * 1988-03-09 1989-09-21 Hildegard Goetz Composition for eliminating body and mouth odour
EP0870507A1 (en) * 1997-04-02 1998-10-14 Farmo-Nat Ltd. Synergistic herbal extracts
US6294161B1 (en) * 1997-01-30 2001-09-25 Takasago International Corporation Deodorant composition
WO2002007697A1 (en) * 2000-07-26 2002-01-31 Cognis France Synergistically active mixture which inhibits hair growth
US20030190300A1 (en) * 2002-04-05 2003-10-09 Scancarella Neil D. Cosmetic compositions containing meadowsweet extract and methods for treating skin
EP1428520A2 (en) * 2002-12-10 2004-06-16 Henkel Kommanditgesellschaft auf Aktien Lipase inhibitors in deodorants and antiperspirants
DE10259016A1 (en) * 2002-12-06 2004-06-17 Henkel Kgaa Moist sponge for cleansing or application of cosmetics or other agents has specified maximum water absorption capacity and is especially of natural or synthetic rubber or polyurethane
WO2006008917A1 (en) * 2004-07-15 2006-01-26 Lion Corporation Deodorant agent, deodorant preparation and method of deodorant treatment for fiber
WO2006027248A2 (en) * 2004-09-11 2006-03-16 Henkel Kommanditgesellschaft Aktien Oral dental and dental prosthesis care product containing substances inhibiting the formation of plaque

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547828A (en) 1968-09-03 1970-12-15 Rohm & Haas Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols
US3772269A (en) 1969-07-24 1973-11-13 Ici America Inc Glycoside compositions and process for the preparation thereof
US3707535A (en) 1969-07-24 1972-12-26 Atlas Chem Ind Process for preparing mono- and polyglycosides
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
DE3001064A1 (en) 1980-01-12 1981-07-16 Basf Ag, 6700 Ludwigshafen METHOD FOR PURIFYING ALKYL GLYCOSIDES BY DISTILLATIVE DETERMINATION OF UNACTIVATED ALCOHOLS
EP0077167B1 (en) 1981-10-08 1985-09-11 Rohm And Haas France, S.A. A process for preparing surface-active glycosides and the use of the glycosides in cosmetic, pharmaceutical and household products
DE3723354A1 (en) 1987-07-15 1989-01-26 Henkel Kgaa SULFATED HYDROXY MIXERS, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE3725030A1 (en) 1987-07-29 1989-02-09 Henkel Kgaa SURFACE ACTIVE HYDROXYSULFONATE
DE3926344A1 (en) 1989-08-09 1991-02-28 Henkel Kgaa METHOD FOR THE PRODUCTION OF LIGHT-COLORED OELSAEURESULFONATES
DE19736906A1 (en) 1997-08-25 1999-03-04 Henkel Kgaa Process for the preparation of sulfated fatty acid alkylene glycol esters
DE19756454C1 (en) 1997-12-18 1999-06-17 Henkel Kgaa Surface-active compositions, especially cosmetics, containing glycerol carbonate as emulsifier
WO2001099376A2 (en) 2001-06-01 2001-12-27 Henkel Kommanditgesellschaft Auf Aktien Arylsulfatase-inhibitors in deodorants and antiperspirants
DE10154368A1 (en) 2001-11-06 2003-05-15 Henkel Kgaa Beta-glucuronidase inhibitors in deodorants and antiperspirants
WO2005011716A1 (en) 2003-07-21 2005-02-10 Henkel Kommanditgesellschaft Auf Aktien Prebiotically active plant extracts
DE102004032734A1 (en) 2004-03-18 2005-10-06 Henkel Kgaa Prebiotic substances for deodorants
CN101107263B (en) 2005-01-31 2014-08-27 弗门尼舍有限公司 Inhibition of sweat malodour

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1241402A (en) * 1969-04-21 1971-08-04 Colgate Palmolive Co Dental creams
GB1514469A (en) * 1974-08-01 1978-06-14 Beecham Group Ltd Oral hygiene compositions
DE3302694A1 (en) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München ORAL CARE PRODUCTS
DE3809457A1 (en) * 1988-03-09 1989-09-21 Hildegard Goetz Composition for eliminating body and mouth odour
US6294161B1 (en) * 1997-01-30 2001-09-25 Takasago International Corporation Deodorant composition
EP0870507A1 (en) * 1997-04-02 1998-10-14 Farmo-Nat Ltd. Synergistic herbal extracts
WO2002007697A1 (en) * 2000-07-26 2002-01-31 Cognis France Synergistically active mixture which inhibits hair growth
US20030190300A1 (en) * 2002-04-05 2003-10-09 Scancarella Neil D. Cosmetic compositions containing meadowsweet extract and methods for treating skin
DE10259016A1 (en) * 2002-12-06 2004-06-17 Henkel Kgaa Moist sponge for cleansing or application of cosmetics or other agents has specified maximum water absorption capacity and is especially of natural or synthetic rubber or polyurethane
EP1428520A2 (en) * 2002-12-10 2004-06-16 Henkel Kommanditgesellschaft auf Aktien Lipase inhibitors in deodorants and antiperspirants
WO2006008917A1 (en) * 2004-07-15 2006-01-26 Lion Corporation Deodorant agent, deodorant preparation and method of deodorant treatment for fiber
WO2006027248A2 (en) * 2004-09-11 2006-03-16 Henkel Kommanditgesellschaft Aktien Oral dental and dental prosthesis care product containing substances inhibiting the formation of plaque

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102381974A (en) * 2011-08-31 2012-03-21 河南科技大学 Method for separating and preparing caffeic tannic acid from honeysuckle by utilizing high speed countercurrent chromatography
DE102011086019A1 (en) 2011-11-09 2012-08-02 Henkel Ag & Co. Kgaa Cosmetic product useful for preventing body odor, comprises composition comprising antiperspirant or deodorant active substance, water, and agent for dissolving or suspending active substance, propellant, and aerosol dispensing device
DE102011087662A1 (en) 2011-12-02 2013-06-06 Henkel Ag & Co. Kgaa Cosmetic aerosol spray with lasting freshness effect
WO2013079349A1 (en) 2011-12-02 2013-06-06 Henkel Ag & Co. Kgaa Cosmetic aerosol spray with lasting freshness effect
DE102011087980A1 (en) 2011-12-08 2012-09-06 Henkel Kgaa Cosmetic and non-therapeutic use of platycodin e.g. for influencing natural pigmentation process of hair and its follicles in armpit region, for reducing shaving or epilation frequency, and as active substance in topically applied agents
WO2013092114A2 (en) 2011-12-19 2013-06-27 Henkel Ag & Co. Kgaa Deodorants and antiperspirants having stabilized antioxidant
DE102011088967A1 (en) 2011-12-19 2013-06-20 Henkel Ag & Co. Kgaa Deodorants and antiperspirants with stabilized antioxidant
DE102011089012A1 (en) 2011-12-19 2013-06-20 Henkel Ag & Co. Kgaa Textile-friendly antiperspirants
WO2013092185A2 (en) 2011-12-19 2013-06-27 Henkel Ag & Co. Kgaa Textile-sparing antiperspirants
DE102011089340A1 (en) 2011-12-21 2013-06-27 Henkel Ag & Co. Kgaa PEG-free antiperspirant oil-in-water emulsions with improved feel
WO2013092186A2 (en) 2011-12-21 2013-06-27 Henkel Ag & Co. Kgaa Peg-free antiperspirant oil-in-water emulsions having improved feel
DE102011089430A1 (en) 2011-12-21 2012-08-23 Henkel Ag & Co. Kgaa Use of a specified hydrocarbon, obtained from non-fossil biomass, as a blowing agent for spray products, preferably a cosmetic product, pharmaceutical product, air care product, home care product or a product for the car or paint care
US9186304B2 (en) 2011-12-21 2015-11-17 Henkel Ag & Co. Kgaa Peg-free antiperspirant oil-in-water emulsions having improved feel
DE102011089560A1 (en) 2011-12-22 2013-06-27 Henkel Ag & Co. Kgaa Antiperspirant suspension spray with improved drug release and reduced textile soiling
WO2013092208A2 (en) 2011-12-22 2013-06-27 Henkel Ag & Co. Kgaa Antiperspirant suspension spray with improved active ingredient release and reduced soiling of textiles
JP2014028778A (en) * 2012-07-31 2014-02-13 Mandom Corp Diketone action inhibitor
DE102012222692A1 (en) 2012-12-11 2013-09-05 Henkel Ag & Co. Kgaa Cosmetic composition useful as antiperspirant and deodorant, comprises 2-benzylheptan-1-ol, and rosemary extract
US9549883B2 (en) 2012-12-21 2017-01-24 Henkel Ag & Co. Kgaa Textile friendly nonaerosol-antiperspirants with methansulfonic
DE102012224156A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly nonaerosol antiperspirants with hydroxycarboxylic acids
WO2014095688A2 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-sparing, non-aerosol antiperspirants with methanesulphonic acid
DE102012224133A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly nonaerosol antiperspirants with methanesulfonic acid
DE102012224157A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly antiperspirant sprays with hydroxycarboxylic acids
US9095520B2 (en) 2012-12-21 2015-08-04 Henkel Ag & Co. Kgaa Textile friendly non-aerosol antiperspirants with a hydroxy acid
DE102012224142A1 (en) 2012-12-21 2014-06-26 Henkel Ag & Co. Kgaa Textile-friendly antiperspirant sprays with methanesulfonic acid
CN103553922A (en) * 2013-11-06 2014-02-05 天津科技大学 Preparation of macranthoin G in eucommia ulmoides, and application of macranthoin G in neuroprotective medicine
DE102014217316A1 (en) 2014-08-29 2016-03-03 Henkel Ag & Co. Kgaa Low-electrolyte preparations against body odor
WO2016062487A1 (en) * 2014-10-23 2016-04-28 Henkel Ag & Co. Kgaa Performance-enhanced antiperspirants
CN107519377A (en) * 2017-08-31 2017-12-29 海南蛛王药业有限公司 A kind of inhibiting bacteria and diminishing inflammation composition and preparation method thereof and oral health care product
CN107519377B (en) * 2017-08-31 2021-04-06 海南蛛王生物科技有限公司 Antibacterial and anti-inflammatory composition, preparation method thereof and oral health care product
CN117682954A (en) * 2024-02-04 2024-03-12 云南西草资源开发有限公司 Chlorogenic acid-enriched coffee extract, preparation method and chlorogenic acid-enriched coffee powder
CN117682954B (en) * 2024-02-04 2024-04-05 云南西草资源开发有限公司 Chlorogenic acid-enriched coffee extract, preparation method and chlorogenic acid-enriched coffee powder

Also Published As

Publication number Publication date
WO2010046291A3 (en) 2010-07-22
DE102008053034A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2010046291A2 (en) Use of hydroxycinnamic acids and derivatives thereof and/or of plant extracts for treating body odor
EP1725210B1 (en) Use of a water/ethanol extract of sudanese tea (hibiscus) for the treatment of body odours
DE102010000746A1 (en) Use of 1,2-alkanediol compounds for the prevention or treatment of body odor, preferably in the axillary or oral area, and in a cosmetic or pharmaceutical agent, which is useful as a deodorant, antiperspirant or a composition for oral care
WO2010031657A2 (en) Use of urea derivatives and phenacylthiazolium salts for the treatment of body odour
EP1658088B1 (en) Prebiotically active composition comprising extracts of pinus sylvestris and ribes nigrum for use in preventing growth of propionibacterium acnes
DE10333245C5 (en) Prebiotic plant extracts
DE102005014687A1 (en) Composition containing β-defensin 2
WO2006015726A1 (en) Prebiotic intimate personal hygiene product
US20070292459A1 (en) Halloysite microtubule processes, structures, and compositions
DE102004011968A1 (en) Cosmetic or pharmaceutical composition e.g. useful for promoting the growth of desirable skin microorganisms comprises a plant extract with prebiotic activity on the skin
DE102009045981A1 (en) Composition, useful e.g. for non-therapeutic treatment and/or minimization of wrinkles, comprises extract from Tripleurospermum, and active agent comprising e.g. antioxidant, preferably 6,7-disubstituted-2,2-dialkylchromane derivative
DE102009029110A1 (en) Composition, useful e.g. for treating skin and hair and combating microorganisms e.g. Staphylococcus aureus and Malassezia furfur, comprises a functionalized dipeptide and an extract of plant of the family Monimiaceae e.g. Peumus boldus
DE102009039393A1 (en) Cosmetic or dermatological topical composition, useful e.g. for minimizing wrinkles, comprises dormancy-regulating agents containing Leucojum aestivum extract and active ingredient e.g. carotenes, xanthophylls or baicalin in carrier
EP2934455B1 (en) Combination of active agents comprising at least one essential oil, one cyclodextrin and one liquid fatty substance and composition comprising it
EP3154509B1 (en) Cosmetic compositions for bleaching the skin
DE102004034691A1 (en) Use of siderophores for control of odor-producing bacteria, particularly for treating or preventing body odor, act by depriving bacteria of iron
EP3383355B1 (en) Use of additives for effective preservation/boost effect of existing preservation of cosmetic emulsions
EP1800119A2 (en) Cosmetic and dermatological compositions containing active substances for improving sensory perception
EP3166694A1 (en) Antiperspirant cosmetics comprising specific proteins from poaceae of the genus triticum and/or oryza and/or avena and containing no aluminum and/or zirconium halides and/or hydroxy halides
DE102021004906A1 (en) Heavy metal-free topical medical devices and cosmetics, processes for their preparation and their use
EP3166588A1 (en) Antiperspirant cosmetics comprising specific proteins from animal, insect or human secretions and containing no aluminum and/or zirconium halides and/or hydroxy halides
DE102004024463A1 (en) Use of ammonium salts of glycyrrhizic acid and glycyrrhetinic acid for epilation
EP1364651A1 (en) Pharmaceutical composition with deswelling properties
DE102014221913A1 (en) Use of an aluminum salt-free and / or aluminum-zirconium salt-free cosmetic composition containing specific amino acid derivatives as well as proteins from cruciferous plants of the genus Brassica for reducing and / or preventing perspiration
DE102014221912A1 (en) Use of an aluminum salt-free and / or aluminum-zirconium salt-free cosmetic composition containing specific amino acid derivatives and proteins of mallow family Adansonia, for the reduction and / or prevention of perspiration

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09744648

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09744648

Country of ref document: EP

Kind code of ref document: A2